‘Investigating the Mur ligases of *Streptococcus agalactiae* for the development of inhibitory fragments’

Rebecca Jane Steventon, MRes

A thesis submitted in partial fulfilment of the requirements for the degree of

Doctor of Philosophy in Life Sciences

University of Warwick
School of Life Sciences

November 2022
# Table of Contents

Table of Figures ........................................................................................................... 9

Table of Tables .............................................................................................................. 12

Acknowledgments ........................................................................................................ 13

Declaration .................................................................................................................... 14

Abstract ....................................................................................................................... 15

Abbreviations ................................................................................................................ 16

## Chapter 1: Thesis Introduction ............................................................................. 17

1.1 *Streptococcus agalactiae* .................................................................................... 18

1.1.1 Polysaccharide capsule ................................................................................. 18

1.2 *S. agalactiae* infection in adults ......................................................................... 18

1.3 Neonatal sepsis ..................................................................................................... 19

1.3.1 Incidence of EOS ......................................................................................... 19

1.3.2 Mortality rate ................................................................................................ 19

1.4 Antibiotic treatment and emergence of antibiotic resistance ................................. 20

1.5 Peptidoglycan ...................................................................................................... 21

1.5.1 Formation ..................................................................................................... 21

1.5.2 Antibiotic targets and current antibiotics .................................................... 23

1.6 Mur Ligases ........................................................................................................... 26

1.6.1 Role within peptidoglycan formation ......................................................... 26

1.6.2 Regulation of the Mur ligase pathway ......................................................... 28

1.6.3 Mechanism of action .................................................................................. 30

1.6.4 Structure of the Mur ligases ....................................................................... 31

1.6.5 Conformational change ............................................................................... 33

1.6.6 Conservation of Mur ligases ....................................................................... 34

1.6.7 Antibiotic target ........................................................................................... 35

1.7 Mur Ligase Complex ............................................................................................ 36

1.7.1 Role of complex formation within bacteria ............................................... 37

1.7.2 Complex formation of MurT/GatD ............................................................. 37

1.7.3 Interaction of Mur ligases with MreB ......................................................... 38

1.7.4 Interaction between Mur ligases ................................................................. 38

1.7.5 Fusion Mur ligases ....................................................................................... 39

1.7.6 Differences in interacting partners ............................................................. 39

1.8 Project Aims and Outline ..................................................................................... 40
Chapter 2: Development and optimization of an assay for identifying low affinity binding fragments for the Mur ligases ......................................................... 41

1. Introduction and Aims ........................................................................... 42

2. Materials and Methods ........................................................................... 43
   2.1 Media ................................................................................................. 43
   2.2 Buffers and solutions ......................................................................... 43
   2.3 Protein Expression and Purification ..................................................... 44
      2.3.1 Expression of Protein .................................................................. 44
      2.3.2 Preparation of cell lysates ......................................................... 44
      2.3.3 Protein Purification ..................................................................... 44
      2.3.4 SDS Page Analysis ..................................................................... 45
      2.3.5 Protein Quantification ................................................................. 45
   2.4 Cloning of MurD ................................................................................ 46
      2.4.1 Transformation of Competent Cells ............................................ 46
      2.4.2 Construct Validation .................................................................... 46
      2.4.3 Protein Purification ..................................................................... 47
   2.5 Synthesis of UDP-MurNAc-L-Ala ....................................................... 47
      2.5.1 Purification of UDP-MurNAc-L-Ala ........................................... 47
   2.6 Pyruvate Kinase/Lactate Dehydrogenase Coupled Assay for Mur ligases .... 48
   2.7 MESG coupled assay ......................................................................... 49
   2.8 Stopped MESG coupled assay ........................................................... 50

3. Results ...................................................................................................... 51
   3.1 Inactivity of previously cloned MurD from S. agalactiae ..................... 51
   3.2 Previously cloned MurD from S. agalactiae lacks an alpha helix ........ 51
   3.3 S. agalactiae MurD protein purification and activity ............................ 53
   3.4 Optimization of a MESG coupled assay for MurD from S. agalactiae ...... 54
      3.4.1 The MESG coupled assay is reliant on the production of free phosphate .... 56
      3.4.2 The MESG coupled assay can track Mur enzyme activity .......... 57
      3.4.3 MurD requires the presence of all substrates for activity ............ 58
      3.4.4 Determination of the $K_m$ values for substrates for MurD from S. agalactiae .... 59
      3.4.5 Positive control inhibitors for a Mur ligase assay ......................... 62
         3.4.5.1 ADPNP and ADPCP can act as inhibitors of MurD from S. agalactiae ........ 63
         3.4.5.2 ADPCP has an $IC_{50}$ value of 24.2 $\mu$M against MurD from S. agalactiae .... 64
         3.4.5.3 ADPCP has a $K_i$ value of 11.7 $\mu$M against MurD from S. agalactiae ........ 65
         3.4.5.4 Z prime score of a MESG coupled assay .................................. 65
   3.5 Optimization of existing assay for fragments targeted towards the ATP-binding site. 67
3.5.1 MurD from *S. agalactiae* lacks activity with alternative nucleotides ......................67
3.5.2 MurD as an enzyme lacks activity with alternative nucleotide ..........................69
3.5.3 MurD is unable to hydrolyse alternative nucleotides .....................................70
3.5.4 Deoxy-ATP can act as an alternative nucleotide for MurD ...............................71

3.6 Development of a stop point assay for Mur ligase activity .................................73
3.6.1 EDTA inhibits the MurD reaction within an assay ........................................74
3.6.2 The initial rate of *S. agalactiae* MurD can be determined within a stop point assay 76
3.6.3 Reduction of PNP levels has no significant effect on 

4. Conclusions and Future Direction ........................................................................... 81
4.1 Optimization of biochemical assays required for inhibitory fragment identification 81
4.2 Nucleotide specificity of MurD could act as a starting point for future antibacterial development .................................................................................................................81
4.3 Use of stopped assays for high-throughput screening ........................................82

Chapter 3: Identification of μM inhibitory fragments that can target multiple Mur ligases ................................................................. 83

1. Introduction and Aims .............................................................................................. 84
2. Materials and Methods ............................................................................................ 86
2.1 XChem .....................................................................................................................86
2.2 Stopped MESG assay ............................................................................................86
2.3 Secondary coupling system assay .........................................................................87

3. Results ...................................................................................................................... 88
3.1 XChem of DSI-Poised fragment library against Mur ligases .................................88
3.1.1 Identification of binding pocket within apo MurD from *S. agalactiae* .............88
3.1.2 Production of elaborated fragment screen .........................................................90
3.2 Determination of inhibition of MurD activity by fragments via biochemical assay ....90
3.2.1 Identification of inhibitory fragments targeted against MurD from *S. agalactiae* ..90
3.3 Six fragments cause interference with assay system resulting in false positives........93
3.4 The binding pocket within MurD from *S. agalactiae* is present within MurE from *S. agalactiae* .........................................................................................................................97
3.5 Identification of fragments that can inhibit MurD and MurE from *S. agalactiae* ....98
The binding pocket within MurD from *S. agalactiae* is present within MurE from *P. aeruginosa* .............................................................. 99

Identification of fragments that can inhibit MurE from *S. agalactiae* and MurE from *P. aeruginosa* .............................................................................. 101

Identification of fragments with micromolar IC_{50} against MurD from *S. agalactiae* ................................................................. 103

4. Conclusions and Future Direction .................................................................. 105

4.1 Use of X-Chem for the design of novel inhibitory fragments .................. 105

4.2 Assay interference and its effects on fragment screening ......................... 105

4.3 Development of multi-targeting inhibitors ............................................... 106

4.4 Targeting novel pockets for the development of inhibitory fragments ......... 107

Chapter 4: Identification of inhibitory fragments via in silico screening and biochemical assays ................................................................. 108

1. Introduction and Aims .................................................................................. 109

2. Material and Methods .................................................................................. 110

2.1 Use of Pymol to compare structures and visually inspect fragments .......... 110

2.2 Structural Sequence Alignment ................................................................. 110

2.3 Production of fragment library ................................................................. 110

2.4 *In silico* screen using Glide .................................................................. 111

2.5 Stopped MESG assay ............................................................................. 111

2.6 Assay interference checks ...................................................................... 112

3. Results ........................................................................................................ 113

3.1 The Mur ligases have a high level of similarity within their ATP binding pockets ...... 113

3.2 Determination of kinases inhibitors as a targeted fragment screen .......... 116

3.3 There is a high degree of similarity in interactions formed during ATP binding between the Mur ligases and kinases ................................................................. 118

3.4 Building the fragment library from known kinase inhibitors .................. 119

3.5 Identification of residues to target within the ATP-binding site of the Mur ligases .. 120

3.6 Evaluation of existing PDB files of Mur ligases for use within the Glide software ..... 123

3.7 Use of Glide to identify fragments that have the potential to target the ATP-binding site of MurC and MurD ................................................................. 124

3.8 Evaluation of fragments identified via the screen ........................................ 125

3.8.1 Top hits were determined via their Le score, molecular weight and glidemodel score 125

3.8.2 Fragments existing as tautomers are unlikely to act as inhibitors of the Mur ligases 126

3.8.3 Fragments with flexible middle regions unlikely to form predicted interactions.. 128
3.8.4 Commercial availability of fragments ..................................................129
3.9 High throughput screen of commercially available kinase inhibitory fragments ......130
3.10 Identification of inhibitory fragments targeted against MurD from *S. agalactiae* ....131
3.11 Certain fragments cause interference with assay system resulting in false positives133
3.12 Inhibitory fragments share similar binding features ..................................138
3.13 Identification of dual inhibitory fragments .............................................141

4. Conclusions and Future Direction ..............................................................143
4.1 Targeting the ATP-binding site for antibacterial development .......................143
4.2 Use of *in silico* screens for fragment identification ......................................144
4.3 Role of multi-targeting inhibitors within novel antibacterial compound design ......144

Chapter 5: Identification of multitargeting inhibitors via a fluorometric assay .. 146

1. Introduction and Aims ......................................................................................147

2. Materials and Methods ..................................................................................148
2.1 Amplex Red assay .........................................................................................148
2.2 Amplex Red assay for IC$_{50}$ determination and binding mode determination ....148

3. Results .............................................................................................................150
3.1 Use of an amplex red assay to follow the activity of a Mur ligase .........................150
3.2 Activity of MurE within an amplex red assay is dependent on substrates being present 151
3.3 Amplex red assay is dependent on enzyme concentration ..................................152
3.4 Activity of MurE is dependent on presence of all substrates within a fluorometric amplex red assay .................................................................153
3.5 Fluorometric amplex red assay is sensitive to inhibition via ADPCP ....................154
3.6 Stopped activity assay ....................................................................................155
3.6.1 EDTA is unable to quench the reaction sufficiently .................................155
3.7 Screening of dual inhibitory fragments .........................................................158
3.7.1 Identification of dual inhibitory fragments with micromolar IC$_{50}$ values ..........158
3.7.2 J06.01 potentially binds to the ATP-binding site of Mur ligases ...............160

4. Conclusions and Future Direction .................................................................163
4.1 Conversion of biochemical assays to a high-throughput assays .........................163
4.2 Role of IC$_{50}$ values in the determinations of the efficacy of novel inhibitory fragments 164
4.3 Repurposing old drugs for new purposes .....................................................165

Chapter 6: MurD and MurE from *S. agalactiae* form a binary complex .......... 167
1. Introduction and Aims .................................................................................168

2. Materials and Methods ............................................................................170
   2.1 KEGG Database for Genomic Layouts .................................................170
   2.2 Cloning of MurE ..................................................................................170
      2.2.1 Polymerase Chain Reaction ..........................................................170
      2.2.2 Agarose Gel Electrophoresis .........................................................170
      2.2.3 Extraction of amplified DNA ..........................................................171
      2.2.4 Restriction Digestion .....................................................................171
      2.2.5 Restriction Cloning Ligation .........................................................171
      2.2.6 Transformation of Competent Cells ...............................................171
      2.2.7 Construct Validation .....................................................................172
   2.3 Protein Purification ...............................................................................172
   2.4 Size Exclusion Chromatography ..........................................................172
   2.5 Cleavage of 6x His tag from MurD ......................................................173
   2.6 Microscale Thermophoresis .................................................................173
   2.7 Mass Spectrometry ............................................................................174
   2.8 Activity assay for Mur ligases ..............................................................174
   2.9 Binary Complex Prediction ..................................................................175
      2.9.1 PRISM .........................................................................................175
      2.9.2 HADDOCK 2.4 .............................................................................175
      2.9.3 AlphaFold 2 ..................................................................................175

3. Results .......................................................................................................177
   3.1 The genomic layout of the Mur ligases differs between bacteria ..........177
   3.2 Experimental determination of a MurD-MurE binary complex .............178
   3.3 Purification of MurE from S. agalactiae ...............................................178
   3.4 Size Exclusion Chromatography .........................................................180
      3.4.1 Attempted demonstration of complex formation between MurD and MurE observed within a 1:1 mixture ..........................................................181
   3.5 Microscale Thermophoresis (MST) .......................................................183
      3.5.1 MurD and MurE from S. agalactiae are able to form a binary complex ........185
      3.5.2 The presence of substrates alters the binding and $K_D$ of MurD to MurE ....186
   3.6 pET DUET Expression System ............................................................190
      3.6.1 MurD and MurE can be purified within a complex .........................190
      3.6.2 Presence of MurD and MurE confirmed via Mass spectrometry ..........191
   3.7 Dual expression of MurD and MurE .....................................................193
      3.7.1 MurD is active within a complex ....................................................195
   3.8 Computational modelling of predicted Mur ligase complex ..................196
3.9 Binary complex prediction of the \textit{E. coli} Mur ligases via PRISM..............................................197
3.9.1 Binary complex prediction of the \textit{E. coli} Mur ligases via HADDOCK........................................198
3.10 Production of homology models of the \textit{S. agalactiae} Mur ligases............................................200
3.11 Binary complex prediction of the \textit{S. agalactiae} Mur ligases via HADDOCK.................................202
3.12 Alphafold for binary complex prediction.........................................................................................204
3.12.1 Binary complex prediction of the \textit{S. agalactiae} Mur ligases via Alphafold.................................206
3.13 Alphafold predictions present in only one state ................................................................................211

4. Conclusions and Future Direction .........................................................................................................213
4.1 Formation of a binary complex between the Mur ligases.................................................................213
4.2 Role of substrates within binary complex formation ...........................................................................213
4.3 Complex formation effect on enzyme activity ....................................................................................214
4.4 Role of computational predictions for structure determination.........................................................215

Chapter 7: Discussion and Final Conclusion .............................................................................................217

1. Impact of fragment screening on the development of novel inhibitors .................................................218
2. Role of multi-targeting in inhibitor design ............................................................................................219
3. Role of complex formation of the Mur ligases within the design of inhibitory fragments .....................219
4. Final conclusions .....................................................................................................................................220

Supplementary .............................................................................................................................................222

Bibliography ..............................................................................................................................................248
Table of Figures

Figure 1. 1: A schematic representation of the cytoplasmic, inner membrane and periplasmic steps of the formation of peptidoglycan. .................................................................22
Figure 1. 2: Schematic diagram of the formation of peptidoglycan with antibiotic targets identified 24
Figure 1. 3: Formation of UDP-MurNAc-pentapeptide by the Mur ligases. .........................................27
Figure 1. 4: Schematic diagram of the regulation of the Mur ligase pathway ........................................28
Figure 1. 5: The catalytic mechanism shared by the Mur ligases. ......................................................30
Figure 1. 6: Models of the structures of the four Mur ligases. ..............................................................31
Figure 1. 7: Alignment of the conserved amino acids within Mur ligases. ..........................................34

Figure 2. 1: Construct map of S. agalactiae MurD within pET 28..........................................................46
Figure 2. 2: Activity assay of MurD shows a lack of activity for the MurD clone from S. agalactiae ...51
Figure 2. 3: A point mutation led to the deletion of an alpha helix......................................................52
Figure 2. 4: Purification and activity assay of purified MurD from S. agalactiae .................................53
Figure 2. 5: Diagram to show the coupling reaction during the PK/LDH coupled assay ..................55
Figure 2. 6: Diagram to show the coupling reaction within a MESG coupled assay .........................55
Figure 2. 7: Secondary coupled reaction is reliant on the presence of free phosphate .......................56
Figure 2. 8: MESG coupled reaction is reliant on MurD concentration ............................................57
Figure 2. 9: The activity of MurD relies on the presence of all three substrates .................................58
Figure 2. 10: Ability of assay to identify competitive inhibitors is dependent on Km value ..........61
Figure 2. 11: Kinetic determinations of substrates for MurD from S. agalactiae .............................62
Figure 2. 12: Structures of ATP analogue inhibitors ........................................................................63
Figure 2. 13: ADPNP and ADPCP can act as inhibitors of MurD from S. agalactiae ....................63
Figure 2. 14: ADPCP has an IC50 value of 24.2 µM against MurD from S. agalactiae .....................64
Figure 2. 15: Schematic diagram of the determination of a Z prime score ........................................66
Figure 2. 16: Structural formulas of ATP and alternative nucleotides .............................................68
Figure 2. 17: MurD from S. agalactiae lacks activity in the presence of alternative nucleotides ......68
Figure 2. 18: MurD as an enzyme lacks activity with alternative nucleotides .....................................69
Figure 2. 19: MurD lacks the ability to hydrolyse alternative nucleotides .........................................70
Figure 2. 20: Skeletal formula of ATP and Deoxy-ATP ....................................................................71
Figure 2. 21: MurD can use deoxy-ATP as an alternative nucleotide ...............................................71
Figure 2. 22: The Km for deoxy-ATP for MurD from S. agalactiae is 477 µM ....................................72
Figure 2. 23: Diagram to compare the set-up of a MESG coupled assay and a stopped MESG assay .73
Figure 2. 24: EDTA is able to stop activity of MurD from S. agalactiae ............................................75
Figure 2. 25: EDTA does not affect the secondary coupling system ...............................................76
Figure 2. 26: Comparison of the measurable V0 of MurD between a MESG coupled assay and a stop point assay ..................................................................................................................77
Figure 2.27: Reducing PNP concentration causes no significant effect on $V_0$ of MurD from S. agalactiae .......................................................... 78

Figure 2.28: ADPCP can act as an inhibitor of MurD within a stop point assay .................................. 79

Figure 2.29: ADPCP has an $IC_{50}$ value of 22.8 $\mu$M against MurD from S. agalactiae within a stop point assay ................................................................. 79

Figure 3.1: Structural formula of four hits from the DSI-poised fragment library identified to bind to MurD from S. agalactiae ................................................................. 88

Figure 3.2: Four fragments were identified to bind within a pocket adjacent to the ATP-binding site ................................................................. 89

Figure 3.3: Activity of MurD in the presence of elaborated fragments ................................................. 91

Figure 3.4: Eighteen fragments produced rates outside standard range ........................................... 92

Figure 3.5: Eleven fragments can act as inhibitors of MurD .......................................................... 93

Figure 3.6: Fragments 758, 786 and 796 show interference with the assay components ............... 94

Figure 3.7: Fragments 773 and 796 show interference with phosphate ........................................ 95

Figure 3.8: Fragments 755 and 786 show interference with PNP .................................................. 96

Figure 3.9: Alignment of binding pocket within MurD to MurE from S. agalactiae ....................... 97

Figure 3.10: Four fragments can act as inhibitors of MurE from S. agalactiae .............................. 99

Figure 3.11: Alignment of binding pocket within MurD to MurE from P. aeruginosa .................. 100

Figure 3.12: Lack of inhibition by fragments against MurE from P. aeruginosa ......................... 102

Figure 3.13: Comparison of activity of ligases in the presence of fragments ............................. 103

Figure 3.14: Dose response curves for inhibitory fragments against MurD from S. agalactiae .... 104

Figure 4.1: Pymol diagrams to show the high level of similarity within the ATP binding pocket of various Mur ligases ................................................................. 114

Figure 4.2: Sequence similarity between the Mur ligases is present within the ATP-binding site .... 115

Figure 4.3: Structural alignment of Mur ligases to kinases .......................................................... 117

Figure 4.4: ATP forms similar interactions with residues present in the Mur ligases and kinases .... 118

Figure 4.5: Fragments were designed based on existing kinase inhibitors .................................... 120

Figure 4.6: Asn271 forms a hydrogen bond with the NH$_2$ group of the adenosine ring ............... 121

Figure 4.7: The Asparagine that forms a hydrogen bond with ATP is well conserved across Mur ligases and bacterial species ................................................................. 121

Figure 4.8: The Lysine that forms a hydrogen bond with ATP is well conserved across Mur ligases and bacterial species ................................................................. 122

Figure 4.9: Fragments existing as tautomers were unlikely to act as inhibitors .......................... 127

Figure 4.10: Fragments with flexible middle regions were unlikely to act as inhibitors ............. 128

Figure 4.11: Comparison of fragments to identify similar regions ............................................... 129

Figure 4.12: Activity of MurD in the presence of Enamine fragments ............................................. 131
Figure 6.16: Activity of proteins within a complex was identified via an amplex red assay
Figure 6.17: Structural diagrams to show the interaction areas between pairs of Mur ligases
Figure 6.18: Homology models of the Mur ligase from S. agalactiae
Figure 6.19: Structural diagrams to show the interaction areas between pairs of Mur ligases from S. agalactiae using HADDOCK
Figure 6.20: Alphafold prediction of the HisF-HisH binary complex
Figure 6.21: Alphafold predicted binary complex between MurC and MurD from S. agalactiae
Figure 6.22: Alphafold predicted binary complex formation between MurD and MurE
Figure 6.23: Alphafold predicted binary complex formation between MurE and MurF
Figure 6.24: Alphafold predicts the MurT/GatD complex in a different conformational state to known complex

Table of Tables

Table 2.1: Composition of media
Table 2.2: Composition of buffers
Table 2.3: Kinetic parameters for substrates against MurD from S. agalactiae
Table 2.4: Determination of the Z prime score for ADPCP within a MESG coupled assay against MurD from S. agalactiae
Table 2.5: Kinetic determinations for deoxy-ATP for MurD from S. agalactiae
Table 2.6: Z prime score determination within a stopped assay

Table 4.1: A consensus sequence is well conserved across the 4 Mur ligases as well as across bacterial species
Table 4.2: Potential PDB files that could be used within the in silico screen
Table 4.3: Skeletal structures of inhibitory fragments

Table 5.1: Determination of the Z prime score for ADPCP within an amplex red assay against MurE from S. agalactiae

Table 6.1: PRISM top hit score for binary complex formation amongst the E. coli Mur ligases
Table 6.2: HADDOCK top hits for binary complex formation between the Mur ligases from E. coli
Table 6.3: HADDOCK top hits for binary complex formation between the Mur ligases from S. agalactiae
Acknowledgments

I would like to thank my supervisors Prof. Chris Dowson and Dr. Allister Crow for their guidance, support and patience during my PhD and allowing me to freely explore ideas and new techniques. I would also like to thank Dr. Joe Eyermann and his lab for allowing me to spend some time in his lab and providing his guidance and chemistry knowledge to the project. I would like to thank Frank von Delft for providing the funding to pursue inhibitor screens, and Prof. Matthew Todd, Dr. Dana Klug and their team at UCL for working with us to screen potential inhibitory fragments.

Particular thanks goes to those individuals who have helped develop my skills and knowledge over the course of my PhD. This includes Dr. Adrian Lloyd for his advice and guidance throughout my PhD in matters of microbiological and enzymology, and Dr Jonathan Cook who provided guidance and support for DNA cloning. Further thanks go to Sarah Bennet and WISB for allowing me to use their facilities as an external user. I would also like to acknowledge the help of the Media Preparation Facility in The School of Life Sciences at the University of Warwick for the supply of all media and selected buffers during the course of this thesis.

I would also like to thank all members of C10 and IBRB 2.17 past and present for their support, advice and friendship throughout my PhD.

Special thanks goes to my family, who have supported my love and passion for science over the years, and to my partner, Nic, who was always there throughout all the long days and stressful moments, and without who I couldn’t have completed this thesis.
Declaration

I hereby declare that I personally have carried out the work submitted in this thesis under the supervision of Prof. Chris Dowson (School of Life Sciences) and Dr. Allister Crow (School of Life Sciences) at the University of Warwick and Dr. Joe Eyermann at the Department of Chemistry, University of Cape Town, South Africa. Where work has been contributed to by other individuals, it is specifically stated in the text. This project was completed as part of the open-source Mur ligase project.

No part of this work has previously been submitted to be considered for a degree or qualification. All sources of information are specifically acknowledged in the form of references.
Abstract

*Streptococcus agalactiae* is the leading cause of early onset neonatal sepsis, and with antibacterial resistance within *S. agalactiae* increasing, it is imperative that new antibacterial drugs are identified. Proteins involved in peptidoglycan formation are an attractive target for the development of novel antibacterial drugs. The Mur ligases form part of the cytosolic stages of peptidoglycan formation, and are responsible for the stepwise addition of amino acids that constructs the peptide component of the peptidoglycan. Due to their similar catalytic mechanism and three domain structure, the Mur ligases are a promising target for the development of new antibacterial compounds.

This project has focused on identifying multi-targeting inhibitory fragments that are able to target MurD and MurE from *S. agalactiae*. To achieve this, biochemical assays have been developed and optimized for high throughput screening of competitive inhibitory fragments targeted towards the Mur ligases. A targeted fragment screen was then developed using *in silico* screening to allow the repurposing of existing protein kinase inhibitors to target the ATP-binding site of the Mur ligases. Screening of potential inhibitory fragments was carried out, allowing the identification of multi-targeting inhibitory fragments. Previous studies have suggested that there may be complex formation amongst the Mur ligases. The ability of MurD and MurE from *S. agalactiae* to form a binary complex was investigated using a range of cloning and expressing systems, and biophysical techniques including Microscale Thermophoresis before possible structural arrangements were predicted using computational techniques.

It is anticipated that the multi-targeting inhibitors identified via the optimized assays within this work, alongside our better understanding of complex formation amongst the Mur ligases, may be used for the development of effective Mur ligases inhibitors in the future and new potential therapeutic approaches to the treatment of bacterial infection.
Abbreviations

Abbreviations used within this thesis follow the nomenclature laid out for authors by the Journal of Biological Chemistry. Any non-standard abbreviations are listed below.

ADPCP  \( \beta,\gamma \)-Methyleneadenosine 5’-triphosphate
ADPNP  Adenosine 5’-(\( \beta,\gamma \)-imido)triphosphate
AUC    Analytical UltraCentrifugation
EOS    Early Onset Sepsis
HRP    Horse radish peroxidase
IMAC   Immobilized metal-ion affinity chromatography
LOS    Late Onset Sepsis
MESG   7 methyl 6 thio guanosine
MRSA   Methicillin-resistant Staphylococcus aureus
MurNAc N-Acetylmuramic acid
MSA    Multiple Sequence Alignment
MST    Microscale Thermophoresis
PEP    Phosphoenolpyruvate
PK/LDH Pyruvate Kinase/Lactate Dehydrogenase
PNP    Purine nucleoside phosphorylase
SEC    Size Exclusion Chromatography
SEDS   Shape, Elongation, Division and Sporulation
SPR    Surface Plasmon Resonance
STPK   Serine-threonine protein kinases
TAE    Tris Acetate EDTA
Chapter 1

Thesis Introduction
1.1 Streptococcus agalactiae

*Streptococcus agalactiae* (*S. agalactiae*), also referred to as Group B streptococcus, is a Gram positive coccus. *S. agalactiae* was first differentiated from other streptococci in the 1930s with human pathogenicity identified in 1938. Since the 1960s there have been increasing reports of invasive *S. agalactiae* infections, with *S. agalactiae* infections being a leading cause of neonatal infections; being responsible for pneumonia, septicaemia and meningitis. *S. agalactiae* can also be a cause of mortality for immunocompromised adults and the elderly.

1.1.1 Polysaccharide capsule

The capsule of *S. agalactiae* is an important virulence factor. Due to different polysaccharide structures, nine different *S. agalactiae* serotypes have been identified. Serotype Ia, Ib, II, III and V are responsible for the majority of invasive human disease, with serotype III being responsible for the majority of neonatal infection cases. The capsule provides protection for the bacteria preventing clearance from the host immune system via processes such as complement deposition and phagocytosis.

1.2 *S. agalactiae* infection in adults

*S. agalactiae* is a leading cause of early onset neonatal infection, with most cases arising due to the mother infecting the child with the bacteria during childbirth. Most mothers are asymptomatic carriers, with few developing symptoms of their own. However, a recent trend has started to emerge with a shift in more disease within nonpregnant adults due to *S. agalactiae* infection. Within the UK, incidence rates of invasive *S. agalactiae* infection within nonpregnant adults trebled between 1996 and 2010, with a incidence rate of 2.9/100 000 population in 2015/2016. *S. agalactiae* infection within adults is predominately seen within the ageing population or within adults with underlying health conditions, especially those who have *diabetes mellitus*. *S. agalactiae* infection
within adults can lead to a multitude of clinical manifestations, including pneumonia, soft-tissue infection, septicaemia and meningitis.

1.3 Neonatal sepsis

*S. agalactiae* is one of the leading causes of early onset neonatal sepsis. Sepsis occurs when an infection spreads throughout the body, and the immune response results in systemic inflammation of tissues and organs. This spread of infection can be lethal, especially to neonates who have a reduced immune system to fight off the infection. Neonatal sepsis is defined as sepsis occurring within the first 28 days of life. However, neonatal sepsis is normally defined as either early onset sepsis (EOS) or late onset sepsis (LOS) depending on when infection occurs within those 28 days. EOS is usually defined as infection occurring within the first 72 hours of life, however this can be extended up to a week in some studies and hospitals. LOS is defined as infection occurring after 72 hours or a week of life. This distinction is important, as EOS and LOS are usually caused by different bacteria, with EOS being caused by bacteria transmitted via the mother or during birth, whereas LOS bacteria are community acquired.

1.3.1 Incidence of EOS

The incidence rate of neonatal sepsis worldwide is roughly 2.5 cases per 1000 live births. Estimates of the incidence of EOS and LOS differ due to the different mechanisms of infection. EOS has a worldwide incidence rate of roughly 0.75 cases per 1000 live births, with most countries showing similar figures. True incidence rates for EOS are hard to determine due to the fact that many studies have different criteria for whether a birth is included in the values, especially in areas where most births take place within the community, but only hospital births are included in the numbers.

1.3.2 Mortality rate

It is estimated that worldwide, 36% of neonatal deaths are due to invasive neonatal infections. Determining true mortality rates for EOS is tricky due to the
same issues that arise from trying to determine true incidence rates. Estimated mortality rates for EOS in Europe is 13%, with a similar rate being seen in the USA. Oceania and Africa show slightly higher estimated mortality rates of 16% and 17.2% respectively. The mortality rate of EOS in Asia is harder to determine, with rates between 10.4% and 34.4% being given.

1.4 Antibiotic treatment and emergence of antibiotic resistance

Typically within the UK, when neonatal sepsis has been identified, therapy is commenced before a causative organism is identified. This means that the common treatment plan is antibiotic intervention. Commonly therapeutic intervention for EOS within the UK consists of empiric antibiotic combinations. The first line therapy within the UK consists of the antibiotic combination of 50 mg/kg/dose amoxicillin with 50 mg/kg/dose cefotaxime if MRSA is not suspected. If MRSA is suspected or the first line therapy is not an option then an antibiotic combination of 50 mg/kg cefotaxime with 15 mg/kg vancomycin is given. The majority of EOS pathogens that are responsible for neonatal sepsis within the UK are susceptible to the most commonly used antibacterial combinations. Cefotaxime shows a susceptibility rate of 98%, while amoxicillin and cefotaxime shows a susceptibility rate of 95%. Amoxicillin and gentamicin, another antibiotic combination commonly used to treat EOS within the UK, shows a susceptibility rate of 96%.

Cefotaxime and amoxicillin currently have breakpoints of 0.25 mg/L against S. agalactiae, allowing them to still be considered as effective treatments for EOS. When S. agalactiae infection is identified within adults, a similar antibiotic treatment is considered with penicillin being the first line treatment. Other beta-lactam antibiotics are also considered such as ampicillin, cephalosporins and carbapenems.

However, antibiotic resistance is becoming a problem for treating S. agalactiae. Within the USA, 46% of S. agalactiae isolates within a study were found to be resistant to erythromycin, and 20% were resistant to clindamycin. Within Asia, erythromycin resistance and clindamycin resistance within S. agalactiae is estimated to be 40%. Within Europe, 18% of S. agalactiae appear to be erythromycin resistant, and 16% resistant to clindamycin. Within the UK, 15%
of invasive *S. agalactiae* infections in 2010 were resistant to erythromycin. Erythromycin currently has a breakpoint of 0.5 mg/L against *S. agalactiae*, allowing it to still be considered as a possible treatment for *S. agalactiae* infection. However, vancomycin currently has a breakpoint of 2 mg/L against *S. agalactiae*, while clindamycin currently has a breakpoint of 1 mg/L against *S. agalactiae*. These breakpoints indicate that these antibiotics are becoming less effective for treatment of *S. agalactiae* infection. These increasing rates of antibiotic resistance make it essential that new antibiotics are developed to tackle *S. agalactiae* infections. One way of doing this is to develop new molecules that are able to effectively target bacterial components, such as the proteins involved in peptidoglycan formation.

### 1.5 Peptidoglycan

Peptidoglycan is an essential component of bacterial cell walls. Peptidoglycan used to be thought of as an inert structure surrounding bacterial cells but has been found to be a highly complex macromolecule that is dynamic and constantly being remodelled. Peptidoglycan consists of the simple building blocks of GlcNAc and MurNAc pentapeptide, with glycan chains being built of alternating units of these two-building blocks. These linear glycan chains then become interlinked by short peptides. This interlinking between the chains creates a macromolecular mesh which has a high tensile strength and rigidity. This strength and rigidity help maintain the structural integrity of the bacterial cell wall. The bacterial cell wall is essential for bacterial survival via its ability to help maintain bacterial cell shape as well as offer mechanical resistance and insulation from differences in osmotic pressure.

### 1.5.1 Formation

Peptidoglycan formation is a multistep process that occurs within the cytoplasm, inner membrane and periplasm of a bacterial cell as seen in Figure 1.1. It begins with the formation of UDP-GlcNAc. UDP-GlcNAc is formed from fructose-6-phosphate via a four step process which is catalysed via GlmS, GlmM and GlmU.
UDP-GlcNAc is then converted to UDP-MurNAc via two enzymes; MurA and MurB. MurA is a transferase enzyme which transfers an enolpyruvate from phosphoenolpyruvate onto UDP-GlcNAc. MurB acts as a reductase enzyme by reducing the enolpyruvate moiety to a D-lactoyl. After the UDP-MurNAc component has been formed, a stepwise addition of amino acids occurs. This is carried out by four Mur ligases, resulting in the formation of the UDP-MurNAc pentapeptide.

Within the cytoplasm, UDP-GlcNAc is converted to UDP-MurNAc via MurA and MurB. UDP-MurNAc passes through four Mur ligases to form UDP-MurNAc-pentapeptide. MraY and MurG then generate Lipid I and Lipid II which is then flipped to the periplasmic space. Within the periplasmic space penicillin binding proteins polymerise Lipid II into long glycan chains. Image generated via Biorender.

Phospho-MurNAc pentapeptide is then transferred to undecaprenyl phosphate by MraY, a membrane bound protein, to form undecaprenyl
pyrophosphoryl MurNAc pentapeptide (Lipid I). MurG than generates Lipid II via the addition of N-acetylgualcosamine to the C-4 position of the MurNAc sugar ring of Lipid I generating undecaprenyl pyrophosphoryl MurNAc (GlcNAc) pentapeptide. At this point in Streptococcus the stem peptide C-1 glutamate is amidated via the enzyme complex MurT/GatD \(^2\), and the stem peptide is branched by the construction of a serine-alanine or alanine-alanine dipeptide to the \(\varepsilon\) -amino group of the stem peptide lysine via MurM and MurN \(^2\). This is then flipped to the periplasm through the actions of the flipase, MurJ \(^2\), and the stem peptide is branched by the construction of a serine-alanine or alanine-alanine dipeptide to the \(\varepsilon\) -amino group of the stem peptide lysine via MurM and MurN \(^2\). This is then flipped to the periplasm through the actions of the flipase, MurJ \(^2\). Polymerisation of these Lipid II monomers then occurs via transglycosylation in reactions catalysed by either bifunctional penicillin binding proteins or SEDS \(^2\) proteins. Penicillin binding proteins are also responsible for the transpeptidation that allows cross linking of the glycan strands to occur. The formation of peptidoglycan occurs in the overwhelming majority of bacteria\(^3\), although the thickness of the peptidoglycan layers varies. Gram negative bacteria have a peptidoglycan layer between 3-6 nm while Gram positive bacteria possess a peptidoglycan layer with a thickness of between 10-20 nm, with a greater level of cross-linking \(^2\).  

### 1.5.2 Antibiotic targets and current antibiotics

Peptidoglycan is absent in higher eukaryotes \(^3\), making it an attractive target for antibacterial agents \(^2\). Many antibiotics exist which are able to target and interfere with the correct biosynthesis and assembly of peptidoglycan, as seen in Figure 1.2. There are two main antibiotics that are able to target the cytoplasmic stages of peptidoglycan formation. Fosfomycin is able to mimic the substrate phosphoenolpyruvate and bind in its place to MurA thereby inhibiting the first Mur enzyme involved in peptidoglycan formation. Fosfomycin is able to bind to MurA via a thioether bond to the key residue Cys115 thereby inhibiting the first committed step of peptidoglycan synthesis. Fosfomycin is a broad spectrum bactericidal antibiotic, and is highly effective against Gram-positive pathogens \(^3\). The other antibiotic targets the D-Ala-D-Ala ligase and the D-Ala racemase. Inhibition of these enzymes starves the bacteria of D-Ala, preventing the
biosynthesis of peptidoglycan. D-cycloserine is an example of such an inhibitor, which acts as a reversible competitive inhibitor, acting as a suicide substrate\textsuperscript{25,33}.

Antibacterial compounds also exist which are able to target the membrane associated stages of peptidoglycan formation. There are a number of naturally occurring inhibitors that are able to act against MraY, such as tunicamycin. However, there is a lack of specificity within these inhibitors due to the structural similarity between MraY and human GlcNAc-1-phosphate transferases, allowing the inhibitors to act against both, preventing it from being used as an antibiotic \textsuperscript{34}.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{peptidoglycan_diagram.png}
\caption{Schematic diagram of the formation of peptidoglycan with antibiotic targets identified}
\end{figure}

Many antibacterial compounds exist which can target and interfere with the correct biosynthesis and assembly of peptidoglycan. Antibacterial compounds are shown here at the stage of formation that they inhibit. Antibacterial compounds used to treat human pathogens are shown in red. Antibacterial compounds in development or not in use against human pathogens are shown in orange. Image generated via Biorender.
Three classes of antibacterial compounds exist which are able to target Lipid II; mannopeptimycins, lantibiotics, and glycopeptide antibiotics. Mannopeptimycins are characterised by a cyclic ring structure formed of six amino acids in alternating D- and L- configurations, and bind to Lipid II, sequestering it preventing bacterial cell wall synthesis.\(^{35,36}\)

Lantibiotics contain the rare thioether amino acids of lanthionine and/or 3-methyllanthionine and are split into two types dependent on their mode of action and structure. Type A lantibiotics are able to form pores in the cytoplasmic membrane of bacteria, allowing for the rapid efflux of small metabolites from the cell, leading to cell death. Nisin, a Type A lantibiotic, uses Lipid II as a docking molecule to be able to bind to the bacterial membrane to aid in the formation of pores.\(^{37}\) Type B lantibiotics comprise of rigid, globular peptides that either have no net charge or a net negative charge. Mersacidin, a Type B lantibiotic, is able to bind to Lipid II and inhibit cell wall biosynthesis.\(^{38,39}\)

Glycopeptide antibiotics are glycosylated non-ribosomal peptides with unique tricyclic or tetracyclic heptapeptide cores. The heptapeptide backbone of the glycopeptide generally binds to the C-terminal L-Lys-D-Ala-D-Ala of Lipid II inhibiting the transglycosylation step of peptidoglycan formation, as with vancomycin.\(^{40}\) Other glycopeptide antibacterial compounds, such as ramoplanin, potentially target the disaccharide head group of Lipid II.\(^{41}\) Targeting Lipid II leads to a weakened cell wall, and subsequently the cell undergoes cytolysis and cell death.\(^{42,43}\)

Moenomycin antibacterial compounds are able to target the transglycosylation stage of peptidoglycan formation. Moenomycins interact with the transmembrane domain of PBPs to prevent the transglycosylation of Lipid II.\(^{44}\) Moenomycins are potent antibacterials, with minimum inhibitory concentrations ranging from 1 ng/mL to 100 ng/L. Currently the only moenomycin in use is Flavomycin, which is used within animal feed.\(^{45}\)

Antibiotics that target the penicillin binding proteins are some of the most widely used antibiotic agents. β-lactams inhibit bacterial cell wall synthesis by binding to penicillin binding proteins, leading to acylation of the active site serine of these enzymes thereby preventing their transpeptidase activity.\(^{46}\) β-lactams have a ring structure that mimics the D-Ala-D-Ala moiety of the pentapeptide terminal
allowing them to act as substrate for the enzyme during the acylation phase of cross-link formation, preventing peptide bond formation and cross-linking from occurring \(^{47}\).

One step of peptidoglycan formation with virtually no targeted antibiotics is the stepwise addition of amino acids onto the UDP-MurNAc component which is controlled by the Mur ligases.

### 1.6 Mur Ligases

#### 1.6.1 Role within peptidoglycan formation

Within the cytoplasmic steps of peptidoglycan formation, the stepwise addition of amino acids onto UDP-MurNAc occurs through the actions of the Mur enzymes as seen in Figure 1.3. There are four Mur enzymes; MurC, MurD, MurE and MurF, which are all ATP-dependent amino acid ligases \(^{25}\).

MurC is the first ligase in the pathway and is responsible for the addition of the first amino acid onto the newly formed UDP-MurNAc. MurC adds L-Ala to UDP-MurNAc generating UDP-MurNAc-L-Ala. MurD, the second ligase in the pathway, catalyses formation of a peptide bond formation between the \(\alpha\)-amino group of D-Glu and the \(\alpha\)-carboxyl of the L-alanyl moiety of UDP-MurNAc-L-Ala-D-Glu yielding UDP-MurNAc-L-Ala-D-Glu.

MurE is the only Mur ligase which has a substrate specificity that differs between bacteria. Typically, MurE catalyses the addition of meso-diaminopimelic (DAP) to the \(\gamma\)-glutamyl carboxyl of UDP-MurNAc-L-Ala-D-Glu within Gram negative bacteria, Gram positive bacillus and mycobacteria. Within Gram positive bacteria, MurE catalyses the addition of L-Lys to UDP-MurNAc-L-Ala-D-Glu. The addition of this amino acid is very important for the survival of the bacteria, as the third residue is involved in the cross-linking of the peptidoglycan macromolecule, and any ‘wrong’ addition would result in cell lysis \(^{48}\).

MurF is the final Mur ligase and catalyses the addition of a dipeptide composed of D-amino acids, generating the final peptidoglycan precursor of UDP-MurNAc-pentapeptide. This addition of a dipeptide is crucial for peptidoglycan formation as the dipeptide bond provides the energy required for glycan strand
cross linking within the periplasm, where there is no ATP. Generally, MurF catalyses the addition of D-Ala-D-Ala, however, MurF is able to catalyse the addition of many dipeptide substrates in the D conformation such as D-Ala-D-Lac. The ability to catalyse the addition of various dipeptide substrates is crucial for high-level resistance to vancomycin which is specific in its recognition of the D-alanyl-D-alanine of peptidoglycan precursors. Substitution of this dipeptide with D-alanyl-D-lactate furnishes peptidoglycan precursors that are not recognised by vancomycin, leading to clinically significant resistance to this antibiotic.

Figure 1. 3: Formation of UDP-MurNAc-pentapeptide by the Mur ligases.
MurC is the initial enzyme which converts UDP-MurNAc to UDP-MurNAc-L-Ala via the addition of L-Ala. MurD then adds D-Glu to the moiety. MurE then either ligates mA2pm or L-Lys before MurF catalyses the final addition of D-Ala-D-Ala.
1.6.2 Regulation of the Mur ligase pathway

The activity of the Mur ligases, and overall peptidoglycan formation is subject to regulation within the bacterial cell. As can be seen from Figure 1.4, substrates and products within the Mur ligase stages of peptidoglycan formation can act as inhibitors of the enzymes involved, leading to a regulation of the formation of peptidoglycan.

![Figure 1.4: Schematic diagram of the regulation of the Mur ligase pathway](image)

Within peptidoglycan formation, the Mur ligase steps are subject to regulation. Various substrates and products act as inhibitors of enzymes within the pathway, leading to negative feedback loops and regulation of the activity of the enzymes. Routes of inhibition are shown in red. Predicted inhibition are shown in dashes. Image generated via biorender.

The activity of MurA is regulated via a negative feedback loop of the product of MurB, UDP-Mur-NAc. An accumulation of this product of MurB causes inhibition of the activity of MurA, potentially via binding within the active site of MurA. UDP-Mur-NAc is able to act as an inhibitor of both MurA substrates, PEP and UDP-GlcNAc, although the method of inhibition is still unknown. This level of regulation may prevent unwarranted peptidoglycan formation as MurA acts as the
first committed step of peptidoglycan formation. This level of regulation can be exploited via antibiotics that target MurC as inhibition of MurC could cause a build-up of its substrate UDP-MurNAc, allowing for secondary inhibition of MurA.

The activity of MurB is regulated via its own substrates, UDP-GlcNAc-enolpyruvate and NADPH. UDP-GlcNAc-EP can act as a strong competitive substrate inhibitor of MurB, while NADPH acts as a weak competitive substrate inhibitor. Inhibition via NADPH and UDP-GlcNAc-EP appears to be pH-dependent, with UDP-GlcNAc-EP exhibiting less inhibition as the pH becomes more basic, while inhibition via NADPH becomes more pronounced as the pH becomes more basic. This regulation may allow an antibiotic that binds in a similar fashion to UDP-GlcNAc-EP or NADPH to be used as an inhibitor of the activity of MurB.

Within peptidoglycan formation, the Mur ligases activity can be regulated via their own respective UDP-MurNAc substrates. Within gram negative bacteria, UDP-MurNAc-L-Ala is able to act as a substrate inhibitor of MurD. UDP-MurNAc-L-Ala-D-Glu can act as a substrate inhibitor of MurE, while UDP-MurNAc-L-Ala-D-Glu-L-Lys/DAP can act as a substrate inhibitor of MurF. MurD activity can also be regulated either via its own UDP-MurNAc product, UDP-MurNAc-L-Ala-D-Glu, or via the final product of the Mur ligase pathway, UDP-MurNAc-pentapeptide. Substrate inhibition can be exploited within antibiotic development via the development of compounds that target the UDP-MurNAc binding site.

Serine-threonine protein kinases (STPKs) are responsible for the phosphorylation of multiple bacterial proteins resulting in the regulation of various bacterial systems. STPKs have been found to interact with all the Mur ligases. The STPK PknA, has been found to cause the phosphorylation of MurC in vitro resulting in a decrease in the activity of MurC. Phosphorylation of the Mur ligases represents a key mechanism in the regulation of peptidoglycan formation, and a key mechanism for antibiotic design. Development of a compound that can interact with the residues that undergo phosphorylation could reduce activity of the Mur ligases.
1.6.3 Mechanism of action

Mur ligases all have similar catalytic mechanisms which rely on the conversion of ATP to ADP and inorganic phosphate. The breaking of the phosphate bond provides the energy required to catalyse the ligation of amino acids onto a growing peptide chain. A set binding order is followed, beginning with ATP, followed by the uridine nucleotide substrate and ending with the amino acid or dipeptide\textsuperscript{57,58}. The reaction follows an ordered kinetic mechanism, beginning with the activation by phosphorylation of the carboxyl group of the nucleotide via ATP as seen in Figure 1.5.

![Catalytic Mechanism Diagram]

*Figure 1.5: The catalytic mechanism shared by the Mur ligases.*

Catalysis requires juxtaposition of two Mg\textsuperscript{2+} ions, one located between the β- and γ- phosphate groups of ATP, the other between ADP and the uridine nucleotide substrate to bridge the negatively charged groups of ATP and the uridine nucleotide substrate\textsuperscript{58}. The Mg\textsuperscript{2+} polarizes the γ-phosphate-oxygen bond of ATP, increasing its reactivity to nucleophilic attack by the carboxyl of the UDP-MurNAc precursor. This leads to phosphorylation of the UDP MurNAc carboxylate group to form an acyl-phosphate intermediate. Subsequently, an S\textsubscript{n}2 nucleophilic attack by the amino group of the condensing amino acid or dipeptide then occurs, resulting in the formation of a peptide bond and a tetrahedral transition state which collapses on expulsion of the phosphate to form the lengthened peptide for the next stage of peptidoglycan intermediate formation\textsuperscript{58}.
1.6.4 Structure of the Mur ligases

The four Mur ligases all share a similar three domain structure, with each Mur ligase comprising of a N-terminal domain, central domain and C-terminal domain, with an active structure being present at the common domain interface as seen in Figure 1.6.

Figure 1.6: Models of the structures of the four Mur ligases.

The Mur ligases all have a similar three domain structure as seen here. The N-terminal domain is seen in blue, the central domain in green and the C-terminal domain in red. Structures shown are *E. coli* proteins. MurC (PDB: 2F00), MurD (PDB: 1E0D), MurE (PDB: 7B53), MurF (PDB: 1GG4).

The N-terminal domain is responsible for the binding of the uridine nucleotide substrate. For the *Escherichia coli* (E. coli) Mur ligases, the N-terminal
consists of a five-stranded parallel β-sheet which is surrounded by α helices; two in MurE, three in MurF and four in MurC and MurD \(^{60,61,62,63}\). The N-terminal of MurC and MurD is reminiscent of the Rossmann dinucleotide-binding fold. Within MurC and MurD there are two hydrophobic loops and a diphosphate-binding pocket with a glycine-rich dinucleotide loop which forms a cleft which the UDP moiety of the uridine nucleotide substrate can bind within. The ribose hydroxyl groups, and uracil ring of the nucleotide substrate are anchored to the N-terminal domain via hydrogen bonding while the lactyl side-chain is able to extend towards the catalytic centre of the ligase, and interact with a Mg\(^{2+}\) ion \(^{63,64}\). To accommodate the longer substrate, MurE and MurF bind the nucleotide substrate in an alternate manner. The diphosphate moiety of the UDP forms four hydrogen bonds with a long loop that extends towards the C-terminal. The uracil ring of the UDP also binds via hydrogen bonding within the N-terminal \(^{60,61}\).

The central domain is responsible for the binding of ATP. Within MurD, MurE and MurF it consists of a six-stranded parallel β sheet, while in MurC this is a seven-stranded β sheet. The β sheet is surrounded by α helices; four in MurC, seven in MurD and MurE and eight in MurF. The domain is also flanked by a smaller antiparallel three-stranded β sheet \(^{58,60,61,62,63}\). The central domain contains a Glu and His residue that are important for the co-ordination of the Mg\(^{2+}\) ions that the UDP moiety binds to \(^{64}\).

The final domain is the C-terminal where the amino acid substrate binds. This domain contains a Rossman dinucleotide-binding fold and consists of a six-stranded β sheet with five parallel and one anti-parallel β strands, and is surrounded by five α helices \(^{60,61,62,63}\). The C-terminal domain contains a loop that becomes inserted into the active site allowing for correct orientation of the amino acid. Within the C-terminal domain there is a well conserved Arg residue that interacts with the amino acid and the α-phosphate of ATP, with the C-terminal domain playing a critical role in the capping of the ATP-binding site \(^{58,59,62}\).
1.6.5 Conformational change

The Mur ligases undergo a conformational change from an ‘open’ substrate free structure to a ‘closed’ structure once substrates have bound. This ‘closed’ structure is also sometimes referred to as the ‘active’ conformation as it is only in this position that the amide bond formation can occur. During the conformational change the C-terminal domain undergoes a rigid body rotation allowing it to be brought towards the N-terminal and central domain. The capping of ATP by the C-terminal domain appears to induce this conformational change, and allows for the binding of the nucleotide substrate. A final rotation of the C-terminal domain then causes the enzyme to enter its active ‘closed’ conformation 63.

Due to their longer nucleotide substrates, MurE and MurF have to undergo a more pronounced domain rotation allowing for a wider interdomain cleft for the substrate to bind to 63. These enzymes position the nucleotide substrate further from the active site allowing the peptide tail to fold up against the central domain. The ATP and nucleotide substrate are then brought together into the correct orientation to form the acyl-phosphate intermediate. The amino acid substrate is then bound, and correctly orientated allowing for the nucleophilic attack to occur. This then results in the stabilization of the tetrahedral transition state, lowering the activation barrier and accelerating catalysis 58–61,63.

It has been suggested that there is a requirement that ATP is bound to the Mur ligase in order to initiate the domain movement 65. However, a study carried out by Sink et al suggests that domain movement may be dependent on more than just the binding of ligands 66. Within this study, an intermediate conformation of MurD was identified in the absence and presence of ligands. The importance of the carbamoylation of Lys198 in MurD was considered a reason why the conformational change did not occur upon the binding of the ligands. Within their ligand bound structure, Lys198 was not carbamoylated, but within previously identified closed structures, Lys198 was carbamoylated, thus presenting a reason why a closed conformation was not observed 66. Residue 198 plays an important role within the Mur ligases as it helps to stabilize Mg$^{2+}$, which is essential for the correct binding of ligands and enzymatic activity of the Mur ligases. This study
presents the idea that the conformational change that the Mur ligases undergo may contain more transition states than previously thought, and so further experimentation is required to fully understand the conformational change that occurs within the Mur ligases.

### 1.6.6 Conservation of Mur ligases

The Mur ligases have a similar three domain structure, undergo similar conformational changes, and follow the same binding order and mechanism of action. This level of similarity could be due to the high level of homology between the residues found within certain regions of the Mur ligases. Around 10-20% of the primary sequence of the Mur ligases is identical, with four regions of homology being described as critical for activity; Region I contains the nucleotide binding motif involved in ATP binding, region II is an extended domain in the middle of the protein, region III contains a dyad of acidic residues, and region IV is a patch of hydrophobic residues. These domains are highlighted in the sequences in Figure 1.7.

![Figure 1.7: Alignment of the conserved amino acids within Mur ligases](image)

<table>
<thead>
<tr>
<th>Region I</th>
<th>Region II</th>
</tr>
</thead>
<tbody>
<tr>
<td>126 131 136</td>
<td>66 171 176 181 186 191 196 201</td>
</tr>
<tr>
<td>MurC-ITGTHGTKTTTTAMVSS</td>
<td>HGRLIAEDSASFLHLHLPVATINEDDMQTYQ</td>
</tr>
<tr>
<td>111 116 121</td>
<td>151 156 161 171 176 181 186</td>
</tr>
<tr>
<td>MurD-ITQGSKSTTVTTLV-</td>
<td>ECELVLLESFQFL-----GAVAALMVTEQMDRCYPF</td>
</tr>
<tr>
<td>116 121 126</td>
<td>176 181 186 191 201 206 211 2</td>
</tr>
<tr>
<td>MurE-VTGTHGTKTTTQTTQ</td>
<td>GATFCAMEVSSHLVGVHRV---FAHSVFTHLSRDLHLD-YHG</td>
</tr>
<tr>
<td>106 111 116</td>
<td>151 156 161 166 176 181 186 191</td>
</tr>
<tr>
<td>MurF-LGGSSGGTKSVKEMTAA</td>
<td>EYDYAVIELANHDEGTI----PEARLYVNLKHLECG---</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Region III</th>
<th>Region IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>231 236</td>
<td>286 291 296 301 306 311 316 321 326 331</td>
</tr>
<tr>
<td>MurC-IMCVDPPVIRELL</td>
<td>LNAPGRHMLAANAAVAVAVTEEIDDEAILLRALESFQGTGRDFDGE</td>
</tr>
<tr>
<td>211 216</td>
<td>261 266 271 276 281 286 291 296 301 306</td>
</tr>
<tr>
<td>MurD-VHADDALT-M</td>
<td>MKLSGMQHTNIALVAAHLADAALPRASSKLATTFTGLPHKEVVL</td>
</tr>
<tr>
<td>241 246</td>
<td>301 306 311 316 321 326 331</td>
</tr>
<tr>
<td>MurE-LNADDEVGRW</td>
<td>SHLMGAFVSNLLLLALATOLLALYPLADLLK--------TARLQP---</td>
</tr>
<tr>
<td>16 221 226</td>
<td>276 281 286 291 296 301 306 311 316 32</td>
</tr>
<tr>
<td>MurF-MNADNNDWLNLO</td>
<td>LPLPGRHNIANIALRAAALSMSYGATLDIAKGLANLKAVPGRLPIQL</td>
</tr>
</tbody>
</table>

There are 4 regions within the sequences of the E. coli Mur ligases that are conserved throughout the family. Region I (shown in red), Region II (shown in green), Region III (shown in blue) and Region IV (shown in orange).
The ATP-binding pocket contained within region I is the most well conserved active site throughout the Mur ligase family, with a consensus sequence of GXXGKT/S being identified as being present within the ATP binding pocket of Mur ligases. Region II is an extended domain that contains a glutamic acid and histidine that are conserved throughout the Mur ligases, with the histidine being flanked by acidic amino acids.

1.6.7 Antibiotic target

For many years the Mur ligases have been an antibacterial target. This is due to their essential role in peptidoglycan formation, as well as the fact that they have no mammalian counterparts making them unique bacterial targets. There are many areas that antibiotics can target within the Mur ligases such as the binding site of the uridine nucleotide substrate, the catalytic mechanism, and the ATP-binding site, the amino acid binding site and exploiting the conformational change that occurs.

Some promising inhibitors have been identified over the years such as 5-benzylidenethiazolidin-4-one compounds that are able to target multiple Mur ligases by preventing the binding of their uridine nucleotide substrates. They are able to inhibit the Mur ligases by binding to residues that flank the UDP-MurNAc binding site, and have been shown to have IC\textsubscript{50} values between 2 and 6 µM.

Phosphinate inhibitors can mimic the structure of the the tetrahedral transition state of the mur ligase directly prior to its collapse to form a new peptide bond with the incoming amino acid. The phosphinate is comprised of a dipeptide analogue linked to a uridine diphosphate by a hydrophobic spacer and can act as an inhibitor of the first transition state. These inhibitors can target multiple Mur ligases with IC\textsubscript{50} values in the micromolar range. Benzene 1,3-dicarboxylic acid derivatives are also able to act as transition state analogue inhibitors with micromolar inhibitors against all four Mur ligases having been identified.

The conformational change that the Mur ligases undergo from a closed to an open structure can present opportunities for antibacterial targets, especially as we continue to develop our knowledge of the exact amino acids involved. Cyanothiophene inhibitors have been developed that are able to target this within
MurF, and have IC\textsubscript{50} values in the nanomolar and micromolar range. These inhibitors bind at the interface between the three structural domains and induce interdomain closure yielding the ‘closed’ conformation of the ligase in the absence of ligands \textsuperscript{74,75}.

However, even though many promising inhibitors with IC\textsubscript{50} values in the nanomolar and micromolar range have been identified, no new antibiotics that are able to target the Mur ligases \textit{in vivo} in wild type cells have been identified. This could be due to issues with insufficient accumulation of drugs within the bacteria due to permeability barriers or the impact of efflux pumps \textsuperscript{76}. Indeed, it has been possible to isolate potent inhibitors of \textit{E. coli} and \textit{Pseudomonas aeruginosa} (\textit{P. aeruginosa}) MurC with nanomolar IC\textsubscript{50} values that are impotent as antibiotics unless targeted at mutated strains that lack efflux capacity \textsuperscript{77}. More recently it has been suggested that inhibitors are unable to act efficiently \textit{in vivo} because the Mur ligases are forming a complex within the cytoplasm. If the Mur ligases are forming a complex within the cytoplasm this would mean that intermediates may be channelled through the complex, making it harder for antibiotics to preferentially bind in the place of substrates. A complex formation may also mean that binding locations targeted by the inhibitors are hidden and inaccessible \textit{in vivo}.

\subsection*{1.7 Mur Ligase Complex}

The Mur ligases have been a target for antibacterial studies for many years, and yet very few antibiotics that are able to act against any of the Mur ligases involved in the stepwise addition of amino acids have been identified that are active against wild type strains. One contributory factor to this issue that has been proposed is that within the cytoplasm, the Mur ligases form a complex which is significantly reducing the inhibitory potency of inhibitors targeting these enzymes\textsuperscript{78}. If a complex is formed within the cytoplasm, this could obscure the targets of known inhibitors preventing them being able to function \textit{in vivo}. A complex could also mean that substrates are sequestered within the complex meaning their local concentrations are much higher than previously identified preventing inhibitors from competing at suitable drug levels \textsuperscript{78}. Understanding if a complex is forming
and how could help in the development of inhibitory molecules against the Mur ligases, or complex formation itself.

1.7.1 Role of complex formation within bacteria

The role of protein complexes within bacteria is wide and varied. Within bacteria, protein complexes exist whereby activity of the proteins is only present when the proteins are in complex together, such as with the GatD/MurT enzyme complex that allows for lipid II amidation \(^\text{26}\). Other protein complexes exist to help regulate the activity of a protein. Although the Mur ligases have been seen to be active independently, complex formation may still play a role in the activity and regulation of the activity of the Mur ligases within the cytoplasm. Protein complexes may also exist to aid in the sequestering of substrates to increase the activity of the pathway. Sequestering of the UDP intermediate within a Mur ligase complex could increase the activity of the peptidoglycan pathway.

1.7.2 Complex formation of MurT/GatD

The MurT/GatD complex is responsible for the amidation of lipid II, and may provide an insight into the potential formation of a Mur ligase complex. MurT is similar in sequence to the substrate binding domains of the Mur ligases and contains a middle and C-terminal domain typical of the Mur ligase family, with MurF from \textit{E. coli} its closest structural homology \(^\text{79}\). A study carried out by Nöldeke et al identified a complex formation between MurT and GatD that occurs between GatD and the MurT C-terminal \(^\text{79}\), suggesting a possible interface within other Mur ligases that may be involved in complex formation. Nöldeke et al also observed that in the absence of Lipid II, the complex appeared to be in an open conformation, but there was flexibility within the complex to allow for a closed conformation upon binding of Lipid II \(^\text{79}\). It is known that upon binding of substrates, the Mur ligases undergo a conformational change whereby the C-terminal undergoes a rigid body rotation allowing it to be brought towards the N-terminal and central domain. The flexibility within the complex formation between MurT and GatD suggests that this
conformational change may still be able to occur within the Mur ligases while in complex formation.

1.7.3 Interaction of Mur ligases with MreB

Understanding of how the Mur ligases may be interacting within a complex is limited. A study carried out by Divakaruni et al investigated the cellular localisation of the Mur ligases. MurC, MurE, and MurF were all seen to localise in a similar cellular location, exhibiting a banded localisation pattern which was perpendicular to the long axis of the cell. This localisation was dependent though on there being intact MreB cables, and when MreB polymerization was inhibited by A22, the Mur ligases were redistributed to the midcell or poles of the cell.

The interaction of MreB and the Mur ligases was further studied by Favini-Stabile et al. Using SPR spectroscopy where MreB was immobilized on a CM5 sensor chip, interactions between MreB and the Mur ligases from Thermotoga maritima (T. maritima) were determined. MurD, MurE and MurF all appeared to be interacting partners of MreB. Using this method, interactions between MurD, MurE and MurF with MurG were also established. However, when MurF was immobilized and the same experiment run with MurD and MurE, no signal could be detected. Pull down assays were also used to assess the interactions between the Mur ligases themselves, with no interaction being seen.

These studies suggested that the Mur ligases were unable to interact with each other, but could interact with MurG or MreB, potentially using these proteins as a backbone for complex formation.

1.7.4 Interaction between Mur ligases

A recent study carried out by Miyachiro et al investigated whether any of the Mur ligases from Streptococcus pneumoniae (S. pneumoniae) were able to form binary complexes. Binary complex formation amongst the Mur ligases was investigated via chemical cross-linking. Mass spectrometry was then used to identify the peptides which were potentially involved in these interactions. Using this methodology, the peptides potentially involved in the binary complex
formation between MurC - MurF and MurD – MurF were determined. Using analytical ultracentrifugation, the ability of MurC-MurD, MurC-MurF and MurD-MurF to form binary complexes was further investigated, with all showing the formation of binary globular complexes. These results showed that the Mur ligases could interact with each other without the presence of other potential binding partners.

1.7.5 Fusion Mur ligases

Along with experimental evidence of complex formation, evolutionary evidence can be used to help predict the likelihood of complex formation amongst the Mur ligases. A study carried out by Laddomada et al investigated the presence of a fusion of the MurE and MurF proteins within Bordetella pertussis (B. pertussis). Within the B. pertussis genome, the MurE and MurF proteins are fused into a single transcript, with a 20 amino acid linker present between the MurE and MurF genes. These proteins when expressed produced an elongated molecule with two distant active sites. Expression of these fusion proteins yielded a bifunctional molecule, with both MurE and MurF being active within this fusion form. The presence of an active fusion of MurE and MurF could point to the ability of these two proteins to form an active binary complex within bacteria where they are not fused within the genome.

1.7.6 Differences in interacting partners

Whether the Mur ligases can form a complex is still controversial. Previous studies appear to contradict each other regarding whether an additional structural protein is required for complex formation amongst the Mur ligases. One suggestion as to why differing results have been seen is that S. pneumoniae, unlike T. maritima does not encode MreB, and so is unable to use this protein to help form a Mur ligase complex. This suggestion could mean that bacteria that do not encode MreB are able to form the complex independently of structural proteins such as MreB. Another suggestion could be that Gram positive and Gram negative bacteria form the complex in different ways, with Gram negative bacteria requiring a structural
protein such as MreB or MurG for complex formation, while Gram positive bacteria are able to form a complex with just the Mur ligases. Further studies will be needed to determine whether the Mur ligases can form a complex, and what proteins are required for complex formation. Understanding if, and how complex formation occurs within bacteria could greatly influence the development of future antibacterial agents targeted towards the Mur ligases.

1.8 Project Aims and Outline

Antibiotic resistance is a growing global threat which requires immediate attention by the global scientific community. The development of new antibiotics is desperately required in order to tackle the growing number of antibiotic resistant bacterial strains. The Mur ligases have been a target for new antibiotic studies for many years due to their role in peptidoglycan formation and lack of human counterpart. The similar catalytic mechanism and structure of Mur ligases presents a unique opportunity to develop multi targeted inhibitors that will help to reduce the emergence of resistance to antibiotics. This thesis aims to optimise and develop methodologies that will improve our ability to identify novel inhibitory fragments designed via in silico screening, along with summarising and contributing to the current understanding of complex formation amongst the Mur ligases, using S. agalactiae as a model organism. Specifically, the work described herein aimed to:

1. Develop and utilise biochemical assays to screen and identify inhibitory fragments targeted towards the Mur ligases of S. agalactiae to help identify novel starting points for the development of antibacterial compounds.
2. Generate a better understanding of the predicted ability of the Mur ligases to form complexes using computational modelling.
3. Characterise the formation of a binary complex between MurD and MurE from S. agalactiae using a range of cloning and expressing system including pET DUET dual expression, and biophysical techniques including Microscale Thermophoresis and activity assays.
Chapter 2

Development and optimization of an assay for identifying low affinity binding fragments for the Mur ligases
1. Introduction and Aims

The Mur ligases have been studied for many years as a potential therapeutic target, with multiple trials undertaken to try and design antibacterial agents. Due to the essential nature of the role performed by these enzymes in bacteria, identification of inhibitory fragments targeted towards the Mur ligases as a route towards development of novel antibacterials formed the main aim of this project.

Biochemical assays are one technique used for determining the inhibitory effects of fragments. Within Warwick, Dr Adrian Lloyd has designed assays that allow the activity of the Mur ligases to be coupled to a secondary reaction that can then be tracked photometrically. These assays allow binding fragments to be tested for their inhibitory effects within a simple, repeatable assay. Optimization of the assay for specific proteins allows for the best chance of detecting inhibitory fragments. The assay can also be optimized and adapted depending on where the inhibitory fragments are targeted towards.

This chapter aimed to confirm previous work done within the Dowson group. Determination of the optimal conditions for S. agalactiae MurD within existing assays was carried out with a focus on targeted fragments screens. Development of a stopped assay based on an existing assay was also carried out.
2. Materials and Methods

2.1 Media

The composition of the culture medias used for the growth of proteins are described in Table 2.1. Selective media was supplemented with either 50 mg/L Kanamycin or 100 mg/L Ampicillin. For media containing agar, antibiotics were added at 50°C and poured into sterile Petri dishes.

<table>
<thead>
<tr>
<th>Name</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>LB Broth</td>
<td>10 g Tryptone, 5 g Sodium Chloride, 5 g Yeast extract, prepared to 1 L in water and autoclaved</td>
</tr>
<tr>
<td>SOC</td>
<td>20 g Tryptone, 0.5 g Sodium Chloride, 5 g Yeast extract, 0.2 g Potassium Chloride, 3.6 g Glucose, 1 g Magnesium Chloride, prepared to 1 L with double distilled water and autoclaved</td>
</tr>
<tr>
<td>2YT</td>
<td>16 g Tryptone, 5 g Sodium Chloride, 10 g Yeast extract, prepared to 1 L in water and autoclaved</td>
</tr>
</tbody>
</table>

Table 2.1: Composition of media

2.2 Buffers and solutions

All chemicals used were of analytical grade unless otherwise stated. MilliQ pure water was used to make all buffers. Composition of protein buffers used for purification and storage are summarised in Table 2.2. Buffers were stored at 4°C for up to 1 month.

<table>
<thead>
<tr>
<th>Name</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Buffers</td>
<td></td>
</tr>
<tr>
<td>TAE</td>
<td>40 mM Tris acetate, 1 mM EDTA</td>
</tr>
<tr>
<td>SDS PAGE</td>
<td>1.2 M Triethanolamine, 0.8 M Tricine, 2.0% (w/v) sodium dodecyl sulfate, pH 8.2</td>
</tr>
<tr>
<td>Sample Buffer</td>
<td>62.5 mM Tris-HCl pH 6.8, 2.5% (w/v) SDS, 0.002% (v/v) Bromophenol Blue, 0.7135 M β-mercaptoethanol, 10% (v/v) glycerol</td>
</tr>
<tr>
<td>Purification of Mur ligases</td>
<td></td>
</tr>
<tr>
<td>Buffer A</td>
<td>50 mM HEPES, 40 mM Imidazole, 150 mM NaCl</td>
</tr>
<tr>
<td>Buffer B</td>
<td>50 mM HEPES, 250 mM Imidazole, 150 mM NaCl</td>
</tr>
<tr>
<td>Storage Buffer</td>
<td>20 mM HEPES, 150 mM NaCl</td>
</tr>
<tr>
<td>Purification of UDP-MurNAc-L-Ala</td>
<td></td>
</tr>
<tr>
<td>Working Buffer</td>
<td>0.25 M Hesper, 50 mM MgCl₂, pH 7.6</td>
</tr>
<tr>
<td>Buffer A</td>
<td>10 mM ammonium acetate, pH 7.6</td>
</tr>
<tr>
<td>Buffer B</td>
<td>1 M ammonium acetate, pH 7.6</td>
</tr>
<tr>
<td>Activity assay</td>
<td></td>
</tr>
<tr>
<td>Storage Buffer</td>
<td>30 mM HEPES pH7.6, 50 mM KCl, 1 mM MgCl₂, 3 mM DTT, 0.2 mM protease inhibitor, 2 µM Leupeptin, 2 µM peptin, 50% glycerol</td>
</tr>
</tbody>
</table>

Table 2.2: Composition of buffers
2.3 Protein Expression and Purification

2.3.1 Expression of Protein

Proteins were over expressed in BL21 *E. coli* strains using isopropyl-D-1-thiogalactopyranoside (IPTG) induction. A sample from a glycerol stock containing the gene of interest was introduced into a 15 mL LB broth containing the relevant antibiotic and incubated overnight at 37°C at 180 RPM.

15 mL of the overnight pre-culture was used to inoculate 1 L of 2YT broth containing the relevant antibiotic and was incubated at 37°C at 180 RPM until an \( \text{OD}_{600}\text{nm} \) of 0.5-0.7 was reached. IPTG was added to each 1 L culture to a final concentration of 1 mM and cultures were then incubated at 37°C at 180 RPM for 4 hours. Cells were harvested via centrifugation at 6,000 x g for 10 minutes at 4°C. The supernatant was discarded, and the cell pellets collected before being flash frozen with liquid nitrogen and being stored at -20°C overnight.

2.3.2 Preparation of cell lysates

The cell pellets were thawed and resuspended in 150 mL of Buffer A supplemented with DNase and lysozyme. The cell suspension was evenly resuspended by homogenisation and then passed through a cell disruptor twice at 30kpsi at 4°C to lyse the cells. Centrifugation of the cells was then carried out at 30,000xg for 30 minutes at 4°C to remove the cell debris and clarify the lysate.

2.3.3 Protein Purification

Proteins with a poly-histidine (x6) affinity tag were purified by immobilised metal affinity chromatography (IMAC) which was carried out at 4°C. The cell lysate was passed over a nickel charged IMAC column at a flow rate of 1 mL/min which had been pre-equilibrated in Buffer A. The column was then attached to an AKTA before 3 column volumes of Buffer A were used to wash the column and remove any unbound protein. The protein was then eluted from the column using Buffer B. The concentration of Buffer B was increased in 10% increments with each new increment occurring either after 3 column volumes had passed through the column or there was no further change in the absorbance of the eluate until 100% Buffer B.
was achieved. Fractions correlating to an increase at 280 nm were then analysed by SDS Page Analysis.

### 2.3.4 SDS Page Analysis

Proteins were separated and visualised under denaturing conditions by Sodium dodecyl sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) with a 10% resolving gel. Protein samples for analysis were prepared in sample buffer (Table 2.2). Gels were loaded into a Mini-PROTEAN tetra system (Bio-Rad) unit and 12 µL of the protein samples and 4 µL of colour protein standard broad range calibration ladder (NEB) were loaded into respective wells. Gels were run in TAE buffer (Table 2.2) for 45 minutes at 180V. SDS-PAGE gels were stained with instant blue (Expedeon) overnight. SDS-PAGE gels were then washed with water 3 times to remove excess staining before being imaged with a Gel Box (Vilber).

### 2.3.5 Protein Quantification

Buffer exchange was carried out either using a PD-10 column (GE Healthcare) following manufacturer’s guidance, or via overnight dialysis. Protein containing fractions identified via SDS-PAGE analysis were pooled and the buffers exchanged from Buffer B to a storage buffer. To determine protein concentrations a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies) was used. Protein absorbance at 280 nm was measured against a storage buffer blank, and protein concentration determined using the molecular weight and molar extinction coefficient of the protein. Concentration of protein samples was carried out by centrifugal ultracentrifugation using 30,000 molecular-weight cut off (MWCO) Vivaspin centrifugal concentrator (Sartorius). Protein was loaded into the concentrator and centrifuged at 3000xg at 4°C until the desired concentration was achieved.
2.4 Cloning of MurD

Synthetic DNA was ordered from IDT (gBlocks) and was codon optimised where appropriate and restriction site sequences added. The N-terminal hexa-histidine tagged *S. agalactiae* MurD was then cloned into inPUC then pET28 by Dr Jonathan Cook.

### 2.4.1 Transformation of Competent Cells

Transformation of chemically competent cells was carried out using NEB5 *E. coli* BL21 (DE3). Cryo-preserved competent cells were thawed on ice before being mixed with ligated DNA provided by Dr Jonathan Cook. Cells were incubated on ice for 30 minutes before being heat shocked via incubation at 42°C for 30 seconds. A further 5 minute incubation on ice was carried out before the cells were added to Super Optimal broth with Catabolite repression (SOC medium) to a final volume 10 times the original cell suspension volume. Cells were incubated at 37°C for one hour at 180 RPM before being plated on selective LB agar.

### 2.4.2 Construct Validation

Plasmid DNA constructs were verified via Genewiz sequencing. 80-100 ng of DNA was sent with relevant primers. Construct maps were then generated via Snapgene.

*Figure 2.1: Construct map of *S. agalactiae* MurD within pET 28*

Construct map of *S. agalactiae* MurD. *S. agalactiae* MurD was cloned into open reading frame 1 of pET 28 using restriction enzyme digest. Restriction enzyme sites used were Ndel and Xhol. Construct map was generated via Snapgene.
2.4.3 Protein Purification

Protein purification of MurD from *S. agalactiae* was carried out following the methodology described in Section 2.3.

2.5 Synthesis of UDP-MurNAc-L-Ala

Synthesis of UDP-MurNAc-L-Ala was carried out following the methodology previously stated in ‘Characterization of tRNA-dependent peptide bond formation by MurM in the synthesis of Streptococcus pneumoniae peptidoglycan’ 27. The synthesis of UDP-MurNAc-L-Ala requires the sequential addition of all reagents into a 2 mL Eppendorf which is then incubated at 37°C overnight. The synthesis mixture contained the following components (final concentrations): 125 mM phosphoenolpyruvate (PEP) from a 1 M PEP stock made in 5x working buffer (Table 2), 1x working buffer from a 5x working buffer solution (including volume used in PEP addition), 1 mM dithiothreitol (DTT), 50 mM KCl, 8.22 mM UDP-GlcNAc, 0.21 mg/mL *E. coli* MurA, 1.24 mg/mL *P. aeruginosa* MurB, 0.2 mM NADP+, 1.48 u/mL IDH, 26 mM DL-isocitrate, 6 mM ATP, 5.53 u/mg rabbit muscle Pyruvate kinase, 0.24 mg/mL *P. aeruginosa* MurC, and 35 mM L-Ala. The final volume of the synthesis was 2 mL.

2.5.1 Purification of UDP-MurNAc-L-Ala

The purification of UDP-MurNAc-L-Ala was carried out using a Source 30Q column. The synthesis mixture was removed from the 37°C incubator and stored on ice. To remove the proteins from the UDP-MurNAc-L-Ala, the contents of the Eppendorf were transferred to a Vivaspin20 10,000 MWCO centrifugal concentrator (Sartorius). The Eppendorf was rinsed with 3 aliquots of 1 mL sterile water which was also added to the concentrator which was then centrifuged at 4500rpm for 45 minutes at 4°C.

A Source 30Q column was attached to an AKTA before being washed at room temperature with 10 column volumes sterile water at a flow rate of 1 mL/min. The column was then equilibrated with 8 column volumes Buffer B and 10 column volumes Buffer A. The sample was loaded onto the column and washed through
with 10 column volumes of Buffer A. The intermediate was then eluted using a
gradient of Buffer B. 10 mL fractions were collected and the elution of the desired
UDP MurNAc product was followed via the absorbance of the column eluate at
280 nm and 254 nm. Fractions likely to contain the desired UDP MurNAc species
were identified as those with an $A_{254}/A_{260}$ ratio of $\sim 2.6$, typical of a uridine 5’-
diphosphate containing species. The appropriate fractions were collected and
placed into a round bottomed flask. The contents of the flask were frozen using
liquid nitrogen and lyophilised overnight to remove the ammonium acetate from
the sample. The sample was resuspended in 30 mL of filtered water, frozen with
liquid nitrogen and freeze dried again, with this step being repeated until the
ammonium acetate had been removed. Once a loose powder of sample had been
formed, it was transferred to a falcon tube and resuspended in 2 mL of filtered
water before being frozen with liquid nitrogen and freeze dried, a process that was
repeated 5 times. The final powder was resuspended in 200 µL of sterile water and
concentration of UDP MurNAc determined at 260 nm using an extinction coefficient
for the uracil chromophore within the molecule of 10,000 M$^{-1}$cm$^{-1}$.86

### 2.6 Pyruvate Kinase/Lactate Dehydrogenase Coupled Assay for Mur ligases

Enzyme activity as defined by the rate of ADP production from ATP was
confirmed using a Pyruvate Kinase/Lactate Dehydrogenase (PK/LDH) assay. The
PK/LDH assay was carried out in a Cary 100 UV/Vis spectrophotometer in a total
reaction volume of 200 µL at 37°C. The reaction mixture contained the following
components (final concentrations): 50 mM HEPES (pH7.6), 10 mM MgCl$_2$, 300 µM
NADH, 25 mM KCl, 1 mM DTT, 2 mM PEP, 1 µL per 100 µL PK/LDH (Stock solution of
6-10 U mL$^{-1}$ PK and 9-14 U mL$^{-1}$ LDH), 2 mM ATP, 100 µM UDP-MurNAc-L-Ala, 1 mM
D-Glu and 50 nM MurD. A Cary 100 UV/Vis spectrophotometer was run using Cary
WinUV kinetics software at 37°C. All components barring one substrate were added
to a Hellman Analytics High Precision QUARTZ cuvette and mixed. A background
rate was determined at 340 nm. The final substrate was added to start the reaction
and the reaction was monitored at 340 nm as a decline in absorbance as a
consequence of the consumption of the NADH chromophore. The gradient of the
slope of the initial rate of catalysis was determined using the tracking function within the software.

2.7 MESG coupled assay

Enzyme activity as defined by the rate of phosphate production from ATP was followed using a 7 methyl 6 thio guanosine (MESG)- coupled assay, which has an extinction coefficient of 10,000 M$^{-1}$.cm$^{-1}$. The MESG coupled assay was carried out in either a Cary 100 UV/Vis spectrophotometer at a total reaction volume of 200 µL at 37°C, or within a Varioskan Flash plate reader at a total reaction volume of 50 µL in 384 well microtitre plates. The reaction mixture contained the following components (final concentrations): 50 mM HEPES (pH7.6), 10 mM MgCl$_2$, 1 mM DTT, 50 mM KCl, 400 µM MESG, 100 U per mL purine nucleoside phosphorylase (PNP), 250 µM ATP, 1 mM D-Glu, 50 µM UDP-MurNAc-L-Ala and 100 nM Mur ligase.

Assays were carried out with the Cary 100 UV/Vis spectrophotometer run using Cary WinUV kinetics software set at 37°C, or within a Varioskan Flash plate reader set at 37°C. All components barring one substrate were added and mixed and a background rate was determined at 360 nm. The final substrate was added to start the reaction, either manually or via the injection system of the Varioskan Flash, and the reaction was followed at 360 nm as an increase in absorbance. The gradient of the slope of the initial rate was determined using the tracking function within the software of the Cary 100 UV/Vis spectrophotometer or manually. $K_m$ determinations for ATP, UDP-MurNAc-L-Ala and D-Glu were carried out using this assay. When $K_m$ was being determined the concentrations for all components remained the same apart from the concentration of the component for which $K_m$ was being determined. The reaction was then carried out using the same protocol as previously described. Nucleotide substitutes were run in place of ATP, with all other components remaining at either $K_m$ or constant levels. The IC$_{50}$ value for ADPNP and ADPCP were determined using this assay. ADPNP/ADPCP were added to the component mixture before the recording of the background rate of the reaction.
2.8 Stopped MESG coupled assay

The ability of a stopped MESG coupled assay to determine protein activity in the absence and presence of inhibitors was determined. The stopped MESG coupled assay was carried out in either a Cary spectrophotometer at a total reaction volume of 200 µL at 37°C, or within a Varioskan Flash plate reader at a total reaction volume of 50 µL. The reaction mixture contained the following components (final concentrations): 50 mM HEPES (pH 7.6), 2 mM MgCl₂, 1 mM DTT, 50 mM KCl, 400 µM MESG, 250 µM ATP, 1 mM D-Glu, 50 µM UDP-MurNAc-L-Ala and 50 nM Mur ligase. All components barring one substrate were added and mixed and a background rate was determined at 360 nm. The final substrate was added to start the reaction and allowed to run for the initial rate period before the reaction was quenched with 10 mM EDTA. A background absorbance was determined photometrically at 360 nm before PNP was added. Absorbance change was followed at 360 nm until the end point was achieved. The absorbance change was then determined.
3. Results

3.1 Inactivity of previously cloned MurD from *S. agalactiae*

MurD from *S. agalactiae* had previously been cloned, expressed and purified within the Dowson laboratory. However, further purification experiments produced a low yield of MurD with no improvement from expression trials. Activity assays, using a spectrophotometer, were carried out on the purified MurD, along with a *P. aeruginosa* MurD species. Activity was seen within the assay for the MurD from *P. aeruginosa* but the MurD from *S. agalactiae* was lacking activity as seen in Figure 2.2.

![Activity assay of MurD](image)

*Figure 2.2: Activity assay of MurD shows a lack of activity for the MurD clone from S. agalactiae*

Activity of different MurD proteins was determined via a PK/LDH coupling reaction. Addition of ATP should induce the Mur ligase reaction, resulting in the formation of ADP. ADP is rephosphorylated by pyruvate kinase generating pyruvate which is reduced to lactate with NADH via lactate dehydrogenase. Consumption of NADH causes a decrease in absorbance at 340 nm. Final protein concentration was 5 µg/ml of MurD for *S. agalactiae* and *P. aeruginosa*. (A) Activity trace of MurD from *S. agalactiae*. No activity was seen after the addition of ATP. (B) Activity trace of MurD from *P. aeruginosa*. Activity was seen after the addition of ATP.

3.2 Previously cloned MurD from *S. agalactiae* lacks an alpha helix

To determine why there was a lack of activity with the *S. agalactiae* MurD clone, sequencing of the MurD plasmid was performed. A point deletion was identified at nucleotide 1302 that resulted in the appearance of a stop codon, highlighted in Figure 2.3A. This caused the truncation of the protein sequence by removal of the last 18 amino acids, which when mapped to the MurD structure (PDB: 3LK7) comprised the final alpha helix of the structure, as seen in Figure 2.3B.
The lack of activity meant that this construct could not be used within the project and a new full-length clone of MurD had to be produced.

(A)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1101</td>
<td>AGATATCAGGACTTAAACATATGTTGTTTTAAGGGGAAATCGGCATCTC</td>
<td></td>
<td>1101</td>
<td>AGATATCAGGACTTAAACATATGTTGTTTTAAGGGGAAATCGGCATCTC</td>
<td></td>
<td>1151</td>
<td>GAGTAAAACGTCGCTGCAACAAAAACAGGAGTAACCTTATAGCGATGCTTTA</td>
<td></td>
</tr>
<tr>
<td>1150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1151</td>
<td>GAGTAAAACGTCGCTGCAACAAAAACAGGAGTAACCTTATAGCGATGCTTTA</td>
<td></td>
<td>1200</td>
<td>GATGTTAGAGATGCGGTACATAAAGCGTATGAGGTGGCACAACAGGCGA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1201</td>
<td>GATGTTAGAGATGCGGTACATAAAGCGTATGAGGTGGCACAACAGGCGA</td>
<td></td>
<td>1250</td>
<td>TGTTATCTTGCTAAATCTCTGCATCATGAGTAACATTTTCTCCAGAAAGTGGCGA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1250</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1251</td>
<td>TGTTATCTTGCTAAATCTCTGCATCATGAGTAACATTTTCTCCAGAAAGTGGCGA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1300</td>
<td>Dom_S.agalact</td>
<td></td>
<td>S. agalactiae.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1301</td>
<td>TCGAAGTCCGTGAGATGAAATCTTGAATCTGACATTTCGAAAATCGTGAAGGGA</td>
<td></td>
<td>1350</td>
<td>GAGTAA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1350</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1351</td>
<td>GAGTAA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(B)

Figure 2. 3: A point mutation led to the deletion of an alpha helix

Using BLAST, the sequence of the previously cloned MurD (Dom_S.agalact) was compared to the known sequence of MurD from **S. agalactiae** (**S. agalactiae**). (A) At position 1302, within the previously cloned MurD, a point deletion of a cytosine had occurred, resulting in the formation of a STOP codon. (B) A Pymol model of MurD from the **S. agalactiae** MurD crystal structure (PDB: 3LK7) with the deleted alpha helix shown in orange.
3.3 *S. agalactiae* MurD protein purification and activity

MurD from *S. agalactiae* was purified and its activity determined via activity assays. (A) SDS-PAGE analysis of IMAC-purified *S. agalactiae* MurD (predicted molecular weight: 49.8 kDa). (B) Activity of MurD within a PK/LDH assay. (C) Activity of MurD within a MESG coupled assay. (D) Comparison of activity of MurD from *S. agalactiae* in a PK/LDH assay (black) and a MESG coupled assay (blue). MurD was at an [assay] of 100nM. Addition of ATP induced the activity of the Mur ligase.
To be able to develop and optimise an *S. agalactiae* MurD assay, an active form of *S. agalactiae* MurD was required. An N-terminal hexa-histidine tagged *S. agalactiae* MurD was cloned into pET28a by Dr Jonathan Cook (School of Life Sciences, University of Warwick). Following sequence conformation, the vector was then transformed into competent *E. coli* BL21 (DE3) cells for protein expression. Protein purification was carried out using IMAC purification via a nickel column and the purity of the protein was assessed via SDS-PAGE, as shown in Figure 2.4a. Pure protein was obtained via this method with a clear band being seen at around 50 kDa, consistent with the predicted subunit molecular weight of 49.8 kDa. Purified protein was tested for activity within a PK/LDH coupled assay and a MESG coupled assay using a spectrophotometer. The purified protein was active within both assays, as seen in Figure 2.4b and Figure 2.4c, with the rate of ADP release equal to the rate of phosphate release as seen in Figure 2.4d.

### 3.4 Optimization of a MESG coupled assay for MurD from *S. agalactiae*

*S. agalactiae* MurD was seen to be active in both a PK/LDH coupled assay and a MESG coupled assay. Both assays rely on coupling the Mur ligase reaction to a secondary reaction that can be tracked photometrically. The PK/LDH coupled assay relies on the production of ADP to convert phosphoenolpyruvate to pyruvate via pyruvate kinase. The pyruvate is then converted to lactate via lactate dehydrogenase, which requires the oxidation of NADH to NAD⁺. This cascade can be seen in Figure 2.5.

NADH contains a quinone ring and can absorb light at 340 nm. However, when NADH is oxidised to NAD⁺ a pyridine ring is formed which is aromatic and does not absorb light at 340 nm. This loss of absorption allows the reaction to be tracked photometrically. The decrease in absorbance at 340 nm on conversion of NADH to NAD⁺, is stoichiometric with the production of ADP by the Mur ligase reaction thus allowing the decrease in absorption to be linked to the activity of the Mur ligase.
Instead of relying on the production of ADP, a MESG coupled assay converts the free phosphate formed during the Mur ligase reaction to ribose 1-phosphate via the actions of PNP, acting upon MESG to convert it to 7-methyl 6 thio guanine, as seen

\[
\text{UDP} + \text{MurNAc} + \text{ATP} + \text{Amino acid} \xrightarrow{\text{Mur ligase}} \text{UDP} \cdot \text{MurNAc} \cdot \text{AA} + \text{ADP} + \text{Pi}
\]

Pyruvate Kinase

Phosphoenol Pyruvate

Lactate dehydrogenase

NADH

NAD⁺

Lactate

\[
\text{UDP} : \text{MurNAc} + \text{ATP} + \text{Amino acid} \xrightarrow{\text{Mur ligase}} \text{UDP} \cdot \text{MurNAc} \cdot \text{AA} + \text{ADP} + \text{Pi}
\]

PNP

MESG

7 methyl 6 thio guanine

Ribose 1-phosphate

**Figure 2. 5: Diagram to show the coupling reaction during the PK/LDH coupled assay**

The Mur ligase reaction results in the conversion of ATP to ADP. The release of ADP initiates a secondary reaction that converts phosphoenol pyruvate to pyruvate via the actions of pyruvate kinase. The pyruvate is then converted to lactate via lactate dehydrogenase, which requires the oxidation of NADH. The oxidation of NADH (shown in blue), causes an absorbance decrease at 340 nm, which can be equated to the activity of the Mur ligase during the initial rate period of the Mur ligase reaction.

**Figure 2. 6: Diagram to show the coupling reaction within a MESG coupled assay**

The Mur ligase reaction results in the conversion of ATP to ADP and phosphate. This free phosphate can be converted to ribose 1-phosphate via PNP, which also converts MESG to 7-methyl 6 thio guanine. The conversion of MESG to 7-methyl 6 thio guanine (shown in blue), results in an absorbance increase at 360 nm, which can be equated to the activity of the Mur ligase during the initial rate period of the Mur ligase reaction.
in Figure 2.6. 7-methyl 6 thio guanine absorbs light at 360 nm, whereas MESG absorbs light at 330 nm. An increase in absorbance at 360 nm corresponds to the conversion of MESG to 7-methyl 6 thio guanine, which is taken to be stoichiometric with the production of phosphate during the Mur ligase reaction, thus allowing assay of activity of the Mur ligase.

Both assays allow for the tracking of Mur ligase activity by equating absorbance change to activity. However, for the purposes required within this project, the MESG coupled assay was more suitable. The MESG coupled assay only required the addition of a single secondary reaction, whereas the PK/LDH assay relied on a two-step secondary reaction, which may potentially result in more interference within the assay from inhibitory compounds. Another benefit of the MESG coupled assay is that it does not rely on the production of ADP, instead tracking the production of free phosphate. Therefore, this assay would function in the presence of other alternative nucleotides such as CTP or GTP, which should have higher \( K_m \)'s allowing for lower affinity binding fragments to be identified within the assay.

3.4.1 The MESG coupled assay is reliant on the production of free phosphate

Within an MESG coupled assay, the activity of the Mur ligase was tracked via the coupling of the Mur ligase reaction to a secondary reaction that was reliant on the production of free phosphate. To confirm that the secondary reaction was

![Figure 2.7: Secondary coupled reaction is reliant on the presence of free phosphate](image)

The activity of the secondary coupled reaction was tracked in the presence of various phosphate concentrations. The initial rate of the reaction was determined and plotted against phosphate concentration. A linear relationship was observed between phosphate concentration and initial rate.
reliant on the presence of free phosphate within our assay system, the secondary reaction was run in the presence of various phosphate concentrations via a Plate reader. As can be seen from Figure 2.7, a linear relationship between phosphate concentration and initial activity rate was seen, with a gradient of $2879 \text{ M}^{-1}\text{cm}^{-1}$, confirming that the secondary reaction was reliant on the presence of free phosphate within our assay system.

3.4.2 The MESG coupled assay can track Mur enzyme activity

The secondary assay system of the MESG coupled assay was shown to be able to effectively track the presence of free phosphate. The ability of the secondary assay system to be coupled to the Mur ligase reaction and effectively track the activity of the Mur ligase via the production of free phosphate was then confirmed. The MESG coupled assay was run, via a Plate reader, in the presence of various $S. agalactiae$ MurD concentrations and the initial rate determined.

As can be seen from Figure 2.8, a linear relationship was seen between MurD concentration and the initial rate determined via the assay. A linear relationship showed that the MESG coupled assay was effectively following the activity of the Mur ligase during the initial rate period without limiting the rate of the reaction catalysed by MurD. Extrapolation of this relationship to the origin of the graph...
indicated the rates being measured were strictly dependent on the presence of MurD.

### 3.4.3 MurD requires the presence of all substrates for activity

![Graphs showing the activity of MurD with different substrates](image)

**Figure 2.9: The activity of MurD relies on the presence of all three substrates**

The activity of MurD was tracked using a MESG coupled assay. All components of the assay were incubated at 37°C barring one substrate which was added after 1 minute. No activity was seen within any of the assays until all three substrates were present. (A) Comparison of initial rate when individual substrates were omitted and when all substrates were present. (B) D-Glu added after 1 minute. (C) UDP-MurNAc-L-Ala added after 1 minute. (D) ATP added after 1 minute.
The Mur ligases require three substrates for activity – a UDP-MurNAc intermediate, a nucleotide and a relevant amino acid. To determine whether the presence of all substrates was required for the activity of \textit{S. agalactiae} MurD during the MESG coupled assay, the assay was run via a spectrophotometer, in the absence of a substrate or the ligase. The absorbance change was followed and the initial rate was determined. The initial rates were compared to the initial rate when all substrates were present, as seen in \textbf{Figure 2.9A}. As can be seen in \textbf{Figure 2.9A}, no initial rate was seen when a substrate or the ligase was omitted. When the omitted substrate was introduced to the assay, an activity rate could be seen, as shown in \textbf{Figure 2.9B,C and D}. These results showed that within the assay, MurD from \textit{S. agalactiae} required the presence of all substrates for activity to be detected.

\subsubsection*{3.4.4 Determination of the $K_m$ values for substrates for MurD from \textit{S. agalactiae}}

MurD from \textit{S. agalactiae} required the presence of all three substrates for activity. Typically each Mur ligase will display a hyperbolic dependence of initial velocity upon each substrate, with the exception of those instances where substrate inhibition is observed\textsuperscript{52}. Under a given set of conditions, these relationships can be defined by two constants, $K_m$ and $V_{max}$. $V_{max}$ relates to the initial velocity of the enzyme at infinite substrate concentration, whereas the $K_m$ relates to the concentration of substrate at which the rate is at half maximal\textsuperscript{88}. The Michaelis Menten equation describes the relationship between initial velocity and substrate concentration [$S$]:

$$V_0 = \frac{V_{max} \cdot [S]}{K_m + [S]}$$

With multi-substrate enzymes, these parameters are determined at fixed finite concentrations of co-substrates, and so these constants are denoted with the superscript ‘App’ for apparent.
The major aim of this chapter was to develop assays suitable for the detection of weakly binding fragments targeted towards the substrate binding sites of the Mur ligases. Competition for this binding site via an inhibitor can be described by the relationship between initial velocity ($V_i$) and substrate concentration in the presence of a concentration of inhibitor [$I$]:

$$V_i = \frac{V_{max} \cdot [S]}{K_m \left(1 + \frac{[I]}{K_i}\right) + [S]}$$

In the presence of a competitive inhibitor, the $K_m$ is increased by a factor of $(1 + [I]/K_i)$ where $K_i$ is the dissociation constant of inhibitor from the enzyme. The degree of competitive inhibition, when defined as $1 - (V_i/V_0)$ can be determined via the combination of the two previous equations:

$$Inhibition = 1 - \left(\frac{K_m + [S]}{K_m \cdot \left(1 + \frac{[I]}{K_i}\right) + [S]}\right)$$

By setting theoretical values for $K_i$ of 2 mM and inhibitor of 100 mM, the impact on $K_m$ over a 105-fold variation of substrate concentration can be simulated in GraphPad Prism.

As seen in Figure 2.10, the ability of an assay to identify a competitive inhibitor is dependent on substrate concentration and $K_m$ value. A decreasing substrate concentration and an increasing $K_m$ value can significantly improve the ability of an assay to detect a weakly competitive inhibitor. The estimation of the $K_m$ is an essential pre-requisite for the development of assays directed towards the identification of competitive inhibitors.
The dependence of *S. agalactiae* MurD activity on ATP, D-Glu and UDP-MurNAc-L-Ala concentrations was determined at constant concentrations while the other substrates remained unvaried (250 µM ATP, 1 mM D-Glu, 50 µM UDP-MurNAc-L-Ala respectively) using a MESG coupled assay at 100 nM MurD *S. agalactiae*.

The concentration of the substrate being investigated was varied to allow for the determination of the apparent values of $V_{\text{max}}$ and $K_m$ for the three substrates. The data was fitted by non-linear regression within GraphPad to the Michaelis Menten equation allowed for the formation of hyperbolic graphs as seen in Figure 2.11, which allowed for the determination of the required constants as seen in Table 2.3.

![Figure 2.10: Ability of assay to identify competitive inhibitors is dependent on $K_m$ value](image)

Simulation of the impact of increasing $K_m$ and substrate concentration on inhibition by an inhibitor at a final concentration of 100 mM with a $K_i$ of 2 mM. $K_m$ values were increased with a 0.0002 increment.

<table>
<thead>
<tr>
<th>Substrate</th>
<th>ATP</th>
<th>UDP-MurNAc-L-Ala</th>
<th>D-Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td>$K_m^{\text{App}}$ (µM)</td>
<td>47.1 ± 6.5</td>
<td>13.3 ± 2</td>
<td>97.8 ± 9.4</td>
</tr>
<tr>
<td>$V_{\text{max}}^{\text{App}}$ (µM Pi/ min$^{-1}$)</td>
<td>121.4 ± 4.4</td>
<td>116.6 ± 6.2</td>
<td>114.7 ± 3.3</td>
</tr>
<tr>
<td>$K_{\text{cat}}^{\text{App}}$ (s$^{-1}$)</td>
<td>20.2</td>
<td>19.4</td>
<td>21.5</td>
</tr>
<tr>
<td>$K_{\text{cat}}^{\text{App}} / K_m^{\text{App}}$</td>
<td>0.42</td>
<td>1.46</td>
<td>0.22</td>
</tr>
</tbody>
</table>

*Table 2.3: Kinetic parameters for substrates against MurD from *S. agalactiae**

The kinetic determinations of all substrates for MurD from *S. agalactiae* was determined using a MESG coupled assay. MurD was at a concentration of 100 nM.
3.4.5 Positive control inhibitors for a Mur ligase assay

To determine whether inhibition via fragments could be established using an MESG coupled assay, a positive control inhibitor was selected. \( \beta,\gamma \)-Methyleneadenosine 5'-triphosphate (ADPCP) and adenosine 5'-(\( \beta,\gamma \)-imido)triphosphate (ADPNP) are ATP analogues that are non-hydrolysable by virtue of replacement of the oxygen atom between the \( \beta \) and \( \gamma \) phosphorous atoms of ATP with a methylene and an amido group in ADPCP and ADPNP respectively, as seen in Figure 2.11: Kinetic determinations of substrates for MurD from \( S. \) agalactiae

The kinetic determinations of all substrates for MurD from \( S. \) agalactiae was determined using a MESG coupled assay. The initial reaction rate of 100 nM MurD was determined at various substrate concentrations to allow determination of \( V_{\text{max}} \) and \( K_m \). Other substrate concentrations were above their \( V_{\text{max}} \) to prevent interference when determining the \( K_m \). Experiments are performed in triplicate with error bars indicating SD. (A) Determination of \( K_m \) for ATP. (B) Determination of \( K_m \) for UDP-1P. (C) Determination of \( K_m \) for D-Glu.
ADPCP and ADPNP may have the potential to bind to the ATP-binding site of the Mur ligases in place of ATP, preventing activity.

**Figure 2.12:** ADPCP and ADPNP can act as inhibitors of MurD from *S. agalactiae*

![Structural formulae of ATP and ATP analogue inhibitors](image)

Structural formulae of ATP and ATP analogue inhibitors. (A) ATP (B) ADPCP. The oxygen has been replaced with a methylene group (shown in red). (C) ADPNP. The oxygen has been replaced with an amido group (shown in blue).

3.4.5.1 ADPNP and ADPCP can act as inhibitors of MurD from *S. agalactiae*

The inhibitory effects of ADPNP and ADPCP were determined using a MESG coupled assay. The assay was run at *V*<sub>max</sub> concentrations of substrate in the presence or absence of 50 µM ADPNP or 50 µM ADPCP, and the initial reaction rate of MurD tracked after the addition of D-Glu. A decrease in the initial rate of MurD shows that ADPNP and ADPCP were acting as inhibitors of MurD from *S. agalactiae.*
To determine if ADPNP and ADPCP were able to inhibit the activity of MurD from *S. agalactiae*, an MESG coupled assay in the absence and presence of each compound was run via a spectrophotometer. As can be seen from Figure 2.13, activity of MurD was reduced in the presence of both ADPNP and ADPCP, confirming that these compounds can act as inhibitors of MurD within a MESG coupled assay. ADPCP is more chemically stable than ADPNP, and so would be used as a positive control inhibitor of the Mur ligases during inhibitory fragment testing.

**3.4.5.2 ADPCP has an IC$_{50}$ value of 24.2 µM against MurD from *S. agalactiae***

ADPCP was shown to be able to act as a positive control inhibitor of MurD from *S. agalactiae* within a MESG coupled assay. For all inhibitors, an IC$_{50}$ value can be determined. The IC$_{50}$ value relates to the concentration of inhibitor required to achieve a 50% inhibition of enzyme activity within the assay. The MESG coupled assay was carried out for MurD from *S. agalactiae* in the presence of various ADPCP concentrations using a Plate reader. The initial rate was determined and plotted against ADPCP concentration. As can be seen from Figure 2.14, the initial rate of MurD from *S. agalactiae* decreases as the concentration of ADPCP increases, with an IC$_{50}$ value of $24.2 \pm 7.6$ µM being determined.
3.4.5.3 ADPCP has a Ki value of 11.7 µM against MurD from *S. agalactiae*

The IC$_{50}$ value for an inhibitor can vary based on enzyme and substrate concentration. To overcome this issue, the IC$_{50}$ value can be related to the affinity of the inhibitor via an absolute inhibition constant, K$_i$.

The IC$_{50}$ value can be related to the affinity of the inhibitor via an absolute inhibition constant, K$_i$. The K$_i$ value of ADPCP against MurD from *S. agalactiae* can be determined using the Cheng-Prusoff equation describing the relationship between IC$_{50}$ and K$_i$ for a simple competitive inhibitor:

$$K_i = \frac{IC_{50}}{1 + \frac{[S]}{K_m}}$$

where [S] is the fixed substrate concentration and $K_m$ is the Michaelis constant. In this equation, the K$_i$ will always be lower than the IC$_{50}$, as the IC$_{50}$ is divided by a number greater than 1. ADPCP was shown to act as an inhibitor of MurD, and as an ATP analogue was likely to be competitive with ATP binding. Therefore, substituting the $K_m^{App}$ value for ATP (47.1 µM), the concentration of ATP used (50 µM) and the observed IC$_{50}$ of 24.2 µM into the equation allowed for the computation of a Ki for ADPCP for ATP-competitive inhibition of MurD from *S. agalactiae* of 11.7 µM.

3.4.5.4 Z prime score of a MESG coupled assay

ADPCP was shown to be able to act as an inhibitor of MurD from *S. agalactiae* within a MESG coupled assay, suggesting that the MESG coupled assay could be used to establish the inhibitory effects of unknown fragments. The final step in evaluating the assay for use within high throughput screening was assessing its effectiveness to distinguish between positive and negative controls. One way to determine this effectiveness is via a Z score. By running an assay in the presence (positive) and absence (negative) of a positive inhibitor control for the assay system, the Z score can provide a numerical value for the effectiveness of the assay for distinguishing inhibition. The Z score takes into account the difference between the means of the positive control and the negative control, (the
‘dynamic range’) as well as the difference between set standard deviation values of the positive and negative controls, (the ‘separation band’), as seen in Figure 2.15.

The Z prime score is defined as the ratio of the separation band to the dynamic range, and can be calculated using the equation 90:

$$Z = 1 - \frac{(3\sigma_s + 3\sigma_c)}{\mu_s - \mu_c}$$

Where \(\sigma\) indicates the standard deviation, \(\mu\) indicates the mean, \(s\) indicates sample and \(c\) indicates control. Using this equation, a value between negative infinity and 1 can be achieved. A value above 0.5 is considered a very good assay, and a value above 0 an acceptable assay 91.

To determine the Z prime score of the MESG coupled assay, the initial rate for MurD in the presence and absence of ADPCP at its IC\(_{50}\) value were compared across 10 repeats using a plate reader. The mean value and standard deviations were
determined, to allow the determination of the Z prime score, as seen in **Table 2.4**. The Z prime score was determined to be 0.86, indicating that the activity assay could identify inhibitors accurately.

<table>
<thead>
<tr>
<th></th>
<th>MurD</th>
<th>MurD + ADPCP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean</strong></td>
<td>0.1715</td>
<td>0.07765</td>
</tr>
<tr>
<td><strong>Standard Deviation</strong></td>
<td>0.00316</td>
<td>0.00118</td>
</tr>
<tr>
<td><strong>Z prime Score</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[ Z = 1 - \frac{(3 \times 0.00316) + (3 \times 0.00118)}{(0.1715 - 0.07765)} ]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[ Z = 0.86 ]</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2. 4: Determination of the Z prime score for ADPCP within a MESG coupled assay against MurD from S. agalactiae**

The Z prime score was determined by calculating the mean $V_0$ for MurD in the presence and absence of ADPCP, along with the standard deviation of the means. The Z prime was then calculated using the formula shown. A Z prime score of 0.86 was determined for ADPCP against MurD from *S. agalactiae* within a MESG coupled assay.

**3.5 Optimization of existing assay for fragments targeted towards the ATP-binding site**

Optimization steps of the MESG coupled assay have focused on the Mur ligase in the presence of its standard substrates. However, if inhibitory fragments are targeted towards the binding site of a substrate it may be beneficial to run the assay with an alternative. An alternative substrate may have a higher $K_m$, which would make the assay more sensitive to fragments targeted towards the binding site of that substrate, as fragments are likely to have low binding affinities. One area inhibitory fragment sets may be targeted towards is the ATP-binding site of the Mur ligases. Finding an alternative nucleotide with a higher $K_m$ for the Mur ligases would be a useful optimization of the assay for potential inhibitory screens.

**3.5.1 MurD from *S. agalactiae* lacks activity with alternative nucleotides**

A variety of nucleotides that have previously been shown to be active against MurC, and having higher $K_m$ values than ATP (A. Lloyd Pers. Commun) were chosen to be tested against MurD from *S. agalactiae*. GTP and ITP are purine-based nucleotides that contain a double bonded oxygen in place of the NH$_2$ present in
ATP, shown in Figure 2.16. CTP maintains the NH$_2$ group but is a pyrimidine rather than purine-based nucleotide, as seen in Figure 2.16.

![Structural formulas of ATP and alternative nucleotides](image)

**Figure 2. 16: Structural formulas of ATP and alternative nucleotides**

Structural formulas of alternative nucleotides tested against MurD from *S. agalactiae*. (A) ATP is a pyrimidine nucleoside that contains an NH$_2$ group but is a pyrimidine rather than purine-based nucleotide, as seen in Figure 2.16.

The activity of MurD from *S. agalactiae* was compared between ATP, and the three alternative nucleotides using a MESG coupled assay in a spectrophotometer. As can be seen from Figure 2.17, activity of MurD could only be established in the presence of ATP, with no activity for MurD being seen in the presence of the three alternative nucleotides after the addition of D-Glu.

![MurD from S. agalactiae lacks activity in the presence of alternative nucleotides](image)

**Figure 2. 17: MurD from *S. agalactiae* lacks activity in the presence of alternative nucleotides**

Using a MESG coupled assay the activity of MurD was determined in the presence of various nucleotides. The activity rate after the addition of D-Glu was followed spectrophotometrically at 360 nm. Alternative nucleotides were tested at 1 mM, while all other substrates were at their $K_m$ concentrations as observed in the presence of ATP. ATP is shown in blue, GTP shown in orange, ITP shown in green and CTP shown in pink. MurD showed no detectable activity with the alternative nucleotides.
3.5.2 MurD as an enzyme lacks activity with alternative nucleotide

Mur ligases have been shown in vitro to be able to utilise alternative nucleotides for activity. However, it appeared that MurD from *S. agalactiae* was inactive in the presence of alternative nucleotides. This could be due to greater nucleotide triphosphate specificity. To determine where the specificity lies, the ability of MurE from *S. agalactiae* and MurD from *P. aeruginosa* to use alternative nucleotides within a MESG coupled assay was determined via a spectrophotometer. MurE from *S. agalactiae* could use all three alternative nucleotides for activity as seen in Figure 2.18A, but MurD from *P. aeruginosa* showed no activity with any of the alternative nucleotides, seen in Figure 2.18B. These results suggest a high level of substrate specificity for ATP within MurD as an enzyme compared to GTP, ITP and CTP.

![Figure 2.18](image)

*Figure 2.18: MurD as an enzyme lacks activity with alternative nucleotides*

Using a MESG coupled assay, the ability of 50 nM MurE from *S. agalactiae* and 50 nM MurD from *P. aeruginosa* to use alternative nucleotides was established. The activity rate after the addition of amino acid was followed spectrophotometrically at 360 nm. Alternative nucleotides were tested at 1 mM, all other substrates were at their *K_m* concentration. ATP is shown in blue, GTP shown in orange, ITP shown in green and CTP shown in pink. (A) MurE from *S. agalactiae* shows activity with all nucleotides tested. (B) MurD from *P. aeruginosa* shows no detectable activity with any nucleotides apart from ATP.
3.5.3 MurD is unable to hydrolyse alternative nucleotides

The lack of activity of MurD with the alternative nucleotides could have been due to an inability of the alternative nucleotides to bind to the ATP-binding site of MurD. Alternatively, the lack of activity could have been due to the inability of MurD to hydrolyse the alternative nucleotides once bound. In order to determine which was occurring, a competition assay with the alternative nucleotides and ATP was run using a spectrophotometer, where the concentration of the alternative nucleotide was increased in relation to the ATP concentration. If the nucleotides were able to bind in place of ATP but were unable to be hydrolysed by MurD, then a decrease in activity would be seen. However, if the alternative nucleotides were unable to bind, the activity would remain the same irrespective of how much alternative nucleotide was introduced into the assay. Using a MESG coupled assay, the ratio of [Alternative nucleotide]: [ATP] was gradually increased and the activity of MurD from *S. agalactiae* determined. As can be seen from Figure 2.19, the activity of MurD decreases as the concentration of all alternative nucleotides increases. This suggests that MurD was able to bind all three alternative nucleotides but was unable to hydrolyse them, resulting in a lack of activity.

*Figure 2.19: MurD lacks the ability to hydrolyse alternative nucleotides*

Using a MESG coupled assay, the ability of 50 nM MurD from *S. agalactiae* to bind or hydrolyse alternative nucleotides was established. Substrates were at their $K_m$ concentrations. Alternative nucleotides were introduced alongside ATP at a concentration that was in relation to the ATP concentration, and the initial rate of MurD determined. GTP shown in orange, ITP shown in green and CTP shown in pink. MurD could bind all three alternative nucleotides to varying degrees but is unable to hydrolyse them.
3.5.4 Deoxy-ATP can act as an alternative nucleotide for MurD

![Skeletal formula of ATP and Deoxy-ATP](image)

Skeletal formula of ATP and deoxy-ATP. Deoxy-ATP maintains the adenine ring of ATP but lacks an OH group on the ribose sugar, highlighted by the purple arrow.

MurD from *S. agalactiae* was unable to hydrolyse the alternative nucleotides when the adenine base was changed. 2′-deoxyadenosine triphosphate (deoxy-ATP) retains the adenine base but removes the 2′ OH group from the ribose sugar, as shown in Figure 2.20.

This could mean that MurD would be able to use deoxy-ATP as an alternative nucleotide to ATP. Using a MESG coupled assay on a spectrophotometer, the activity of MurD from *S. agalactiae* in the presence of deoxy-ATP was determined. As can be seen from Figure 2.21, an activity rate could be seen for MurD in the

![MurD can use deoxy-ATP as an alternative nucleotide](image)

Using a MESG coupled assay, the ability of MurD to utilise deoxy-ATP as an alternative nucleotide was established. All substrates were present at their *Kₘ* values, and deoxy-ATP was run at 200µM. The activity rate after the addition of D-Glu was tracked spectrophotometrically at 360 nm. MurD was able to utilise deoxy-ATP, with a reduced activity rate, making it a suitable alternative nucleotide.
presence of deoxy-ATP, suggesting that deoxy-ATP may be able to act as a suitable alternative nucleotide for MurD within targeted fragment screens.

As MurD was able to use deoxy-ATP as an alternative nucleotide, the $K_m$ of deoxy-ATP was established to determine if deoxy-ATP had a higher $K_m$ than ATP against MurD from *S. agalactiae*, which would make it more effective in targeted fragment screens. Using a MESG coupled assay on a Plate reader, the activity of 80 nM MurD from *S. agalactiae* at increasing concentrations of deoxy-ATP were assayed. The resulting initial rates were plotted against deoxy-ATP concentration. The data was plotted and then fitted by non-linear regression within GraphPad to the Michaelis Menten equation resulted in the graph seen in Figure 2.22. As can be seen from Table 2.5, the $K_m$ of deoxy-ATP with MurD from *S. agalactiae* was determined to be 476.1 $\pm$ 81.2 $\mu$M.

![Figure 2.22: The $K_m$ for deoxy-ATP for MurD from *S. agalactiae* is 477 $\mu$M](image)

The $K_m$ for deoxy-ATP for MurD from *S. agalactiae* was determined using a MESG coupled assay. The initial reaction rate of MurD was determined at various deoxy-ATP concentrations to allow determination of $V_{max}$ and $K_m$. Other substrate concentrations were above their $V_{max}$ to prevent interference when determining the $K_m$. Experiments are performed in triplicate with error bars indicating SD.

<table>
<thead>
<tr>
<th>Substrate</th>
<th>$K_m^{App}$ ($\mu$M)</th>
<th>$V_{max}^{App}$ ($\mu$M Pi/ min$^{-1}$)</th>
<th>$K_{cat}^{App}$ (s$^{-1}$)</th>
<th>$K_{cat}^{App}$/$K_m^{App}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deoxy-ATP</td>
<td>476.1 $\pm$ 74</td>
<td>110.7 $\pm$ 5.3</td>
<td>23</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Table 2.5: Kinetic determinations for deoxy-ATP for MurD from *S. agalactiae*

The kinetic determinations of deoxy-ATP for MurD from *S. agalactiae* was determined using a MESG coupled assay. MurD was at a concentration of 80 nM.
3.6 Development of a stop point assay for Mur ligase activity

Previously used assays have relied upon a secondary coupled reaction running concurrently with the primary Mur ligase reaction. This requires the components of the secondary reaction to be at high concentrations to allow the consumption of phosphate generated during the initial rate period of the Mur ligase reaction to be fast enough to not itself be rate limiting. This makes the assay expensive when scaled up to run high throughput screening of fragments. Other issues with scaling up this version of the assay for high throughput screening were the amount of data interpretation required for each assay. Typically, continuous assay plate-reader rate data comprised of up to 1000 data points which required manual analysis for each individual run of the assay, making data analysis extremely inefficient.

![Diagram](Figure 2.23: Diagram to compare the set-up of a MESG coupled assay and a stopped MESG assay)

Previously used assays relied on the coupling reaction running concurrently with the Mur ligase reaction. Within a stop point assay, the coupling reaction would be run after the Mur ligase reaction. (A) In previously used assays, all reactions would be running simultaneously; as the Mur ligase converts its substrates into its UDP intermediate and free phosphate, the phosphate would immediately be used by the coupling reaction to convert MESG into 7 methyl 6 thio guanine, resulting in an absorbance change at 360 nm. (B) In a stopped assay, the Mur ligase reaction would occur, converting the substrates into the UDP intermediate product and free phosphate. The Mur ligase reaction would then be stopped before the free phosphate formed would be used within the coupling reaction to convert MESG into 7 methyl 6 thio guanine resulting in an absorbance change at 360 nm.
Additionally, following \( V_0 \) requires the very initial portion of the assay to be tracked with a large amount of data points to make it as accurate as possible, therefore precluding the testing of a large number of samples simultaneously.

To combat these issues, a stop point assay could be designed whereby the coupling reaction and Mur ligase reaction are run consecutively. This would mean running the Mur ligase reaction over the initial rate period before stopping the reaction. The free phosphate formed during the initial rate period of the Mur ligase reaction could then be used within the coupling reaction which would be tracked to its end point to give the initial rate of the ligase, as seen in Figure 2.23.

By tracking the end point of the coupling reaction, the requirement to collect a large volume of data points during the initial stage of the reaction to get an accurate rate of the Mur ligase activity is removed. Running the coupling reaction separately also removes the requirement of having the coupling reaction components at high concentrations to keep pace with the Mur ligase reaction during its initial rate period. Instead, the coupling reaction components can be decreased reducing the cost of the assay. In order to design a stopped assay, a stopping agent that could stop Mur ligase activity, but not affect the secondary assay was required. Comparison of the recordable initial rate of the ligase across both assays would also need to be carried out. Furthermore, the effect of dropping the coupling reaction components on the recordable initial rate of the Mur ligase would need to be determined to conclude if a stop point assay was a viable alternative to the existing assays.

3.6.1 EDTA inhibits the MurD reaction within an assay

In order to develop a stop point assay, the first step was to determine if the Mur ligase reaction could be stopped during the initial rate period in order to be able to separate the Mur ligase reaction from the coupling reaction. Mur ligases require the presence of \( \text{Mg}^{2+} \) to form the magnesium-chelate of ATP. Ethylene diamine tetra acetic acid (EDTA) can chelate divalent cations, and so would be able to chelate the Mg that is present in the buffer of the assay. Removing the Mg from the buffer system would stop the Mur ligases from binding their substrates,
effectively preventing their activity. EDTA and EDTA in complex with Mg do not absorb at 360 nm and so any change in absorption seen would be due to the effect EDTA was having on the Mur ligase reaction. The activity of MurD from *S. agalactiae* was tracked photometrically via a MESG coupled assay on a spectrophotometer with a reduced Mg concentration of 2 mM. Once the initial rate period had occurred, 10 mM EDTA, in a 5 to 1 ratio to Mg, was introduced into the assay. After introduction of EDTA into the assay system a plateau in absorbance was observed, as seen in Figure 2.24. A plateau in absorbance suggests that there was no longer any phosphate being produced within the assay system for the PNP to act upon to convert MESG to 7 methyl 6 thio guanine suggesting that there was no longer any activity of MurD.

![Figure 2.24: EDTA is able to stop activity of MurD from *S. agalactiae*](image)

Using a MESG coupled assay, the ability of EDTA to impede the reaction of MurD from *S. agalactiae* was determined. The MESG coupled assay was run using standard conditions with substrates at their *K*_m values. The Mur ligase reaction was initiated with ATP and the initial rate of the reaction tracked spectrophotometrically. After a minute and a half of tracking the initial rate, a final concentration of 10 mM EDTA was added. A plateau in absorbance shows that the MurD reaction is impeded by the addition of EDTA.

To confirm that the addition of EDTA was affecting the activity of the Mur ligase reaction, and not the ability of the coupling system to track the free
phosphate, the coupling assay was run in the presence of EDTA on a Plate reader. As can be seen from Figure 2.25, a linear relationship between $V_0$ and [Phosphate] was still seen in the presence of EDTA. The gradient of the line was determined to be 2719 M$^{-1}$cm$^{-1}$, which was not statistically different to the gradient of the MESG assay in the absence of EDTA, as seen in Section 3.4.1, suggesting that the addition of EDTA was effectively stopping the Mur ligase reaction only.

Figure 2.25: EDTA does not affect the secondary coupling system

The activity of the secondary coupled reaction in the presence of EDTA was determined. The initial rate of the reaction at various phosphate concentrations was determined. Initial rate was plotted against phosphate concentration. A linear relationship was observed between phosphate concentration and initial rate, showing the addition of EDTA was not affecting the secondary assay system.

3.6.2 The initial rate of *S. agalactiae* MurD can be determined within a stop point assay

As EDTA was able to stop the activity of MurD but caused no effect on the ability of the secondary system to use free phosphate, EDTA could be used as a stopping agent allowing the separation of the Mur ligase reaction from the secondary reaction. However, the effect of stopping the Mur ligase reaction with EDTA and then running the secondary reaction separately on the measurable $V_0$ of the Mur ligase had to be determined. To understand the effect stopping the reaction and running the secondary reaction separately had on the recordable $V_0$, the $V_0$ of MurD from *S. agalactiae* was determined via a MESG coupled assay on a spectrophotometer and compared to the $V_0$ determined using the stopped MESG assay on a spectrophotometer, as seen in Figure 2.26.
The \( V_0 \) of MurD within a MESG coupled assay was determined to be 0.1/min, while within the stop point assay it was determined to be 0.098/min. These results were not statistically significantly different, suggesting that the addition of EDTA, and the uncoupling of the reaction did not influence the measurable \( V_0 \) of \( S. \text{agalactiae} \) MurD, suggesting that accumulation of phosphate in the stopped assay (which did not occur in the continuous variant of the assay) did not inhibit MurD catalysis.

![Graphs](image)

*Figure 2. 26: Comparison of the measurable \( V_0 \) of MurD between a MESG coupled assay and a stop point assay*

The measurable \( V_0 \) of MurD from \( S. \text{agalactiae} \) was compared between a MESG coupled assay and a stop point assay. Experiments were run in triplicate with an example run shown. (A) Using a MESG coupled assay, under \( K_m \) conditions, the \( V_0 \) of MurD from \( S. \text{agalactiae} \) was determined, highlighted with a red line. The \( V_0 \) was determined to be 0.1/min. (B) Using a stop point assay, under \( K_m \) conditions, the \( V_0 \) of MurD from \( S. \text{agalactiae} \) was determined, highlighted with a red line. The \( V_0 \) was determined to be 0.098/min.

### 3.6.3 Reduction of PNP levels has no significant effect on \( V_0 \)

Previously the coupling reaction components were present within the assay at concentrations that would not interfere with the determination of the \( V_0 \) of the Mur ligase. This meant the components were at concentrations that allowed for there to be an excess within the assay, allowing all the phosphate produced by Mur ligase activity to be immediately consumed by PNP, allowing for accurate determination of the activity of the Mur ligase. This however, meant the assay was expensive to run for high throughput screening. By reducing the concentration of
PNP, the assay could become more cost effective for high throughput screening. To ensure reducing the secondary coupling enzyme did not affect the recordable \( V_0 \) of the Mur ligase, the stopped assay was run in the presence of various PNP concentrations on a spectrophotometer, and the MurD \( V_0 \) was determined. As can be seen from Figure 2.27, reducing the PNP concentration caused no statistically significant difference on the recordable \( V_0 \) of MurD from \textit{S. agalactiae}.

![Figure 2.27: Reducing PNP concentration causes no significant effect on \( V_0 \) of MurD from \textit{S. agalactiae}](image)

The measurable \( V_0 \) of MurD from \textit{S. agalactiae} was determined at various PNP concentrations. Using a stop point assay with all substrates at their \( K_m \) values the \( V_0 \) of MurD from \textit{S. agalactiae} was determined at various PNP concentrations. Reducing the PNP concentration caused no significant effect on the measurable \( V_0 \) of MurD.

### 3.6.4 Quality of assay for high throughput screening

The stopped MESG assay was developed to improve upon the existing assays to facilitate screening for inhibitory fragments. The stopped MESG assay would allow more fragments to be tested simultaneously, requiring less data analysis, and being more cost effective than existing assays. However, the effectiveness of the assay for determining inhibition would need to be established before it could be used for screening of inhibitory fragments.

#### 3.6.4.1 Inhibition of the MurD reaction within a stopped MESG assay

One way to determine the effectiveness of the stopped MESG assay to identify inhibitors was to test a known inhibitor within the assay. ADPCP was already shown to act as an inhibitor within a MurD assay. The stopped MESG assay was run in the
presence and absence of ADPCP on a spectrophotometer and the $V_0$ determined.

As can be seen from Figure 2.28, ADPCP reduced the $V_0$ of *S. agalactiae* MurD by greater than 30%.

![Figure 2.28: ADPCP can act as an inhibitor of MurD within a stop point assay](image)

The activity of MurD from *S. agalactiae* was tracked using a stop point assay in the absence and presence of 10 µM ADPCP. The Mur ligase reaction was run in the presence or absence of ADPCP for the initial rate period before being quenched with EDTA. The secondary coupling reaction was then initiated by PNP and tracked spectrophotometrically at 360 nm. Absence of ADPCP shown in dark blue, presence shown in light blue.

![Figure 2.29: ADPCP has an IC50 value of 22.8 µM against MurD from *S. agalactiae* within a stop](image)

The IC50 value of ADPCP against MurD was determined using a stop point assay. Substrate concentrations were at their $K_m$ values. The concentration of ADPCP was increased and the initial rate of MurD determined. The IC50 value was determined as the concentration of ADPCP that reduced activity of MurD by 50%. All experiments were run in triplicate with error bars indicating SD.
ADPCP was still able to inhibit *S. agalactiae* MurD within a stopped assay, and so the IC\(_{50}\) value of ADPCP was determined. The \(V_0\) of *S. agalactiae* MurD was determined at varying concentrations of ADPCP via a Plate reader. The impact of increasing ADPCP concentration of MurD \(V_0\) was then established. As can be seen from Figure 2.29, ADPCP had an IC\(_{50}\) of 22.8 \(\pm\) 7.5 \(\mu\)M which was not statistically different from that seen within existing assays (24.2 \(\pm\) 7.6 \(\mu\)M, Section 3.4.5.2).

3.6.4.2 Z prime score for assay shows high level of effectiveness for determining inhibition

The effectiveness of the stopped MESG assay to determine inhibition was also determined by calculating the Z prime score. A Z prime score between 0.5 and 1 shows a high level of effectiveness within the assay for determining inhibition. To determine the Z prime score of the stopped MESG assay, the \(V_0\) for MurD from *S. agalactiae* in the presence and absence of ADPCP at its IC\(_{50}\) value within a stopped MESG assay were compared. 10 repeats were run via a Plate reader. The mean value and standard deviations were determined, to allow the determination of Z prime score, as seen in Table 2.6. The separation band was then divided by the dynamic range to determine that the Z prime score for the assay was 0.73. This Z prime score was able to show that the assay would be effective in determining the inhibitory effects of fragments.

<table>
<thead>
<tr>
<th></th>
<th>MurD</th>
<th>MurD + ADPCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>0.11</td>
<td>0.048</td>
</tr>
<tr>
<td>Standard Deviation</td>
<td>0.0013</td>
<td>0.0042</td>
</tr>
<tr>
<td>Z prime Score</td>
<td>[Z = 1 - \frac{(3 \times 0.0013) + (3 \times 0.0042)}{(0.11 - 0.048)}]</td>
<td>(Z = 0.73)</td>
</tr>
</tbody>
</table>

Table 2.6: Z prime score determination within a stopped assay

The Z prime score was determined by calculating the mean \(V_0\) for MurD in the presence and absence of ADPCP, along with the standard deviation of the means. The Z prime was then calculated using the formula shown. A Z prime score of 0.73 was determined for ADPCP against MurD from *S. agalactiae* within a stopped assay.
4. Conclusions and Future Direction

4.1 Optimization of biochemical assays required for inhibitory fragment identification

Activity assays can be used to biochemically test fragments for their ability to inhibit the activity of a protein\textsuperscript{92}. By optimising the activity assays developed for the Mur ligases, a system was produced that would provide the greatest opportunity for identifying inhibitory fragments. Identification of the $K_m$ values for the substrates allowed optimization of the assay for the identification of competitive inhibitors\textsuperscript{92}. Identifying a positive control inhibitor, ADPCP, provided a standardized control to which all inhibitory fragments could be compared to. Determination of a Z prime score of 0.86 for ADPCP within the assay confirmed that the assay has been optimized to a standard consistent with other published assays used for the identification of inhibitors\textsuperscript{93,94}. These optimization steps produced an assay that was at a stage that it could be used for screening inhibitory fragments.

4.2 Nucleotide specificity of MurD could act as a starting point for future antibacterial development

During the optimization of the activity assay, it was determined that MurD shows a high level of nucleotide specificity. Activity assays in the presence of GTP, ITP and CTP showed that MurD lacked activity with these alternative nucleotides. Further experiments identified that MurD from\textit{S. agalactiae} was, however, able to bind these nucleotides. Understanding the difference in binding that occurs between ATP and these alternative nucleotides, which resulted in \textit{S. agalactiae} MurD being unable to hydrolyse the nucleotide could provide a starting place for the development of inhibitory fragments targeted towards the ATP-binding site of MurD. Understanding the binding mode of fragments that inhibit the activity of a protein, and how binding differs from the intended substrate is a key technique in the development of inhibitory compounds. Understanding which residues to target to prevent activity allows for the development and optimization of inhibitory compounds targeted towards a specific region of a protein. This approach has previously been used by Hameed et al to improve fragments targeted towards the ATP-binding site of MurC from \textit{E. coli} and \textit{P. aeruginosa}\textsuperscript{77}. Crystal structures of \textit{S. agalactiae} MurD bound to ATP and the alternative nucleotides could reveal...
different binding modes that might suggest new routes for the development of MurD inhibitors.

4.3 Use of stopped assays for high-throughput screening

By converting the current activity assay into a stopped assay, limitations of the current assay system for high throughput screening could be overcome. The introduction of an enzyme quenching step within an assay is a common technique used for the conversion of an assay system into one suitable for high throughput screening, as seen by Sullivan et al introducing ZnSO$_4$ to quench purine enzymes and form a suitable high throughput assay screen for purine biosynthesis. Conversion of the current assay system into a stopped assay reduced the requirement for data collection within the initial rate period of the assay, as well as reduced the data analysis after collection, allowing the assay to become more efficient to run and analyse, a key requirement for high throughput screens. Conversion to a stopped assay also allowed the assay to become more cost effective by allowing a reduction in the concentration of the secondary coupling enzyme, PNP. These alterations allowed for an assay that can complete multiple runs within a day allowing for the testing of large numbers of inhibitory fragments per day, a hallmark of high throughput screening. Limitations were still present within the stopped assay, such as sensitivity and the interference of fragments at the recorded absorbance, aspects which were tackled within the fluorometric assay described in Chapter 5.
Chapter 3

Identification of μM inhibitory fragments that can target multiple Mur ligases
1. Introduction and Aims

The Mur ligases are attractive targets for the development of new antibiotics due to their presence in all bacterial species, with no eukaryotic counterpart\(^{64}\). Developing new antibiotics is a daunting task, and there are many ways in which to start the process. One approach is by using screening of small chemical scaffolds (fragment screening), which if inhibitory, can act as the initial building blocks which can be further elaborated to improve binding potency\(^{97}\), and deliver \textit{in vivo} activity, which can hopefully lead to effective antibiotic development.

Fragment screening is now a well-established starting point for the development of inhibitory compounds. The initial stages of fragment screening can be carried out \textit{in silico} or via X-ray crystallography. X-ray crystallography is a biophysical technique that can be used to identify fragments that are able to bind to a protein of interest and structurally characterise such an interaction. XChem is a service developed by Diamond that allows users to screen fragments via X-ray crystallography. XChem involves soaking a protein of interest with a fragment screen before determining the crystal structure of the protein in the presence of the fragment\(^{98}\). This allows for the characterization of the binding of fragments to the macromolecular target. Fragments that appear to bind in an area of interest can then be developed and tested further, either biochemically or via another XChem screen, allowing the enhancement of selectivity and potency as inhibitors of target activity.

XChem is able to identify fragments that are able to bind to a protein of interest, however, a biochemical approach is required to determine if bound fragments can inhibit the activity of the protein. Activity assays can be used to establish the effect fragments have on the activity of the protein, and determine which fragments have inhibitory effects.

This chapter describes the use of XChem, which was carried out by our collaborators at University College London (UCL) and Diamond within the open-source Mur Ligase project, to identify binding fragments to MurD from \textit{S. agalactiae}. Biochemical assays were then carried out on the fragments, to identify the inhibitory effects of these fragments on MurD from \textit{S. agalactiae}. Assay
interference checks were then completed, before fragments were tested for their ability to act as dual inhibitors and target Mur ligases from other bacteria. Further enzymological analysis was carried out on inhibitory fragments to determine the IC$_{50}$ values.
2. **Materials and Methods**

2.1 XChem

An XChem fragment screen was carried out by Dr Dana Klug at UCL. A Diamond-SGC-iNEXT Poised (DSI-poised) fragment library $^{99}$, consisting of ~ 768 fragments at 500 mM in d6-DMSO was screened against apo MurD from *S. agalactiae*. Further experimental details can be obtained by contacting Dr Dana Klug.

2.2 Stopped MESG assay

Fragments were biochemically tested for inhibition via a stopped MESG assay. Fragments were provided in powdered form and diluted to a stock concentration of 10 mM in DMSO. In a final volume of 50 µL, 1 mM of fragment was incubated with the relevant concentration of Mur ligase, in the presence of 50 mM HEPES (pH7.6), 2 mM MgCl$_2$, 1 mM DTT, 50 mM KCl, 400 µM MESG, and the relevant substrates barring ATP for 10 minutes. The assay was then initiated with 50 µM ATP and allowed to run for the initial rate period before the reaction was quenched with 10 mM EDTA. A background absorbance was determined photometrically via the Varioskan plate reader (ThermoFisher) at 360 nm before 24.2 U per litre PNP was added. Absorbance change was tracked at 360 nm for 40 minutes to allow the end point to be achieved. The absorbance change was then determined. Each fragment was run in triplicate in the presence and absence of the Mur ligase to determine background rate. Background rates were removed from the final activity rate for each fragment. The activity rate was compared to control groups of 10% $^\vee/V$ DMSO and 5 µM ADPCP. Assays were carried out at 37°C.

To determine the inhibitory activity of fragments against MurD from *S. agalactiae*, 100 nM MurD was incubated with 1 mM of fragment in the presence of 60 µM UDP-MurNac-L-Ala and 250 µM D-Glu. To determine the inhibitory activity of fragments against MurE from *S. agalactiae*, 100 nM MurE was incubated with 1 mM of fragment in the presence of 60 µM UDP-MurNac-L-Ala-D-Glu and 200 µM L-Lys. To determine the inhibitory activity of fragments against MurE from *P. aeruginosa*, 100 nM MurE was incubated with 1 mM of fragment in the presence of 60 µM UDP-MurNac-L-Ala-D-Glu and 200 µM DAP.
2.3 Secondary coupling system assay

In a final concentration of 50 µL, 400 µM MESG, 50 mM HEPES (pH7.6), 1 mM MgCl₂, 1 mM DTT, and 50 mM KCl were incubated with 1 mM fragment and the absorbance change at 360 nm was followed in a Varioskan plate reader (ThermoFisher) over the course of 10 minutes. 130 µM Na(H₂)PO₄ was then introduced and the absorbance change at 360 nm was followed over the course of 5 minutes. 24.2 U per litre PNP was then introduced and the absorbance change at 360 nm was followed for 40 minutes to allow the end point to be attained. The absorbance change for each stage was then determined and compared to a control group of 10% v/v DMSO. Assays were carried out at 37°C.
3. Results
3.1 XChem of DSI-Poised fragment library against Mur ligases

In order to identify fragments that bind to the Mur ligases, XChem was carried out via our collaborating partners at UCL and Diamond. The initial fragment screen was carried out using a DSI-poised fragment library screen produced by Diamond Light source. The DSI-poised fragment library was designed to allow rapid and cheap follow-up synthesis of fragment hits by having fragments that contained at least one functional group that could be synthesised using well-characterised reactions. The library consisted of 768 fragments that were present at a concentration of 500 mM in deuterated-DMSO. The library was screened against apo MurD from *S. agalactiae* and apo MurE from *E. coli* at Diamond and the results were interpreted by Dr Dana Klug at UCL.

3.1.1 Identification of binding pocket within apo MurD from *S. agalactiae*

The XChem fragment screen against apo MurD from *S. agalactiae*, run by our collaborators at Diamond and UCL, identified 4 hits, as shown in Figure 3.1. These fragments were identified as binding to a pocket adjacent to the ATP-binding site, as shown in the XChem generated structure in Figure 3.2A.

![Figure 3.1: Structural formula of four hits from the DSI-poised fragment library identified to bind to MurD from *S. agalactiae*](image-url)
Fragments were identified to bind within a pocket adjacent to the ATP-binding site. UMA is shown bound as well. (B) Fragment 349. (C) Fragment 373. Forms an interaction between the nitrogen and Glu132, and between the oxygen and Lys311. (D) Fragment 374. Forms an interaction between the hydroxyl group and Glu132, and the oxygen and Lys311. (E) Fragment 378. Forms an interaction between the oxygen and Lys311.

Fragment 349 was unable to form hydrogen interactions, as seen in the XChem interaction in Figure 3.2B, but likely formed van der Waal interactions. As seen in the XChem interaction in Figure 3.2C, fragment 373 formed an interaction between
the piperazine nitrogen and Glu132 as well as an interaction between the carbonyl oxygen of 373 and the Lys311 peptide bond amide nitrogen. Fragment 374 formed interactions with Glu132 and Lys311, with an interaction between the propane diol hydroxyl group and Glu132, and the carbonyl oxygen of 374 and the Lys311 peptide bond amide nitrogen, as seen in the XChem interaction in Figure 3.2D. Fragment 378 was also able to form hydrogen bonds through its carbonyl oxygen atom and Val 310 and Lys311 as seen in the XChem interaction in Figure 3.2E. These fragments were all suitable building blocks for the development of a fragment screen that elaborated and built upon these parental fragments with the aim of targeting the binding site present within MurD from \textit{S. agalactiae}.

### 3.1.2 Production of elaborated fragment screen

Based on the parental fragments 349, 373 and 378 an elaborated fragment screen containing seventy-eight fragments was produced by Dr Dana Klug. The elaborated fragment screen contained analogues of the parental fragments, such as piperazine analogues, aryl analogues and sulphonamide analogues. A full list of the elaborated fragment screen can be found in \textit{Supplementary 1}, and further information on its development can be found under the issue ‘Follow up for the fragment hits for MurD Ligase’ within the open source Mur ligase project GitHub.

### 3.2 Determination of inhibition of MurD activity by fragments via biochemical assay

As the parental fragments were binding to a pocket adjacent to the \textit{S. agalactiae} MurD ATP-binding site, these fragments and those within the elaborated fragment screen derived from the parental fragments may have had no effect on activity of the ligase and may be unable to cause inhibition. To determine the effect these fragments had on the activity of MurD, a biochemical approach was required.

#### 3.2.1 Identification of inhibitory fragments targeted against MurD from \textit{S. agalactiae}

In order to determine the effect the elaborated fragments had on the activity of MurD, a stopped MESG assay was used, which was validated in \textit{Chapter 2}. Our
collaborators at UCL and Diamond produced the constituent fragments of the elaborated screen which were typically reconstituted in 100% (v/v) DMSO. However, fragments 779, 784, 790, 799 and 806 of the elaborated screen could not be reconstituted, and so were not tested biochemically. The ability of the reconstituted fragments to inhibit the activity of \textit{S. agalactiae} MurD was then determined using the stopped MESG assay. Fragments were incubated at a final concentration of 1 mM with \textit{S. agalactiae} MurD prior to initiation of the activity assay. The activity of MurD in the presence of fragments was compared to a control of the activity in the presence of 10% (v/v) DMSO alone. The percentage activity of MurD in the presence of fragments was determined, as seen in Figure 3.3. A positive control inhibitor of ADPCP was also used to confirm inhibition within the assay system. As can be seen from Figure 3.3, the fragments had a varied effect on the activity of MurD.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{activity_of_mur_d}
\caption{Activity of MurD in the presence of elaborated fragments}
\end{figure}

The ability of the elaborated fragments to inhibit the activity of MurD from \textit{S. agalactiae} was determined via a stopped MESG assay. Fragments were incubated at a final concentration of 1 mM with 100 nM MurD before activity of MurD was determined. Activity of MurD in the presence of fragments was compared to a control group of DMSO and the percentage activity of MurD determined and plotted. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean percentage activity of compounds was plotted. Black line indicates 100% activity of MurD. Red line indicates 20% activity of MurD.
Thirty two fragments were able to reduce activity of MurD by 25% or more. Twenty four fragments were able to reduce activity by 50% or more. Twenty three fragments caused an increase in activity of MurD, with seven increasing activity to a level greater than that shown on Figure 3.3. Triplicate activity levels can be seen in Supplementary 2. Eighteen fragments produced activity that fell outside of the range of the graph, either due to an increase in activity or a negative activity rate after removal of the background rate, as seen in Figure 3.4. Extreme values above 100% and below 0% of control values could have been due to interference with the assay components, precipitation of the fragment within the assay or natural absorbance by the fragment at 360 nm. Due to their activity rates falling outside a range that was deemed acceptable for interference within the assay, greater than 150% activity of MurD and below -10% activity of MurD, the ability of these fragments to inhibit the activity of MurD could not be determined within this assay system, and so were removed from further studies.

Figure 3.4: Eighteen elaborated fragments produced rates outside standard range
Eighteen elaborated fragments produced rates outside the acceptable range for the assay. Fragments were incubated at a final concentration of 1 mM with 100 nM MurD before activity of MurD was determined. Activity of MurD in the presence of fragments was compared to control assays in the presence of DMSO and the percentage activity of MurD determined and plotted. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with triplicate repeat data shown with error bars showing SD.
A threshold of an 80% reduction in activity of MurD was set for fragments to be considered as inhibitors of MurD activity within this study. As can be seen from Figure 3.3 and Figure 3.5, eleven fragments satisfied this criterion. Fragments 754 and 786 were able to almost completely inhibit MurD within the assay, as seen in Figure 3.5. These eleven fragments were therefore selected for further validation.

3.3 Six fragments cause interference with assay system resulting in false positives

Initial screening of the elaborated fragments identified eleven fragments that were able to reduce the activity of MurD by 80% or more. If however, the fragments interfered with any of the assay components, it could have resulted in a reduced absorbance change which would have been interpreted as a reduction in activity due to inhibition of MurD by the fragment. To determine if any of the fragments had behaved in this manner, the fragments were tested against the

\[ \text{Activity of MurLigase} (\%) \]

\[ \text{Fragment Id} \]

Figure 3.5: Eleven fragments can act as inhibitors of MurD

Eleven elaborated fragments were able to reduce the activity of MurD from *S. agalactiae* by 80% or more. Fragments were incubated at a final concentration of 1 mM with 100 nM MurD before activity of MurD was determined. Activity of MurD in the presence of fragments was compared to a control group of DMSO and the percentage activity of MurD determined and plotted. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with triplicate repeat data shown with error bars showing SD.
assay components, phosphate and PNP. The fragments were incubated at 1 mM final concentration with the assay components, phosphate and PNP, and the absorbance was tracked at 360 nm. The absorbance change for each fragment in the presence of the components was determined and compared to a control group of MurD in the presence of 10% (v/v) DMSO. The statistical difference in results was determined using a Welch’s T-test.

As can be seen from Figure 3.6, fragment 786 interacted with the assay components resulting in a large increase in absorbance change at 360 nm. Fragments 758 and 796 both caused statistically significant increases in absorbance change in the presence of the assay components, with p values of 0.023 and 0.0163 respectively. All three fragments also caused statistically significant increases in the range of data. An increase in absorbance change in the presence of the assay components could suggest that the fragments were interacting with the MESG present converting it to its corresponding free base 2-amino-6-mercapto-7-methylpurine, which absorbs at 360 nm. A reduction in the MESG available within the assay for PNP to act upon could result in a reduction in absorbance change after activity, leading to a false positive recording of inhibition via the fragments. Fragment 788 caused a significant decrease in absorbance in the presence of the assay components. A decrease in absorbance change may also represent an interference with the assay components.

Figure 3.6: Fragments 758, 786 and 796 show interference with the assay components. Fragments that had reduced activity of MurD in initial screening were tested for their effect on the assay components. Fragments 786, 758 and 796 caused significant increases in absorbance compared to the control group. 788 caused a significant decrease in absorbance compared to the control group. All experiments were run in triplicate with mean results being plotted, with individual data points shown. Error bars show SD.
Phosphate is generated and used within a stopped MESG assay to determine the activity of the Mur ligase. Interaction of the fragments with the phosphate thus generated could result in false positive recordings of inhibition. The effect the fragments had on the absorbance change after the addition of phosphate was determined.

As can be seen from Figure 3.7, fragments 773 and 796 caused statistically significant increases in the absorbance change at 360 nm when phosphate was present, with $p$ values of 0.0278 and 0.0024 respectively. A significant difference in the absorbance change suggests that the fragment was interacting with the phosphate present. This could result in a change in the phosphate concentration present within the sample. Activity of MurD was determined via the amount of phosphate present within the sample after the MurD reaction was quenched. Altering the amount of phosphate present within the sample could result in a reduction in absorbance change after activity, leading to a false positive recording of inhibition via the fragments.

The final check carried out was to determine the effect the fragments had on the ability of PNP to convert phosphate to ribose-1 phosphate and MESG to 2-amino-6-mercapto-7-methylpurine to result in an absorbance change at 360 nm. As can be seen from Figure 3.8, fragments 755, 758 and 786 caused statistically significant decreases in the absorbance change at 360 nm, with fragment 755
having a p value of 0.0086, fragment 758 a p value of 0.02 and fragment 786 having a p value of 0.0011. A decrease in the absorbance change after the addition of PNP suggested that these fragments were interfering with the coupling enzyme PNP, preventing it from being able to convert phosphate to ribose-1 phosphate and MESG to 2-amino-6-mercapto-7-methylpurine. This resulted in a decreased absorbance change which was used to determine activity of MurD, and so gave false positive readings of inhibition for these fragments.

Across the three experiments, six fragments caused interference with the assay system. Fragments 758 and 786 caused statistically significant increases in absorbance in the presence of the assay components as well as statistically significant decreases in activity after the addition of PNP. Due to this interference, the ability of these fragments to inhibit the activity of MurD could not be determined within this assay system. Fragment 773 and fragment 796 caused statistically significant increases in absorbance in the presence of phosphate, with fragment 796 causing a statistically significant increase in absorbance in the presence of the assay components. Due to this interference, the ability of fragments 773 and 796 to inhibit the activity of MurD could not be determined within this assay system. Fragment 755 caused a statistically significant decrease in activity after the addition of PNP. Due to this interference, the ability of fragment 755 to inhibit the activity of MurD could not be determined within this assay system.

Figure 3.8: Fragments 755 and 786 show interference with PNP

Fragments that had reduced activity of MurD in initial screening were tested for their effect on PNP. Fragments 755 and 786 caused significant decreases in absorbance change compared to the control group. Fragment 754 caused a significant increase in absorbance change compared to the control group. All experiments were run in triplicate with mean results being plotted, with individual data points shown. Error bars show SD.
system. The interference with the assay system by these fragments meant that the inhibition data generated via the initial screen relating to them was unreliable and so inhibition of MurD with these fragments could not be established, and so they were not considered further.

3.4 The binding pocket within MurD from *S. agalactiae* is present within MurE from *S. agalactiae*

Fragments that were able to reduce activity of MurD from *S. agalactiae* by 80% or more, and passed the assay interference checks were then screened for inhibition of *S. agalactiae* MurE activity. The Mur ligases share a similar catalytic mechanism and 3 domain structure and therefore inhibitors that can inhibit the activity of one Mur ligase may potentially be able to inhibit the activity of another. The parental fragments that the elaborated screen was based upon bound to a pocket within MurD from *S. agalactiae* that was adjacent to the ATP binding pocket. To determine if this pocket was present within MurE from *S. agalactiae*, a homology model of MurE generated by SWISS-MODEL was aligned to the structure of MurD (PDB: 3LK7). As can be seen from the alignment of the predicted structure of MurE and the known structure of MurD in Figure 3.9, the alpha helices that line the pocket were in similar positions in both MurD and MurE.

![Figure 3.9: Alignment of binding pocket within MurD to MurE from S. agalactiae](image)

Alignment of MurD from *S. agalactiae* and MurE from *S. agalactiae*. The binding pocket where the parental fragments bound to MurD is aligned to MurE. There is a similar structure between both proteins. Interacting residues within MurD are aligned to residues with MurE. Glu132 is aligned to His132, while Lys311 is aligned to Pro330. MurD is shown in green, while MurE is shown in purple. Fragment 373 is shown bound within the binding pocket.
A flexible region within the MurE homology model was seen to intrude into the binding pocket for the fragments, which might interfere with the binding of the fragments to this area of the protein.

Sequence alignment of MurE from *S. agalactiae* to MurD from *S. agalactiae* showed a 38% sequence similarity within the pocket. Within MurD, Glu132 and Lys311 were involved in forming interactions with the parental fragments. The corresponding residues within MurE from *S. agalactiae* were His132 and Pro330, as seen in Figure 3.9. The switch from the negatively charged Glu residue to the positively charged His residue may result in fragments being unable to bind within this pocket. The change in interacting residues may hinder the binding of certain fragments within this binding site, but a similar structure within the binding pocket may still allow certain fragments to bind and inhibit the activity of MurE from *S. agalactiae*.

3.5 Identification of fragments that can inhibit MurD and MurE from *S. agalactiae*

The presence of a binding pocket within MurE from *S. agalactiae* that is similar in structure to the binding pocket within MurD from *S. agalactiae* suggests that the fragments identified to have inhibitory effects against MurD from *S. agalactiae* may also be able to bind and inhibit the activity of MurE from *S. agalactiae*. The fragments that were identified to reduce activity of MurD by 80% or more and showed no assay interference were screened against MurE from *S. agalactiae* using a stopped MESG assay. Validation of assay for MurE was carried out, see Supplementary 3. Fragments were incubated at a final concentration of 1 mM with 100 nM MurE from *S. agalactiae* prior to initiation of the activity assay. The activity rate of MurE in the presence of fragments was compared to a control group where 10% (v/v) DMSO was present, and the percentage activity of MurE in the presence of fragments relative to their absence was determined, as seen in Figure 3.10. A positive control inhibitor of ADPCP was also used to confirm inhibition within the assay system. As can be seen from Figure 3.10, all the fragments were able to inhibit the activity of MurE. Fragment 749 was only able to reduce activity of MurE by 35%, but all other fragments were able to reduce activity by 70% or more, and
so were considered significant inhibitors of MurE. Of the five fragments identified as inhibitors of MurD, four were considered as dual inhibitors of MurD and MurE from *S. agalactiae*.

3.6 The binding pocket within MurD from *S. agalactiae* is present within MurE from *P. aeruginosa*

The Mur ligases have very similar catalytic mechanisms and domain structure. This similarity is present across the four Mur ligases, across bacterial species. Across differing bacterial species, MurE changes which amino acid it links to the UDP-intermediate. Typically, MurE catalyses the addition of meso-DAP to UDP-MurNAc-L-Ala-D-Glu within Gram negative bacteria, bacilli and mycobacteria. Within other Gram positive bacteria, MurE is able to catalyse the addition of L-Lys to UDP-MurNAc-L-Ala-D-Glu. The difference in amino acid addition may affect the way in which inhibitors are able to target and inhibit MurE from various bacteria. Due to

*Figure 3. 10: Four fragments can act as inhibitors of MurE from *S. agalactiae**

Fragments that had reduced activity of MurD in initial screening were tested for their effect on MurE from *S. agalactiae*. Fragment 749 was only able to reduce activity of MurE by 35%. All other fragments were able to reduce activity by 70% or more. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with triplicate repeat data shown with error bars showing SD. Skeletal formula of fragment present. Activity of MurD shown in blue, activity of MurE shown in purple.
the clinical significance of Gram-negative infection, it was important to investigate whether this difference would affect the ability of inhibitors identified from the elaborated fragment screen, to additionally target MurE from *P. aeruginosa* where L-Lysine, utilised by *S. agalactiae* was now replaced by meso-DAP.

The structure of MurE from *P. aeruginosa* was aligned to that of MurD from *S. agalactiae* to predict if the binding pocket that the parental fragments were identified to bind to within MurD from *S. agalactiae* was present within the structure. The structure of MurE from *P. aeruginosa* was taken from Alphafold (AF-Q59650-F1) and aligned to the structure of MurD from *S. agalactiae* (PDB:3LK7) within Pymol.

As can be seen from the alignment of the predicted structure of MurE and the known structure of MurD in Figure 3.11, the binding pocket is present within MurE from *P. aeruginosa*. Sequence alignment of MurE from *P. aeruginosa* to MurD from *S. agalactiae* showed a 75% sequence similarity within the pocket. Within MurD, Glu132 and Lys311 were involved in forming interactions with the parental fragments. The corresponding residues within MurE from *P. aeruginosa* were Glu129 and Ala307 as seen in Figure 3.11.

*Figure 3. 11: Alignment of binding pocket within MurD to MurE from P. aeruginosa*
Alignment of MurD from *S. agalactiae* and MurE from *P. aeruginosa*. The binding pocket where the parental fragments bound to MurD is aligned to MurE. There is a similar structure shared by both proteins. Interacting residues within MurD are aligned to residues with MurE. Glu132 is aligned to Glu129, while Lys311 is aligned to Ala307. MurD is shown in green, while MurE is shown in blue. Fragment 373 is shown bound within the binding pocket.
The change from a Lys residue to an Ala residue may hinder the binding of certain fragments within this binding site, but a similar structure within the binding pocket may still allow certain fragments to bind and inhibit the activity of MurE from *P. aeruginosa*, allowing for the potential identification of fragments that can target Mur ligases across bacterial species.

**3.7 Identification of fragments that can inhibit MurE from *S. agalactiae* and MurE from *P. aeruginosa***

Structural alignment of the *P. aeruginosa* MurE to the *S. agalactiae* MurD structure identified a similar binding pocket where the parental fragments originally bound to. Fragments identified to inhibit MurD and MurE from *S. agalactiae* might also bind and inhibit the activity of MurE from *P. aeruginosa*. To determine if fragments that had been identified to reduce activity of MurD and MurE from *S. agalactiae* by 70% or more were able to act as inhibitors of MurE from *P. aeruginosa*, a stopped MESG assay was run in the presence of fragments against MurE from *P. aeruginosa*. Fragments were incubated at a final concentration of 1 mM with 100 nM MurE from *P. aeruginosa* prior to initiation of the activity assay. The activity rate of MurE in the presence of fragments was compared to a control assay where 10% (v/v) DMSO was added in place of a fragment, and the percentage activity of MurE in the presence of fragments relative to that in their absence was determined, as shown in Figure 3.12. A positive control inhibitor of ADPCP at 5 µM was also used to confirm inhibition within the assay system. Fragments 742 and 789 did not significantly impact the activity of MurE, as seen in Figure 3.12. Fragments 759 and 754 were able to reduce activity by around 50%.
A comparison of the effect the four fragments had on the activity of the three ligases can be seen in Figure 3.13. All fragments were more effective at reducing the activity of the *S. agalactiae* ligases compared to the *P. aeruginosa* ligase. All fragments were more effective at reducing activity of MurD compared to MurE from *S. agalactiae*.

These results suggest that the binding and action of these fragments was better targeted towards *S. agalactiae*, and particularly MurD. These fragments were based on parental fragments that bound to a pocket adjacent to the ATP-binding site within MurD from *S. agalactiae*. The way in which the fragments were produced was biased towards the specific residues present within this binding site in MurD, and so fragments may be unable to interact with the residues present in the binding site of MurE. The binding site may be in a slightly different conformation in

*Figure 3.12: Lack of inhibition by fragments against MurE from P. aeruginosa*

Fragments that had reduced activity of MurD and MurE from *S. agalactiae* were tested for their effect on MurE from *P. aeruginosa*. Fragments 742 and 789 caused no significant difference in MurE activity compared to the control. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with triplicate repeat data shown with error bars showing SD.
MurE compared to MurD due to the domain movements that occurred when substrates bind to Mur ligases, preventing the fragments from binding as well to the MurE ligases.

3.8 Identification of fragments with micromolar IC\textsubscript{50}s against MurD from \textit{S. agalactiae}

Fragments were identified to inhibit MurD from \textit{S. agalactiae} at 1 mM concentration. To develop a better understanding of the inhibitory potency of the fragments, dose response curves were generated to determine the concentration of fragment required to inhibit the activity of enzyme by half. An IC\textsubscript{50} can provide a measure by which to compare the efficacy of the fragments. To determine the IC\textsubscript{50} of the fragments, the stopped MESG assay was run at various concentrations of fragment against MurD from \textit{S. agalactiae}. The activity of MurD was determined in the absence and then presence of increasing concentrations of fragments, and the remaining activity, relative to that in the absence of fragment was plotted against the log concentration of fragment. As seen in Figure 3.14, Fragment 742 had an IC\textsubscript{50}
of 107 /+ 15 µM against MurD from *S. agalactiae*. Fragments 754 and 789 also had similar IC₅₀ values of 93 /+ 13 µM and 147 /+ 25 µM respectively. Fragment 759 had the lowest IC₅₀ of 22 /+ 2.5 µM against MurD from *S. agalactiae*. Fragment 759 reduced the activity of MurD by 50% at the lowest fragment concentration, making it the most attractive fragment for future studies.

Figure 3. 14: Dose response curves for inhibitory fragments against MurD from *S. agalactiae*

The IC₅₀ of 4 fragments hits were identified using a stopped MESG assay. Various concentrations of fragment were incubated with MurD from *S. agalactiae* before activity of MurD was established. Activity was then plotted against log fragment concentration and the IC₅₀ determined. (A) IC₅₀ determination of fragment 742. (B) IC₅₀ determination of fragment 754. (C) IC₅₀ determination of fragment 759. (D) IC₅₀ determination of fragment 789. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with error bars showing SD. A variable response curve was the plotted via PRISM.
4. Conclusions and Future Direction
4.1 Use of X-Chem for the design of novel inhibitory fragments

Biophysical and biochemical techniques can be used to identify fragments that are able to bind and inhibit the Mur ligases. Our collaborators at Diamond and UCL were able to use XChem to identify four parental fragments from a DSI-poised fragment library that were able to bind to a pocket adjacent to the ATP-binding site of MurD from *S. agalactiae*. An elaborated fragment screen produced by our collaborators at UCL based upon these hits was evaluated for inhibition of MurD activity. Identification of a parental scaffold provides a useful starting point for the development of an elaborated fragment screen; providing structural information upon which fragments can be based. This can lead to the development of fragments that already have high levels of potency against their intended target which have a greater potential for becoming antibacterial fragments. This approach was taken in the development of a selective inhibitor of the oncogenic B-Raf kinase which possessed potent antimelanoma activity, which was developed from an XChem screen of a poised library and elaborated fragments. Biochemical screening of the elaborated fragment set developed by UCL identified five fragments that had inhibitory effects against MurD from *S. agalactiae*, providing five fragment scaffolds which can act as a good starting points for the development of antibacterial compounds.

4.2 Assay interference and its effects on fragment screening

Biochemical techniques such as activity assays can provide information on the inhibitory effects of fragments. However, there are limitations to every assay, and sometimes false positives occur. To determine whether false positive results occurred within the fragment screen, the effect the fragments had on the assay components, phosphate and PNP were taken into consideration when determining whether the fragments were having an inhibitory effect on MurD. Fragments that caused significant differences in absorbance change in the presence of these components compared to the control group of DMSO were ruled out as inhibitors as their true effects on MurD activity could not be determined within our assay.
This approach prevented the inclusion of false positive results within our final evaluations but may have led to the removal of inhibitory fragments.

Fragments that themselves absorb at 360 nm may have been ruled out within the initial screen. To overcome this issue, all fragments could be retested within another assay system that does not track absorbance at 360 nm, such as the amplex red assay, which was used for high throughput screening of NOX inhibitors \(^\text{101}\), and is described in Chapter 5. Fragments that cause interference with the assay system were removed from further studies but may have the ability to inhibit the activity of the protein. To overcome this issue, fragments could be retested within another assay system that does not use the same secondary assay system to determine activity, such as a PK/LDH assay which was used to determine inhibition of D-Ala: D-Ala by D-cycloserine\(^\text{33}\). By changing the absorbance at which the assay is tracked, and changing the secondary assay system, any fragments that do absorb at 360 nm or interfere with the assay components could be accurately tested for their ability to inhibit the activity of MurD.

4.3 Development of multi-targeting inhibitors

Of the five fragments identified to inhibit the activity of MurD from \textit{S. agalactiae}, four were identified as having dual inhibitory effects; being able to inhibit the activity of MurE from \textit{S. agalactiae} as well as MurD from \textit{S. agalactiae}. Two fragments were identified as having cross bacterial inhibitory effects; with fragments 754, and 759 reducing the activity of MurE from \textit{P. aeruginosa} by 50% or more. An antibacterial compound that can target multiple Mur ligases may be possible based upon these results. An antibacterial compound that can bind to multiple targets is becoming considered more therapeutically advantageous compared to a highly specific compound due to the potential to prevent emergence of antibiotic resistance. The development of multi-targeting fragments able to bind to the Mur ligases is not a novel concept, with previously identified multi-targeting Mur ligases inhibitors with IC\(_{50}\)s ranging from 59 µM to 368 µM against MurC- MurF from \textit{E. coli} being identified by Hrast et al \(^\text{102}\). The ability of a fragment to have
cross-species targeting abilities is less common and provides an interesting starting point for future studies into these fragments.

Further elaboration of these fragments will need to be carried out to improve their potency and their ability to enter the bacterial cell. Elaboration of the inhibitory fragments is currently being undertaken by our collaborators at UCL. Once these more elaborated fragments have been produced, their ability to inhibit the activity of the Mur ligases can be reaffirmed via biochemical assays before the ability of the fragments to enter the bacterial cell are confirmed via minimum inhibitory concentration experiments.

4.4 Targeting novel pockets for the development of inhibitory fragments

The original XChem screen carried out by our collaborators identified parental fragments that were able to bind to a pocket adjacent to the ATP-binding site of MurD. Allosteric binding sites are an attractive target for the development of novel inhibitors as they offer alternative mechanisms for enzyme inhibition. However, within the development of inhibitory compounds targeted towards the Mur ligases, inhibitory compounds are mostly targeted towards either the catalytic site of the Mur ligases, such as with phosphinate inhibitors that were shown to target the active site of MurE \(^{72}\), or target the binding site of the substrates, such as targeting the ATP-binding site of \(E. coli\) MurD \(^{103}\). Identification of inhibitory fragments binding to a novel pocket of the Mur ligases could provide a new starting point for the development of antibacterial compounds.

Confirmation of the binding mode of these fragments needs to be carried out to continue their development into an antibacterial compound. Crystallographic studies could be carried out to confirm if the fragments are still binding within the novel pocket identified within the original XChem screen. Biochemical assays could be carried out to identify if the fragments are acting in a competitive manner towards any of the substrates.
Chapter 4

Identification of inhibitory fragments via *in silico* screening and biochemical assays
1. **Introduction and Aims**

Fragment screening is a well-established starting place for the development of inhibitory compounds. The initial stages of fragment screening can be carried out *in silico* or via X-ray crystallography. *In silico* screening, a computational technique for identifying potential binding fragments, involves using prediction software to identify fragments that may have the potential to bind to a protein of interest. *In silico* screening allows for the screening of large collections of fragments against multiple proteins without the cost and time associated with biophysical techniques such as XChem or SPR\(^{104,105}\).

*In silico* screening can identify fragments that may have the potential to bind to a protein of interest and inhibit its activity. Once a fragment list has been generated via *in silico* screening, experimental techniques can be used to establish the true binding potential and inhibitory effects of the fragments. A biochemical approach, such as activity assays, can be used to determine if fragments can inhibit the activity of the protein.

This chapter describes the development of an *in silico* screen and the steps taken to identify a target area within the Mur ligases. A suitable fragment library was established that could be used within a targeted *in silico* screen against the Mur ligases. Examination of the fragment set generated via the *in silico* screen identified issues within the fragment set that led to another *in silico* screen being carried out. Biochemical assays were then carried out on the fragment set, which was identified via the second *in silico* screen, to identify the inhibitory effects on MurD and MurE from *S. agalactiae*. The *in silico* screening and evaluation of *in silico* results was done in collaboration with Dr Joe Eyermann, of H3D department of the University of Cape Town, South Africa and latterly of Northeastern University, Boston, MA, USA.
2. **Material and Methods**

2.1 **Use of Pymol to compare structures and visually inspect fragments**

Pymol (The PyMOL Molecular Graphics System, Version 2.2, Schrödinger, LLC.) was used to compare structural alignments, sequence alignments and fragment alignments. Structures were imported into Pymol either by fetching via their Protein Data Bank (PDB) ID [https://www.rcsb.org/](https://www.rcsb.org/), from downloaded Crystallographic Information Files (CIF), or PDB files generated via Glide. Alignments were generated via the align function of Pymol either for the whole molecule or specified areas. Residues of interest were shown in line function with important elements shown in the standard setting colour scheme. Polar contacts between important residues and substrates or fragments were predicted via the find polar contacts function of Pymol either for the whole substrate/fragment or important elements.

2.2 **Structural Sequence Alignment**

Structural sequence alignments between the Mur ligases and kinases were run using the pairwise structure alignment software within the RCSB Protein Databank. The PDB ID of a Mur ligase and a kinase were entered into the pairwise structure alignment software, before a jFATCAT (flexible) alignment was run using default settings. A jFATCAT (flexible) alignment detects and aligns fragment pairs based on similarities in local geometry, while allowing for the introduction of ‘twists’ into the alignment to allow for protein flexibility within the comparison. The sequence alignment of the two proteins was visualised using the flexible alignment tab. The structural alignment was visualised by downloading the superimposed structures and comparing them using Pymol.

2.3 **Production of fragment library**

A kinase fragment library was generated via the Schrodinger Scaffold Decomposition tool. 3861 kinase inhibitor complexes were identified via PDB and papers which were then inputted into the scaffold software. A fragment list was generated via the scaffold software by breaking down the known inhibitor
structures into large scaffolds via the removal of side chains from ring structures. Large scaffolds were then split into sub scaffolds by removal of linkers between rings, if a fused ring was not present. A final list of scaffolds was then generated which was used for the fragment screen.

2.4 In silico screen using Glide

An in silico screen was run using the Glide software from Schrodinger. The PDB files chosen for each run were processed using the protein preparation wizard, converting them into files which were more suitable for ligand binding within Glide. During the protein preparation, water molecules that were not directly involved within the active site were deleted. After protein preparation was complete, a receptor grid was generated. A receptor grid defined the space in which ligand binding was carried out by the software. A receptor grid centred on the ATP-binding site of the Mur ligases was established. Specific constraints determined to be important for binding were set. H-bond constraints were used within both in silico screens to specific that a receptor-ligand hydrogen bond must be formed for Glide to consider the fragment a ‘hit’. One H-bond constraint set was between asparagine 271 of MurD from E. coli, or equivalent asparagine in other bacteria, and the receptor protein. For the second in silico screen, a second constraint that a receptor-ligand hydrogen bond needed to form within the area of lysine 115 within MurD of E. coli, or equivalent lysine in other bacteria was also included. The ligands to be docked were then loaded into the system and the docking job established.

2.5 Stopped MESG assay

Fragments identified via the in silico screen were purchased from Enamine and shipped to Warwick at 50 mM concentration in 100% DMSO. Full fragment list is shown in Supplementary 4. Fragments were biochemically tested for inhibition of MurD from S. agalactiae within a stopped MESG assay. In a final volume of 50 µL, 1 mM of fragment was incubated with 80 nM MurD from S. agalactiae in the presence of 50 mM HEPES (pH7.6), 2 mM MgCl₂, 1 mM DTT, 50 mM KCl, 400 µM MESG, 30 µM UDP-MurNAc-L-Ala and 300 µM Deoxy-ATP for 10 minutes. The assay
was then initiated with 150 µM D-Glu and allowed to run for the initial rate period before the reaction was quenched with 10 mM EDTA. A background absorbance was determined photometrically via the ClarioStar plate reader (ThermoFisher) at 360 nm before 24.2 U per litre PNP was added. Absorbance change was tracked at 360 nm for 40 minutes to allow the end point to be achieved. The absorbance change was then determined. Each fragment was run in triplicate in the presence and absence of MurD to determine a background rate. Background rates were removed from the final activity rate for each fragment. The rates obtained in the presence of inhibitors were compared to control groups of 10% (v/v) DMSO and 30 µM ADPCP. All stages of the assay were carried out at 37°C.

In order to identify dual inhibitory fragments, a stopped MESG assay was carried out in the presence of MurE from *S. agalactiae*. 80 nM MurE was incubated with fragments at a final concentration of 1 mM in the presence of 75 µM UDP-MurNac-L-Ala-D-Glu and 20 µM ATP, before activity was initiated with 300 µM L-Lys.

### 2.6 Assay interference checks

To determine if inhibition identified via the stopped MESG assay was due to interference with the secondary coupling system, assays to determine the effect fragments had on the secondary coupling components was carried out. In a final concentration of 50 µL, 400 µM MESG, 50 mM HEPES (pH7.6), 2 mM MgCl₂, 1 mM DTT, and 50 mM KCl was incubated with 1 mM fragment and the absorbance change at 360 nm was tracked photometrically over the course of 10 minutes. 130 µM Na(H₂)PO₄ was then introduced and the absorbance change at 360 nm was tracked photometrically over the course of 10 minutes. 10 mM EDTA was then introduced and the absorbance change at 360 nm was tracked photometrically over the course of 10 minutes. 24.2 U per litre PNP was then introduced and the absorbance change at 360 nm was tracked photometrically for 40 minutes to allow the end point to be achieved. The absorbance change for each stage was then determined and compared to a control group of 10% (v/v) DMSO. All stages of the assay were carried out at 37°C within a ClarioStar plate reader (ThermoFisher).
3. Results

In order to run a targeted \textit{in silico} screen against the Mur ligases, certain criteria had to be established. A domain or binding pocket within the Mur ligases that is well conserved and can be targeted via fragments had to be identified. An initial data set for the fragments that would be predicted to bind to the designated domain or binding pocket would also need to be established. Finally, specific residues that could be targeted via the fragment set within the designated domain or binding pocket were established before the \textit{in silico} screen was carried out.

3.1 The Mur ligases have a high level of similarity within their ATP binding pockets

A domain or binding pocket within the Mur ligases that could be targeted via the \textit{in silico} fragment screen had to be determined. To effectively target multiple Mur ligases within the fragment screen, an area that is well conserved across multiple Mur ligases and across bacterial species needed to be identified. Consultation of Eveland et al and Bouhss et al\textsuperscript{68,69}, suggested a large level of consensus within the structure and sequence of the ATP binding pocket of the Mur ligases. By overlaying the known structures of MurC, MurD, MurE and MurF from \textit{E. coli}, and overlaying the known structures of MurD from \textit{E. coli}, \textit{S. agalactiae} and \textit{Staphylococcus aureus} (\textit{Sta. aureus}) it was seen that the secondary structure of the ATP binding pocket has a high level of similarity across the Mur ligases and different species, as seen in Figure 4.1. Across the Mur ligases, a difference of less than 1 Å was seen between three residues involved in the ATP-binding site of the Mur ligases, as seen in Figure 4.1A. A difference of less than 2 Å was seen between these three residues within the ATP-binding site of MurD across bacterial species, as seen in Figure 4.1B.
As seen in Figure 4.1, there is a high degree of structural similarity within the ATP-binding site of the Mur ligases. To determine whether this similarity was also present within the amino acid sequences of the Mur ligases, sequence alignments of the Mur ligases was carried out using EMBOSS-Needle. The full amino acid sequences of the proteins determined to have structural similarity within their ATP-binding site were compared using EMBOSS-Needle and regions of amino acids that corresponded to areas of structural similarity were highlighted and the percentage sequence identity determined, as seen in Figure 4.2. All Mur ligases showed at least 30% sequence identity of the residues involved in ATP binding apart from area 3 in *E. coli* C: *E. coli* E, as shown in Figure 4.2. MurD across bacterial species showed a greater level of sequence similarity when compared to the Mur ligases across *E. coli*, with MurE showing the lowest sequence similarity within an area. The percentage sequence identity of amino acid sequences suggests that the Mur ligases have a high level of similarity within their amino acid sequences of the ATP-binding site.

*Figure 4.1: Pymol diagrams to show the high level of similarity within the ATP binding pocket of various Mur ligases*

Pymol diagrams showing the ATP binding pocket of the Mur ligases overlayed to show the high level of similarity. A lysine, histidine and asparagine are shown to compare distance between amino acids involved in the ATP-binding site. (A) ATP binding pocket of MurC (purple), MurD (teal), MurE (blue) and MurF (green) from *E. coli* overlayed to show the high level of similarity across the Mur ligases. (B) ATP binding pocket of MurD from *E. coli* (pink), *S. agalactiae* (teal) and *Sta. aureus* (orange) overlayed to show the high level of similarity across bacterial species.
It has previously been seen that the Mur ligases contain a nucleotide binding motif within the ATP binding pocket which consists of a consensus sequence of GXXGKT/S. This consensus sequence was present within all the Mur ligases previously seen to have structural and sequence similarity, as seen in Table 4.1. The structural similarity, sequence similarity and the presence of a consensus sequence within the ATP-binding site of the Mur ligases suggests that fragments targeted towards these areas could target multiple Mur ligases across multiple bacterial species. For this reason, the ATP-binding site was chosen as the area into which the in silico screen would be targeted for binding fragments.
3.2 Determination of kinases inhibitors as a targeted fragment screen

With the ATP-binding site being determined as the target within the Mur ligases for the in silico screen, the fragment data set needed to be determined. The basis of a fragment set can be varied, with previous screens being run using existing drugs as the fragment basis, previous inhibitor screens acting as the basis or natural substances providing a fragment set. In order to effectively target the ATP-binding site of the Mur ligases, a fragment set based upon drugs that have previously been seen to target the ATP-binding site of a protein would be a good starting point. Drugs that are able to target the ATP-binding site of kinases have previously been used as the basis for determining new antibacterial development, with kinase inhibitors being seen to effectively target the ATP-binding site of biotin carboxylase. Kinase inhibitors have also previously been used to effectively inhibit the activity of the Mur ligases, although not via binding to the ATP-binding site of the Mur ligases. In order to determine if kinase inhibitors would be an effective starting point for the development of a fragment screen, the structural

<table>
<thead>
<tr>
<th>Location of consensus sequence</th>
<th>MurC</th>
<th>MurD</th>
<th>MurE</th>
<th>MurF</th>
</tr>
</thead>
<tbody>
<tr>
<td>121 126 131 136</td>
<td>IGIAIAAGTHKKTYYAMLYS</td>
<td>106 111 116 121</td>
<td>IVAITGSKSTTVTLVEI</td>
<td>111 116 121 126</td>
</tr>
<tr>
<td>106 111 116 121</td>
<td>IVAITGSKSTVTTLVEI</td>
<td>116 121 126 131</td>
<td>GITGSKKTTTMTIAEVI</td>
<td>111 116 121 126</td>
</tr>
</tbody>
</table>

Table 4. 1: A consensus sequence is well conserved across the 4 Mur ligases as well as across bacterial species
The ATP binding pocket of the Mur ligases contains a conserved nucleotide binding motif, consisting of a consensus sequence of GXXGKT/S, highlighted in red. This sequence is conserved across all four Mur ligases, as shown here across E.coli as well as across bacterial species, shown here in MurD across E.coli, S. agalactiae and S. aureus.
similarity between the ATP-binding site of kinases and the Mur ligases was evaluated. Structural similarity between the Mur ligases and kinases was determined using structural pairwise alignment software available via PDB. Areas of structural alignment were then aligned to the full Mur ligase and kinase structures, and analysed in Pymol, as seen in Figure 4.3.

(1)(A)  
(2)(A)  
(B)  
(B)

Figure 4.3: Structural alignment of Mur ligases to kinases

Structural sequence alignment of Mur ligases to kinases was carried out to determine areas of similarities. Areas of structural alignment were determined via a pairwise structural alignment. Areas of structural alignment were highlighted on the full protein structure within Pymol. The ATP-binding site of the Mur ligases and kinases fall within areas of structural similarity. The ATP binding consensus motif within the Mur ligases falls within a region of structural similarity with the kinase, and is highlighted in blue. (1) Structural sequence alignment of MurD from E.coli (A) (PDB: 2UAG) and ALK tyrosine kinase from Homo Sapiens (B)(PDB: 6CDT). Areas of structural similarity are highlighted in green. (2) Structural sequence alignment of MurC from E.coli(A) (PDB: 2F00) and Human MST3 kinase from Homo Sapiens (PDB: 3A7H). Areas of structural similarity are highlighted in purple.
The ATP-binding site of the Mur ligases was seen to have structural similarity with the kinases, with the consensus sequence of the ATP-binding site being present in an area of structural similarity, as seen in Figure 4.3A. When aligned, the areas of structural similarity also fell in an area within the kinases which is involved in ATP binding, as seen in Figure 4.3B. The structural similarity between the ATP-binding sites of the Mur ligases and kinases suggested that fragments based on kinase inhibitors may be able to effectively target the ATP-binding site of the Mur ligases.

### 3.3 There is a high degree of similarity in interactions formed during ATP binding between the Mur ligases and kinases

Structural similarity between the Mur ligases and kinases had been established. In order to determine if kinase inhibitors targeted towards the ATP-binding site would be able to correctly interact with the ATP-binding site of the Mur ligases, determination of the interactions that form between ATP and the surrounding residues in the Mur ligases and kinases had to be established. Using known structures of the Mur ligases and known structures of kinases bound to ATP, the residues involved in forming interactions with ATP within each protein could be established.

![Image of ATP interactions](A)

![Image of ATP interactions](B)

*Figure 4. 4: ATP forms similar interactions with residues present in the Mur ligases and kinases*

ATP forms interactions within the hinge region of kinases which are similar to those seen between ADP and the ATP-binding site of the Mur ligases (A) Hydrogen bonds formed between ADP and surrounding residues in MurD (PDB: 2UAG). (B) Hydrogen bonds formed between ATP and surrounding residues in Human cyclin-dependent kinase 2 (PDB: 1HCK). The ATP/ADP adenosine moiety is shown in green where the oxygen is highlighted in red, nitrogen is highlighted in blue and phosphorus in orange. Interactions are shown with red dotted lines.
As can be seen from Figure 4.4A, within the ATP-binding site of the Mur ligases a hydrogen bond is formed between the NH2 of the adenosine ring and the oxygen of Asn271, while the nitrogen of Asn271 forms a hydrogen bond with the neighbouring nitrogen on the adenosine ring. The phosphate groups of the ATP can form multiple interactions with surrounding residues. An interaction can form between the nitrogen of residue Lys115 and the second phosphate group present, as seen in Figure 4.4A. Similar interactions were seen between ATP and the kinase. A hydrogen bond forms between the oxygen of residue Glu81 and the nitrogen of the adenosine ring, as shown in Figure 4.4B. A second hydrogen bond is also able to form between another nitrogen of the adenosine ring and residue Leu83 of the kinase. The final phosphate of the ATP can form a hydrogen bond with residue Thr14 within the kinase as seen in Figure 4.4B.

The similarity in the interactions that occur between ATP and the residues present within the ATP-binding site of the Mur ligases and kinases suggests that inhibitors that can bind to the ATP-binding site of a kinase may also be able to bind to the ATP-binding site of the Mur ligases.

3.4 Building the fragment library from known kinase inhibitors

Similarity between the structure of the ATP-binding site of Mur ligases to the ATP-binding site of kinases, and similarity in the interactions formed between ATP within the ATP-binding site of both proteins allowed kinase inhibitors to be used as the basis of the fragment set for the in silico screen. To build a fragment library, the structures of known kinase inhibitors had to be sourced. This was achieved by researching papers of kinase inhibitors as well as searching PDB for kinases with inhibitors bound to the ATP-binding site. 3861 kinase inhibitors were identified and these were then broken down into fragment size. Inhibitors were broken down into fragments using the Schrodinger Scaffold Decomposition tool which identified ‘ring systems’ in the kinase inhibitor complexes, as shown in Figure 4.5. A known kinase inhibitor, such as that seen in Figure 4.5A can be broken down into ring systems via the decomposition tool, as shown in Figure 4.5B.
The inhibitors and fragments were collated into one fragment library. The library was processed by the LigPrep software of Glide, generating multiple structures from each input structure with various tautomers, sterochemistries and ring conformations being produced. Structure files for all fragments were produced which could then be used within in silico screening.

3.5 Identification of residues to target within the ATP-binding site of the Mur ligases

Similarity in the interactions formed between ATP within the ATP-binding site of both Mur ligases and kinases allowed kinase inhibitors to be used as the basis of the fragment set for the in silico screen. The next step in setting up the targeted in silico screen was to determine the exact residues to which binding must occur for the fragment to be considered a ‘hit’. Within the ATP-binding site of the Mur ligases, residues which form interactions which are similar to that formed between ATP and the hinge region of the kinase would be most suited for targeting via the in silico screen. Within the kinase ATP-binding site, a hydrogen bond is formed between the NH$_2$ group of the adenosine of ATP and an oxygen on a neighbouring residue. Targeting the residue within the Mur ligases which is able to hydrogen bond to this NH$_2$ group would provide an interaction point for the fragments which is similar across both proteins. This interacting residue was determined by identifying the

Figure 4.5: Fragments were designed based on existing kinase inhibitors

To generate a fragment library, PDB files of kinases with inhibitors bound were found and the inhibitors broken down into fragments. (A) PDB 4F4P shows an inhibitor (shown in green) bound to a kinase. (B) Inhibitor was broken down into fragments for the screen.
polar contacts between ADP and MurD from *E. coli* (PDB:2UAG) within Pymol. As can be seen from the known structure in **Figure 4.6**, residue Asn271 in MurD from *E. coli* is able to form a hydrogen bond with the NH$_2$ group of the adenosine ring of ATP.

![Figure 4.6: Asn271 forms a hydrogen bond with the NH$_2$ group of the adenosine ring](image)

ATP forms a hydrogen bond between the NH$_2$ group of the adenosine ring and Asparagine 271 of MurD *E.coli*. ATP is shown in green, with the asparagine being highlighted in pink within the secondary structure and within the amino acid sequence. PDB ID: 2UAG.

To be an interacting residue of value within the *in silico* screen, the Asn residue must be well conserved across the Mur ligases and bacterial species. Comparison of the sequence of the previously studied Mur ligases showed that the Asn is well conserved across bacterial species and the Mur ligases, as seen in the structural alignment in **Figure 4.7**, and so could be used as a target within the *in silico* screen.

![Figure 4.7: The Asparagine that forms a hydrogen bond with ATP is well conserved across Mur ligases and bacterial species](image)

Pymol diagrams showing the asparagine that forms a hydrogen bond to the adenosine ring of ATP is well conserved across Mur ligases and bacterial species (A) The asparagine is present within MurC (purple), MurD (teal), MurE (blue) and MurF (green) from *E.coli*. (B) The asparagine is present within MurD from *E.coli* (pink), *S. agalactiae* (teal) and *Sta. aureus*(orange).
Within the kinase ATP-binding site, other interactions are also formed between the final phosphate group of ATP and the oxygen and nitrogen groups of residue Thr14. Targeting the residue within the Mur ligases which is able to hydrogen bond to one of the phosphates would provide an interaction point for the fragments which is similar across both proteins. This interacting residue was determined by identifying the polar contacts between ADP and MurD from *E. coli* (PDB:2UAG) within Pymol.

As can be seen from the known structure in Figure 4.8A, residue Lys115 within MurD from *E. coli* is able to form an interaction with the oxygen of the phosphate group of ADP. To be an interacting residue of value within the *in silico* screen, the Lys residue must be well conserved across the Mur ligases and bacterial species.

![Figure 4.8: The Lysine that forms a hydrogen bond with ATP is well conserved across Mur ligases and bacterial species](image)

ADP forms an interaction between the oxygen of the final phosphate and a Lysine within Mur ligases (A) Lysine 115 of MurD *E. coli* forms hydrogen bonds with the final phosphate of ADP. ADP is shown in orange, with the lysine being highlighted in pink within the secondary structure and within the amino acid sequence. PDB ID: 2UAG. (B) The lysine is present within MurC (purple), MurD (teal), MurE (blue) and MurF (green) from *E. coli*. (B) The lysine is present within MurD from *E. coli* (pink), *S. agalactiae* (teal) and *Sta. aureus* (orange).
Comparison of the sequence of the previously studied Mur ligases showed that the Lys115 is well conserved across bacterial species and the Mur ligases and so could be used as a target within the \textit{in silico} screen, as seen in the structural alignments in \textbf{Figure 4.8B} and \textbf{Figure 4.8C}. As both the asparagine and lysine are well conserved across Mur ligases and form interactions with ATP similar to the interactions seen between ATP and eukaryotic protein kinases, Lys 115 and Asn 271 were selected for targeting within the \textit{in silico} screen.

\subsection*{3.6 Evaluation of existing PDB files of Mur ligases for use within the Glide software}

In order to run the \textit{in silico} screen, suitable Mur ligase structures would need to be chosen that would act as the target for the fragments to bind to. PDB structures provide detailed information on ligands bound within the structure, resolution of the structure and the organism that the protein came from, and so PDB structures were chosen as the starting point for determining suitable Mur ligase structures. The first step in determining suitable Mur ligase structures was to determine which Mur ligases the screen would be targeted towards. The targeting of two Mur ligases within the screen increased the chances of finding a multi targeting fragment. Previous work at Warwick had investigated the ability of fragments to bind and inhibit the activity of MurD, and so MurD was chosen as one of the targets to be able to continue to build on previous work. Dr Eyermann had previous experience working with MurC and so this was chosen as the second Mur ligase.

With the Mur ligases chosen that would be targeted via the screen, other criteria could now be set. The structure of the Mur ligase would need to consist of only one chain. The presence of a secondary chain within the structure could result in a change in the folding of the protein at the point of contact which may affect the ability of the fragments to bind to the target. The final criterion was that for this screen, an ATP equivalent would need to be bound to the ATP-binding site of the Mur ligase. The presence of a molecule within the target site for the fragments would aid in setting up the targeted \textit{in silico} screen. With the Mur ligases chosen, and the criteria set, a list of potential PDB files could be generated, as seen in \textbf{Table 4.2}. 

123
From these potential PDB files, it was decided to use 6CAU for MurC and 5A5F from MurD. For MurD, all PDB files were from *E. coli* and had resolutions of less than 2 angstroms. Therefore, 5A5F was chosen as it was the newest entry. For MurC, all three PDB files came from three different bacteria; 1P3D, 4HV4 and 6CAU described the *Haemophilus influenzae*, *Yersinia pestis* and *Acinetobacter baumannii* MurC structures respectively. 1P3D was ruled out as it contained a mutation. 4HV4 was ruled out as it is from a biothreat pathogen and not a WHO priority pathogen or a Warwick pathogen and so 6CAU was used for the screen.

### 3.7 Use of Glide to identify fragments that have the potential to target the ATP-binding site of MurC and MurD

With the PDB files that would act as the structures for the screen chosen, along with the production of the fragment set, and determination of the residues that would be targeted via the screen, the *in silico* screen could be run. The *in silico* screen was run using the Glide software from Schrödinger. The chosen PDB files were inserted into the software, and a grid was formed around the ATP-binding site before the ADP was removed. The grid allowed the binding of the fragments to be targeted towards a specific region within the protein. Within the grid, further constraints could be placed, to further target the fragments. The previously identified residues, the conserved asparagine 271 and lysine 115 (*E. coli* numbering), were set as binding constraints for the fragments. By setting the binding to these residues as constraints, only fragments that were able to bind in some capacity to the residue would be returned as a hit. Due to the size of some of the fragments, some fragments may have been unable to form hydrogen bonds to both the lysine and asparagine. Therefore a priority was placed upon the binding

<table>
<thead>
<tr>
<th>MurC</th>
<th>1P3D</th>
<th>4HV4</th>
<th>6CAU</th>
</tr>
</thead>
<tbody>
<tr>
<td>MurD</td>
<td>2UAG</td>
<td>3UAG</td>
<td>5A5F</td>
</tr>
</tbody>
</table>

Table 4. 2: Potential PDB files that could be used within the *in silico* screen

In order to run the *in silico* screen, a suitable protein structure needed to be determined. Using set criteria; that something must be bound within the ATP-binding site, and the structure must only contain one chain, a list of potentially suitable PDB files was generated.
constraints, with the ability of the fragment to form a hydrogen bond to the asparagine being placed as a higher priority, allowing fragments that only form this hydrogen bond to be returned as hits. With the grid in place, and constraints set, the 12,000 fragments identified via LigPrep could be run within the in silico screen.

3.8 Evaluation of fragments identified via the screen

For the initial in silico run, 12,000 fragments were targeted towards the ATP-binding site of MurD (5A5F) using the Glide software from Schrodinger. Of the 12,000 fragments, 4,000 were found to bind within the desired region under the constraints set. For these 4,000 fragments, the molecular weight of the fragment, and its glide score were taken into account for deciding the top 100 fragments that would be passed onto the second run.

3.8.1 Top hits were determined via their Le score, molecular weight and glidemodel score

After the initial run, 4,000 fragments were returned as potentially being able to bind within the ATP-binding site of MurD under the set constraints. In order to determine the top hits from these fragments, the molecular weight and the glidemodel score were taken into account to determine the Le score of each fragment. The Le score, glidemodel score and molecular weight of each fragment were then taken into consideration when determining the top hits from the screen.

The molecular weight of the fragment was taken into consideration when determining the top hits of the screen as the smaller the molecular weight, the more likely the fragment is to have high ligand efficiency. Smaller fragments provide better opportunities for development of the fragments into compounds at a later stage. A cut-off point of 600 MW was set for the fragment screen, with fragments with a molecular weight of less than 600 being considered for the second run.

The glidemodel score is a score generated via the Glide software. The score helps to predict binding affinity via the ligand binding free energy. The score takes into account many factors including van der Waals energy, ionic charges on
groups as well as penalizing or rewarding interactions that are known to influence ligand binding. The system was optimized for docking accuracy and binding affinity prediction. As the glidemodel approximated ligand binding free energy, the more negative the score, the tighter the potential binding of the fragment was. A cut-off value for the glidemodel score of -50 was set, with fragments having a glidemodel of less than -50 being considered for the second run.

The Le score for each fragment was determined by dividing the glidemodel score by the molecular weight of the fragment. This score was used to predict which fragments were most likely to bind to the ATP-binding site. An Le score cut-off of -0.2 was set with fragments having an Le score of less than -0.2 being considered for the second run.

With cut-off values set, the 4,000 fragments were analysed, and the top 100 fragments were chosen to be run through a second fragment screen against MurC (6CAU) using the same constraints as previously set against MurD. These 100 fragments had glidemodel scores ranging from -197 to -82, with Le scores ranging from -0.398 to -0.227. After the second run, 80 fragments were found to bind to both MurD and MurC under the set constraints. These fragments were then analysed for their glidemodel score and Le score again before undergoing visual inspection.

3.8.2 Fragments existing as tautomers are unlikely to act as inhibitors of the Mur ligases

Visual inspection of the fragments that were able to bind to both MurC and MurD was carried out to identify issues which may prevent the fragments from being able to act as inhibitors of the Mur ligases. Inspection of the fragments identified the presence of tautomers within the fragments. Tautomers are isomers that can convert between each other with the movement of a proton via the rearrangement of a double bond. Protons can freely move between two positions via the rearrangement of the double bond, but the proton will favour one position, allowing a dominant tautomer to exist. The LigPrep software used in the production of the fragment data set produced fragments with multiple tautomeric forms. When visual inspection of the fragments was carried out, a
certain number of fragments were seen to contain a nitrogen within a ring structure, which would tautomerise, as seen in the predicted interaction in Figure 4.9.

![Figure 4.9: Fragments existing as tautomers were unlikely to act as inhibitors](image)

Upon visual inspection, fragments were identified to contain tautomers. Fragments containing tautomers were seen to mostly fall into the unfavoured state, and the favoured state would break the hydrogen bonds set as criteria for the fragment screen, making them less likely to be able to act as inhibitors of the Mur ligases. One of these fragments is shown here bound to MurD (PDB: 5A5F), with the fragment shown in red and the asparagine shown in purple. (A) The nitrogen is present in the tautomer provided by Glide. In this tautomer, the nitrogen is able to form a hydrogen bond to the oxygen of the asparagine. (B) The nitrogen is present in the naturally occurring tautomer. The nitrogen is no longer able to form the hydrogen bond with the asparagine.

Inspection of the fragments identified certain fragments that contained unfavourable tautomers. The favoured tautomers of these fragments were unable to form hydrogen bonds to the asparagine, which had been set as a constraint within the screen, as seen in the predicted interactions in Figure 4.9. The inability to form the required hydrogen bonds to the asparagine meant these fragments were less likely to be able to act as inhibitors and so were removed from the list of hits from the fragment screen.
3.8.3 **Fragments with flexible middle regions unlikely to form predicted interactions**

Visual inspection of the fragments that were able to bind to both MurC and MurD was carried out to identify flexible regions within the fragments. Flexible regions within fragments can increase the negative effects of the binding entropy of the fragment-protein complex, making them less favourable binding partners for the protein. Fragments were considered to have flexible middle regions if they contained more than three carbons in a row within the backbone, such as that seen in the predicted fragment layout shown in Figure 4.10. Flexible regions may also prevent favourable interactions occurring, such as the hydrogen bond between the fragment and the conserved lysine. Due to increased negative effects of flexible regions and the potential for favourable interactions to be broken due to flexible regions, fragments containing flexible regions were considered to be unable to act as inhibitors of the Mur ligases and so were removed from the list of hits from the fragment screen.

Upon visual inspection it was seen that certain fragments contained flexible middle regions that made them unsuitable as potential inhibitors. Flexible regions increase the binding entropy and reduce the potential for accurate binding. One of these fragments is shown here bound to MurD (PDB: 5A5F). The conserved asparagine and lysine are shown in purple, with interactions between residues and fragments shown in red. The middle region consists of 4 carbons in a chain, making it very flexible and unsuitable as a potential inhibitor.
3.8.4 Commercial availability of fragments

After visual inspection of the fragments and removal of any fragments that contained unfavourable tautomers or flexible regions, the remaining fragments were compiled and compared to look for similar features, as shown in the predicted fragment layout in Figure 4.11. Fragments that contained similar structures were visually inspected for their ability to form interactions with residues present within the ATP-binding site of MurD and MurC. Fragments that formed more favourable interactions were kept and a final list of fragments compiled. In order to biochemically test the fragments to determine their inhibitory effects, the fragments would need to be produced or ordered via a commercial source. The final fragment list was inputted into the Enamine store database to determine the commercial availability of the fragments. Many fragments were not commercially available and required specialist production. Specialist production of the fragments would not have been cost effective for a high throughput biochemical screen. Another in silico screen would need to be carried out to produce commercially available fragments that were suitable for a high throughput biochemical screen.

Upon visual inspection it was seen that certain fragments contained similar features. Two fragments are shown here bound to MurC (PDB: 6CAU). Both fragments contain a ring structure containing a nitrogen that forms a hydrogen bond to the asparagine with a neighbouring nitrogen forming another hydrogen bond to the asparagine.
3.9 High throughput screen of commercially available kinase inhibitory fragments

A second *in silico* fragment screen was carried out by Dr Eyermann. Instead of developing a fragment library, a commercially available Enamine kinase inhibitor library was used to prevent the issue of commercial availability preventing biochemical testing of the fragments. The second *in silico* screen was carried out against MurD and MurE, instead of MurC and MurD. This switch in protein targeting was made due to the availability of proteins for biochemical testing of the fragments, once a final fragment set had been established. For MurD, two PDB structure files were used within the *in silico* screen. An *E. coli* structure of MurD in complex with UDP-MurNAc-L-Ala with ADP bound within the ATP binding pocket (PDB: 5A5F), along with an *S. agalactiae* structure of MurD which has nothing bound within the ATP binding pocket (PDB: 3LK7) were used within the screen. The second MurD structure was included as previous work at Warwick in collaboration with H3D department of the University of Cape Town, South Africa had focused on *S. agalactiae* as a priority pathogen associated with neonatal sepsis and so MurD from this organism was chosen to be included within the second screen. The MurE structure used within the screen came from *E. coli* and has nothing bound within the ATP binding pocket (PDB: 1E8C).

Before docking was carried out, an initial constraint was placed on the 40,000 fragments contained within the Enamine kinase inhibitor library, limiting the fragment molecular weight to less than 350 to reduce the number of fragments that would be run through the *in silico* screen against the Mur ligases. The previous constraints of docking within the ATP-binding site and forming hydrogen bonds to the asparagine present within the ATP-binding site were used within the *in silico* screen. From this fragment screen, 724 fragments were found to bind to at least one of the three proteins and satisfy the constraints placed upon them. Fragments were then visually inspected using the same criteria as previously used; satisfactory tautomer arrangement, and level of flexibility within the backbone. 624 fragments met the constraints placed upon them, and contained no unnatural tautomers or flexibility within the backbone. These 624 fragments were then commercially produced by Enamine to allow biochemical testing to be carried out.
3.10 Identification of inhibitory fragments targeted against MurD from *S. agalactiae*

The fragments identified to potentially bind to the ATP-binding site of the Mur ligases via the *in silico* screen were produced by Enamine. 624 fragments were shipped to Warwick at 50 mM concentration in 100% DMSO in 364 well plates ready to be tested biochemically. *In silico* screening predicted what fragments may be able to bind to the ATP-binding site of the Mur ligases. Biochemically testing the fragments within an activity assay would provide information on the ability of the fragments to bind and inhibit the activity of a Mur ligase.

In order to determine the effect the fragments had on the activity of MurD from *S. agalactiae*, a stopped MESG assay was used. The activity rate of 80 nM *S. agalactiae* MurD in the presence of fragments at a final assay concentration of 1 mM was compared to a control group of 10% (v/v) DMSO, and the percentage activity of MurD in the presence of fragments was determined, as seen in

![Figure 4. 12: Activity of MurD in the presence of Enamine fragments](image)

The ability of the fragments to inhibit the activity of MurD from *S. agalactiae* was determined via a stopped MESG assay. Fragments were incubated at a final concentration of 1 mM with 80 nM MurD for 10 minutes at 37°C before activity of MurD was determined. Activity of MurD in the presence of fragments was compared to a control group of DMSO and the percentage activity of MurD determined and plotted. All fragments were run in triplicate with a triplicate background rate average being removed from the individual replicate activity rates. The mean percentage activity of compounds was plotted. Black line indicates 100% activity of MurD. Red line indicates 30% activity of MurD.
Figure 4.12. A positive control inhibitor of 30 \( \mu M \) ADPCP was also used to confirm inhibition within the assay system. As can be seen from Figure 4.12, the fragments had a varied effect on the activity of MurD.

One hundred and forty two fragments precipitated in the conditions of the assay, and so activity of MurD could not be established in the presence of these fragments. Twenty one fragments stimulated MurD activity by over 150\%. This could have been due to interference with the assay components, or natural absorbance by the fragment at 360 nm. Two hundred and twenty three fragments were able to reduce activity of MurD by 25\% or more. Ninety six fragments were able to reduce activity by 50\% or more. One hundred and one fragments caused an increase in activity of MurD to no more than 150\%. Triplicate activity levels can be seen in Supplementary 5. A threshold of a 70\% reduction in activity was used as a cut-off point for considering fragments as inhibitors of \textit{S. agalactiae} MurD activity.

![Graph showing effects of fragments on MurD activity](image)

**Figure 4.13: 38 fragments can act as inhibitors of MurD**

38 Enamine fragments were able to reduce the activity of MurD from \textit{S. agalactiae} by 70\% or more. Fragments were incubated at a final concentration of 1 mM with MurD before activity of MurD was determined. Activity of MurD in the presence of fragments was compared to a control group of DMSO and the percentage activity of MurD determined and plotted. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with triplicate repeat data shown with error bars showing SD.
As can be seen from Figure 4.12 and Figure 4.13, thirty eight fragments satisfied this criterion. Fragments B14.02 and O05.02 were able to reduce activity of MurD within the assay by more than 95%, as seen in Figure 4.13. These thirty eight fragments were seen to inhibit the activity of MurD from *S. agalactiae* within this assay, and so were selected for further validation.

### 3.11 Certain fragments cause interference with assay system resulting in false positives

Initial screening of the Enamine fragments identified thirty eight fragments that were able to reduce the activity of MurD from *S. agalactiae* by 70% or more. The reduction in activity was determined by tracking an absorbance change at 360 nm. This absorbance change was dependent on the PNP-catalysed phosphorolysis of MESG to generate ribose-1 phosphate and methyl thioguanine. If the fragments interfered with any of these components, it could have resulted in a reduced absorbance change which would have been interpreted as a reduction in activity due to inhibition of MurD by the fragment. To determine if any of the fragments had produced false positive results, the fragments were tested against the assay components, phosphate, the stopping agent EDTA and PNP. The fragments were incubated at 1 mM final concentration with the assay components and the absorbance tracked at 360 nm. After 10 minutes, phosphate was introduced, and the absorbance monitored at 360 nm for 10 minutes before EDTA was introduced. The absorbance was followed at 360 nm for 10 minutes before PNP was introduced and the absorbance followed until an end point had been reached. The absorbance change, and absorbance range for each fragment in the presence of the components was determined and compared to a control group of DMSO.

As can be seen from Figure 4.14A, fragments A03.01, C04.01, H03.01, D21.01, D17.02, and I19.02 all caused an increase in absorbance change at 360 nm. These fragments also all had a large range in their absorbance readings as seen in Figure 4.14B. An increase in absorbance change in the presence of the assay components could suggest that the fragments were interacting with the MESG present, converting it to methyl thioguanine, which absorbs at 360 nm.
A reduction in the MESG available within the assay for PNP to act upon could result in a reduction in absorbance change after activity, leading to a false positive recording of inhibition via the fragments. Fragment O04.01 had a large range in its absorbance readings and showed a large decrease in absorbance change at 360 nm. A large range could suggest that the fragment was causing precipitation within the assay which affected the ability of the plate reader to record the absorbance of the
Due to their interference with MESG, the ability of these fragments to inhibit the activity of MurD could not be determined within this assay system, and so were removed from further studies.

Phosphate was generated and used within the stopped MESG assay to determine the activity of the Mur ligase. Interaction of the fragments with the phosphate present could result in false positive recordings of inhibition.

Figure 4. 15: Fragments interfered with the phosphate present within the assay

Fragments that had reduced activity of MurD in initial screening were tested for their effect on phosphate. (A) The absorbance change after the addition of assay components in the presence of fragments was determined. (B) The absorbance range after the addition of assay components in the presence of fragments was determined. All experiments were run in triplicate with mean results being plotted, with individual data points shown. Error bars show SD.
The effect the fragments had on the absorbance change, and absorbance range after the addition of phosphate was determined. As can be seen from Figure 4.15A, fragments M21.01, A14.02, B11.02 and K13.02 all caused an increase in the absorbance change after the addition of phosphate. Fragments M21.01, B11.02 and K13.02 all had a significant range in their absorbance readings as seen in Figure 4.15B. An increase in the absorbance change, and absorbance range suggests that the fragment was interacting with the phosphate present. This could result in a change in the phosphate concentration present within the sample. Activity of MurD was determined via the amount of phosphate present within the sample after the MurD reaction was quenched. Altering the amount of phosphate present within the sample could result in a reduction in absorbance change after activity, leading to a false positive recording of inhibition via the fragments. Due to their interference with phosphate detection, the ability of these fragments to inhibit the activity of MurD cannot be determined within this assay system, and so were removed from further studies.

EDTA was used to quench the activity of MurD within the assay. Interaction of the fragments with the EDTA present could result in false positive recordings of inhibition. The effect the fragments had on the absorbance change, and absorbance range after the addition of EDTA was determined. As can be seen from Figure 4.16A, fragments L17.01 and O05.02 caused an increase in absorbance change after the addition of EDTA. Fragment C04.01 caused a significant decrease in absorbance change, along with having a significant increase in absorbance range, as seen in Figure 4.16A and Figure 4.16B. A significant difference in the absorbance change, and absorbance range suggests that the fragment was interacting with the EDTA present. Due to their interference with EDTA, the ability of these fragments to inhibit the activity of MurD cannot be determined within this assay system, and so were removed from further studies.
The final check carried out was to determine the effect the fragments had on the ability of PNP to convert phosphate to ribose-1 phosphate and MESG to methyl thioguanine to result in an absorbance change at 360 nm. As can be seen from Figure 4.17, fragments E05.01, F08.01, H07.01, M05.01, J17.02 caused statistically significant decreases in the absorbance change at 360 nm. A decrease in the absorbance change after the addition of PNP suggested that these fragments were
interfering with the coupling enzyme PNP, preventing it from being able to convert
phosphate to ribose-1 phosphate and MESG to methyl thioguanine. Prevention of
the conversion of MESG may have resulted in a decreased absorbance change
which was used to determine activity of MurD, giving false positive readings of
inhibition for these fragments. Due to their interference with PNP, the ability of
these five fragments to inhibit the activity of MurD from *S. agalactiae* could not be
determined within this assay system, and so were removed from further studies.

![Figure 4.17: Fragments interfered with PNP present in assay](image)

Fragments that had reduced activity of MurD in initial screening were tested for their effect on
PNP. Five fragments caused significant decreases in absorbance change compared to the control
group. All experiments were run in triplicate with mean results being plotted, with individual data
points shown. Error bars show SD.

### 3.12 Inhibitory fragments share similar binding features

Fragments that were able to reduce activity of MurD from *S. agalactiae* by 70%
or more, and passed the assay interference checks were then analysed for similarity
in structure and binding ability to MurD. As can be seen from **Table 4.3**, eleven
fragments contained a double ring structure similar to that of the adenine base of ATP.

<table>
<thead>
<tr>
<th>Fragment</th>
<th>Percentage Activity of MurD</th>
</tr>
</thead>
<tbody>
<tr>
<td>MN02.01</td>
<td>10%</td>
</tr>
<tr>
<td>NO01.01</td>
<td>20%</td>
</tr>
<tr>
<td>G04.01</td>
<td>23%</td>
</tr>
<tr>
<td>J03.01</td>
<td>24%</td>
</tr>
<tr>
<td>J06.01</td>
<td>12%</td>
</tr>
<tr>
<td>P08.01</td>
<td>27%</td>
</tr>
<tr>
<td>F09.01</td>
<td>20%</td>
</tr>
<tr>
<td>N17.01</td>
<td>16%</td>
</tr>
<tr>
<td>G20.01</td>
<td>24%</td>
</tr>
<tr>
<td>G02.02</td>
<td>30%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fragment</th>
<th>Percentage Activity of MurD</th>
</tr>
</thead>
<tbody>
<tr>
<td>J04.02</td>
<td>15%</td>
</tr>
<tr>
<td>E05.02</td>
<td>23%</td>
</tr>
<tr>
<td>I06.02</td>
<td>15%</td>
</tr>
<tr>
<td>C13.02</td>
<td>16%</td>
</tr>
<tr>
<td>B14.02</td>
<td>4%</td>
</tr>
<tr>
<td>N15.02</td>
<td>14%</td>
</tr>
<tr>
<td>C16.02</td>
<td>23%</td>
</tr>
<tr>
<td>N17.02</td>
<td>7%</td>
</tr>
<tr>
<td>D19.02</td>
<td>26%</td>
</tr>
<tr>
<td>G19.02</td>
<td>8%</td>
</tr>
</tbody>
</table>

*Table 4.3: Skeletal structures of inhibitory fragments*

Skeletal structures of fragments that had reduced activity of MurD in initial screening and passed assay interference checks. Fragment ID, skeletal structure, and percentage activity of MurD are shown.

Seven of these fragments contain a five-membered ring structure attached to a six-membered ring structure, with nitrogen present within the double ring structure. Comparison of the potential binding position of the fragments via VIDA showed that all inhibitory fragments have a nitrogen that has the potential to form
a hydrogen bond with the oxygen of Asn282 of MurD from *S. agalactiae* equivalent to Asn 271 of the *E. coli* enzyme. Eighteen fragments were predicted to be able to form hydrogen bonds to both the oxygen and nitrogen of Asn282 of MurD from *S. agalactiae*, with an example fragment in this binding mode shown in the predicted interaction in Figure 4.18A.

![Figure 4.18A](image)

**Figure 4.18: Predicted binding of inhibitory fragments**
The predicted binding of fragments that had reduced activity of MurD and passed assay interference checks was compared. Nitrogen is shown in blue, oxygen in red, sulphur in yellow and chloride in green. Polar contacts are shown in dotted red lines. (A) 18 fragments are predicted to be able to form hydrogen bonds with both the oxygen and nitrogen of Asn282. (B) Fragments were seen to kink towards the Lys123 involved in ATP binding. (C) Fragment G04.01 was the only fragment that is predicted to not kink towards the Lys123.

All inhibitory fragments, apart from G04.01, have a ‘kink’ within their structure, allowing them to potentially form interactions with the Lys123 (equivalent to Lys 115 of the *E. coli* enzyme) that interacts with the phosphate of ADP, as shown in the predicted interactions in Figure 4.18B and Figure 4.18C. The presence of these interactions may help provide information on why these fragments have inhibitory effects against MurD from *S. agalactiae*. 

140
3.13 Identification of dual inhibitory fragments

The initial *in silico* screen was run against MurD from *S. agalactiae* and MurE from *E. coli*, with fragments identified as having the potential to be able to bind to both proteins. To determine if the fragments that had been identified as being able to reduce the activity of MurD from *S. agalactiae* by 70% or more were able to act as inhibitors of MurE as well, a stopped MESG assay was run in the presence of fragments against MurE from *S. agalactiae*. Fragments were incubated at a final concentration of 1 mM with 80 nM MurE from *S. agalactiae* prior to initiation of the activity assay. The activity rate of MurE in the presence of fragments was compared to a control assay where 10% (v/v) DMSO was added in place of a fragment, and the percentage activity of MurE in the presence of fragments relative to that in their

![Figure 4.19: Four fragments were able to inhibit the activity of MurE from *S. agalactiae*](image-url)

Fragments that had reduced activity of MurD in initial screening were tested for their effect on MurE from *S. agalactiae*. Four fragments were able to reduce activity of MurE from *S. agalactiae* by 70% or more. All experiments were run in triplicate with mean results being plotted, with individual data points shown. Error bars show SD.
absence was determined, as shown in Figure 4.19. A positive control inhibitor of ADPCP at 5 µM was also used to confirm inhibition within the assay system. As can be seen in Figure 4.19, four fragments were able to reduce the activity of MurE from *S. agalactiae* by 70% or more. Fragment J06.01 was able to reduce activity by over 90%, with fragments G04.01, M02.01 and L06.02 able to reduce activity of MurE from *S. agalactiae* by around 80% or more. These four fragments were considered to be able to act as dual inhibitory fragments due to their ability to inhibit the activity of both MurD and MurE from *S. agalactiae*. 
4. Conclusions and Future Direction

4.1 Targeting the ATP-binding site for antibacterial development

Within the initial stages of fragment screening, a specific region within the protein of interest can be selected to be specifically targeted by the fragment screen. The ATP-binding site of Mur ligases was specifically targeted via the *in silico* fragment screen to allow for the potential of developing multi-targeting inhibitors. The ATP-binding site within the Mur ligases was seen to have a high level of structural similarity, as well as having a high degree of sequence similarity across the four Mur ligases and across bacterial species. This level of similarity may allow for the development of a multitargeting inhibitor.

The ATP-binding site of bacterial enzymes was not considered in the development of new antibacterial compounds for many years due to the belief that inhibitory compounds would not be able to outcompete the ATP present within the bacterial cell. Human cells contain an equivalent amount of ATP as to that found within bacterial cells, and so the emergence of protein kinase inhibitors, which mostly act upon the ATP-binding site of kinases within humans led to a change in that belief.

Due to their ability to target the ATP-binding site of kinases, protein kinase inhibitors have been used as the template for the design of novel inhibitors targeted towards the ATP-binding site of other proteins. Triola et al took a similar approach to our study, determining a similarity that existed between the ATP-binding site of kinases and D-Ala-D-Ala ligases, allowing them to use protein kinase inhibitors as scaffolds for the development of ATP competitive inhibitors with $K_i$ of 60 $\mu$M against D-Ala-D-Ala ligase. Protein kinase inhibitors have also been used as the basis for the development of inhibitors targeted towards the Mur ligases. Hrast et al used a protein kinase inhibitor set within biochemical assays to identify a kinase inhibitor that was also able to act as a D-Glu competitive inhibitor of MurD with a $K_i$ of 65 $\mu$M. The use of kinase inhibitors as the basis for the fragment screen provides a solid foundation for the development of an inhibitory compound that has the potential to bind to the ATP-binding site of the Mur ligases, and potentially act in a competitive manner.
4.2 Use of *in silico* screens for fragment identification


*In silico* screening can act as a useful tool to provide an initial starting point for the development of inhibitory fragments. *In silico* screening allows for the testing of large volumes of fragments without the requirement for protein crystals. Within our testing, 40,000 fragments were screened for their ability to bind to the Mur ligases. Much larger volumes of fragments can be tested though, with Azam et al testing 1.6 million fragments to identify potential hits against MurD from *Sta. aureus*.

However, certain limitations are present within the process of *in silico* screening. Use of the LigPrep software from Glide to generate a fragment library can lead to the docking of unnatural tautomers, due to the software considering different tautomers, sterochemistries and ring conformations when generating fragments. Other limitations, such as flexibility within the backbone of the fragments can also lead to inclusion of fragments within the hits that are unlikely to be able to act effectively as inhibitors. Limitations within the software can be mitigated against via the docking process but cannot be eliminated entirely and so fragment results require further screening before biochemical testing can be carried out.

4.3 Role of multi-targeting inhibitors within novel antibacterial compound design

Of the twenty fragments identified as having inhibitory effects against MurD from *S. agalactiae*, four were seen to have dual inhibitory effects, reducing the activity of MurE from *S. agalactiae* by 80% or more. These four fragments are good initial starting points, but further biochemical testing is required to determine if the fragments can target multiple Mur ligases across multiple bacteria. The ability of an inhibitory fragment to target multiple Mur ligases is essential for the development of a multtargeted antibacterial compound. Development of a multtargeted antibacterial compound is becoming considered a better option for future drugs due to the reduced emergence of antibacterial resistance compared to single target drugs. Due to their similarity in structure and catalytic mechanism, multtargeted inhibitors against the Mur ligases are possible, and some have been
identified that are able to target the entire cascade of Mur ligases, with Hrast et al identifying inhibitors with IC₅₀ values ranging from 157 µM to 39 µM across MurC-MurF of *E. coli*¹⁰².

In order to continue to develop these fragments into multi-targeting compounds, the IC₅₀ of these fragments against MurD and MurE from *S. agalactiae* would need to be determined to better understand the inhibitory effects of the fragments and their efficacy. Understanding the binding mode of these fragments would also need to be carried out to determine if these fragments are binding in a competitive manner to ATP. Chapter 5 details further biochemical testing carried out on these inhibitory fragments.
Chapter 5

Identification of multitargeting inhibitors via a fluorometric assay
1. **Introduction and Aims**

In order to identify inhibitory fragments, biochemical testing is required. High throughput screening of fragments can be costly and time consuming. In Chapter 2, a stopped MESG assay was developed to reduce the time and cost involved in high throughput assay screening compared to a continuous assay of the same nature. However, limitations remained with this assay system that could be overcome with a different assay system, including the effect of natural absorbance of fragments at A360 and volume of fragment required for testing.

In the presence of hydrogen peroxide, amplex red can be converted to resorufin via HRP which can be coupled to the production of phosphate via PNP and Xanthine Oxidase \(^{122}\), allowing it to act as a Mur ligase activity assay system. An amplex red assay can be followed spectrophotometrically at 555 nm or fluorometrically at 545 nm excitation and 585 nm emission wavelengths.

This chapter describes the optimization of an amplex red assay for use with Mur ligases for determining inhibition within an absorbance and fluorometric assay. Development of a stopped amplex red assay was then attempted. A continuous amplex red assay was used for the determination of the IC\(_{50}\) values of dual inhibitory fragments previously identified in Chapter 4, after which the mode of fragment inhibition was investigated.
2. Materials and Methods

2.1 Amplex Red assay

Mur ligase activity within an amplex red assay was confirmed. The amplex red assay was carried out in either a Cary 100 spectrophotometer at a total reaction volume of 200 µL at 37°C where absorbance was followed at 555 nm, or within a Varioskan Flash plate reader at 37°C at a total reaction volume of 10 µL. Fluorometric tracking was carried out at an emission of 545 nm and excitation of 585 nm. The reaction mixture contained the following components (final concentrations): 50 mM MOPs (pH 7.6), 10 mM MgCl₂, 2.5 U per mL PNP, 500 µM Inosine, 50 µM Amplex red, 25 U/mL Horse radish peroxidase (HRP), 1.25 U/mL Xanthine Oxidase, 100 µM ATP, 500 mM L-Lys, 50 µM UDP-MurNAc-L-Ala-D-Glu and 20 nM Mur ligase. To determine dependence on substrate, all components apart from one substrate were added and mixed and a background rate was determined. The substrate was added to start the reaction and the reaction was followed. The IC₅₀ value for ADPCP was determined using this assay. ADPCP was added to the component mixture before the recording of the background rate of the reaction. Investigation into a stopped assay was carried out using this assay, with the MgCl₂ concentration decreased to 2 mM. All components were added barring one substrate, before the background rate was determined. Activity was initiated via the addition of a substrate and the initial rate period of the assay was allowed to proceed before 10 mM EDTA was added to the reaction. The assay was then allowed to proceed to allow determination of rate after addition of EDTA.

2.2 Amplex Red assay for IC₅₀ determination and binding mode determination

Fragments were biochemically tested for IC₅₀ determination via a continuous amplex red assay run using a Varioskan Flash plate reader. In a final volume of 10 µL, various concentrations of fragment were incubated with the relevant concentration of Mur ligase, in the presence of 50 mM MOPs (pH 7.6), 10 mM MgCl₂, 2.5 U per mL PNP, 500 µM Inosine, 50 µM Amplex red, 25 U/mL HRP, 1.25 U/mL Xanthine Oxidase and the relevant substrates without an amino acid for 10 minutes. The assay was then initiated with the relevant amino acid and allowed to
run past the initial rate period. A background absorbance was determined fluorometrically via the Varioskan plate reader (ThermoFisher) at 545 nm and 585 nm before the relevant amino acid was added. Fluorescent change was followed to allow the initial rate to be determined. The fluorescent change during the initial rate period was then determined. Each fragment concentration was run in triplicate in the presence and absence of the Mur ligase to determine background rate. Background rates were removed from the final activity rate for each fragment. The activity rate in the presence of fragment was compared to a control group of 10% γ/ν DMSO. Assays were carried out at 37°C.

To determine the IC₅₀ of fragments against MurD from *S. agalactiae*, 5 nM MurD was incubated with various fragment concentrations in the presence of 100 µM UDP-MurNAc-L-Ala and 15 µM ATP, before activity was initiated with 150 µM D-Glu. To determine the IC₅₀ of fragments against MurE from *S. agalactiae*, 5 nM MurE was incubated with various fragment concentrations in the presence of 100 µM UDP-MurNAc-L-Ala-D-Glu and 20 µM ATP, before activity was initiated with 400 µM L-Lys. To determine the binding mode of J06.01, MurD was incubated with various fragment concentrations in the presence of 100 µM UDP-MurNAc-L-Ala and either 15 µM, 30 µM or 60 µM ATP, before activity was initiated with 150 µM D-Glu.
3. Results

3.1 Use of an amplex red assay to follow the activity of a Mur ligase

The amplex red assay can couple the activity of a Mur ligase reaction to a secondary coupling reaction via the formation of phosphate. In the same manner as the MESG coupled assay, the free phosphate formed during the Mur ligase reaction can be converted to ribose 1-phosphate via the actions of PNP. However, instead of acting upon MESG to convert it to 2-amino-6-mercapto-7-methylpurine, the PNP acts upon inosine to form hypoxanthine, as seen in Figure 5.1.

The hypoxanthine generated via PNP acting upon inosine can be converted to xanthine and uric acid via xanthine oxidase. Hydrogen peroxide is generated during this reaction and reacts with amplex red in a reaction catalysed by HRP to form resorufin, as seen in Figure 5.1. Resorufin has excitation and emission maxima of ~545 and 585 nm, allowing its production to be followed either spectrophotometrically at 555 nm or fluorometrically. An increase in absorbance or fluorescence corresponds to the conversion of amplex red to resorufin, which is taken to be twice the production of phosphate during the initial rate period of the Mur ligase reaction, thus allowing the following of the activity of the Mur ligase.
The amplex red assay was considered as an alternative to the MESG assay for several reasons. The amplex red assay follows the activity of the Mur ligases spectrophotometrically at 555 nm, while the MESG assay follows activity at 360 nm. Due to their composition, fragments may cause interference at lower wavelengths. The increase in wavelength of the amplex red assay should reduce the impact of this phenomenon. Spectrophotometrically, by virtue of the 4.7 times greater extinction coefficient of the amplex red assay relative to the MESG assay, it is intrinsically more sensitive to the presence of phosphate. Furthermore, the fluorescence properties of the amplex red product, resorufin, enables the assay to be performed at low volume because the assay depends upon emitted light, removing the impact of pathlength.

In order to determine if an amplex red assay could be used as a better biochemical assay for high throughput screening of fragments targeted towards the Mur ligases, the ability of the assay to follow the activity of MurE from *S. agalactiae* was determined both spectrophotometrically and fluorometrically. The sensitivity of the assay to inhibition was then determined via a positive control inhibitor and the determination of the Z prime score.

### 3.2 Activity of MurE within an amplex red assay is dependent on substrates being present

In order to establish whether an amplex red assay could be used for high throughput screening of the Mur ligases, the ability of the assay to follow the Mur ligase activity had to be established. The Mur ligases require the presence of three substrates to be active: the UDP intermediate, a nucleotide, and an amino acid. To determine whether the presence of all substrates was required for the activity of the Mur ligases within the amplex red assay, the assay was run with one substrate omitted on a spectrophotometer. The absorbance change was then followed and the omitted substrate introduced. As can be seen from **Figure 5.2**, no activity was seen within the assay until all substrates were present showing that within an amplex red assay, all substrates must be present for activity of the Mur ligases.
3.3 Amplex red assay is dependent on enzyme concentration

Within the amplex red assay, the absorbance change is dependent on the presence of phosphate. The Mur ligases generate phosphate when ATP is broken down into ADP and phosphate during the addition of an amino acid onto the UDP intermediate. The absorbance change of the amplex red assay should therefore be dependent on the concentration of the Mur ligase present. To confirm that this was the case, the enzyme concentration within the assay was varied and the initial rate determined using a Plate reader plate reader.

Figure 5. 2: The activity of *S. agalactiae* MurE relies on the presence of all three substrates

The activity of MurE was followed using an amplex red assay. All components of the assay were incubated at 37°C barring one substrate which was added after 1 minute. No activity was seen within any of the assays until all three substrates were present. (A) ATP added after 2 minutes. (B) L-Lys added after 2 minutes. (C) UDP-MurNAc-L-Ala-D-Glu added after 2 minutes.

Figure 5. 3: Amplex red assay is dependent on Mur ligase concentration

The activity of *S. agalactiae* MurE was followed using an amplex red assay. The amplex red assay was run in the presence of various concentrations of MurE. The initial rate was determined and plotted against [MurE]. A linear relationship was seen. All data points were run in triplicate.
As can be seen from Figure 5.3, as the enzyme concentration was increased, the initial rate determined via the assay increased in a linear fashion. The amplex red assay was therefore dependent on the Mur ligase concentration within the assay, and so was able to track the activity of the Mur ligase.

3.4 Activity of MurE is dependent on presence of all substrates within a fluorometric amplex red assay

Within the amplex red assay, the product resorufin is produced from amplex red. Resorufin can be followed spectrophotometrically at 555 nm but can also be followed fluorometrically. Fluorometric assays have higher sensitivity than photometric assays, and so would be more amenable for the detection of inhibition via fragments within high throughput screening.

In order to determine if the amplex red assay could be used fluorometrically for high throughput screening of fragments against the Mur ligases, the ability of the assay to follow the activity of the Mur ligases had to be established. Once again, the dependence of the assay on the presence of all three substrates was determined by running the assay with one substrate omitted before adding the latter and following the fluorometric change via a Plate reader. As can be seen from Figure 5.4, all three substrates were once again required for activity of the Mur ligase within the assay, showing that the amplex red assay in fluorometric form was able to follow the activity of the Mur ligase.

The activity of MurE was followed fluorometrically using an amplex red assay. All components barring one substrate were incubated before the final substrate was added. No activity was seen within any of the assays until all substrates were present.
3.5 Fluorometric amplex red assay is sensitive to inhibition via ADPCP

To be able to use the amplex red assay within high throughput screening of inhibitory fragments against the Mur ligases, the assay must be able to determine inhibition of the Mur ligases. ADPCP had previously been shown to act as an inhibitor of the Mur ligases, as well as previously being used as a positive control inhibitor of the Mur ligases within high throughput screens. To confirm the ability of the amplex red assay to identify Mur ligase inhibitors, and confirm ADPCP could still act as a positive control inhibitor of the Mur ligases within an amplex red assay, the determination of an IC$_{50}$ of ADPCP against MurE from *S. agalactiae* was attempted. As can be seen from Figure 5.5, ADPCP was able to inhibit the activity of MurE within the amplex red assay.

ADPCP was seen to have an IC$_{50}$ of 2.67 ± 0.7 µM against *S. agalactiae* MurE, which was not statistically different to the IC$_{50}$ value previously seen for ADPCP against *S. agalactiae* MurE within a stopped MESG assay (*Supplementary 3*), allowing ADPCP to be effective as a positive control inhibitor against MurE within an amplex red assay.

To determine how effective the amplex red assay was at identifying inhibition, the Z prime score was determined. To determine the Z prime score of the amplex red assay, the initial rate for MurE from *S. agalactiae* in the presence and absence of ADPCP at its IC$_{50}$ value were compared across 10 repeats. The mean value and
standard deviations were determined, to allow the determination of the Z prime score, as seen in Table 5.1. A Z prime score of 0.84 was seen when ADPCP was at its IC$_{50}$ value within the amplex red assay, indicating that the activity assay could identify inhibitors accurately.

<table>
<thead>
<tr>
<th></th>
<th>MurE</th>
<th>MurE + ADPCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>0.24894</td>
<td>0.1276</td>
</tr>
<tr>
<td>Standard Deviation</td>
<td>0.00222</td>
<td>0.00423</td>
</tr>
<tr>
<td>Z prime Score</td>
<td>$Z = 1 - \frac{3(0.00222) + 3(0.00423)}{(0.24894 - 0.1276)}$</td>
<td>$Z = 0.84$</td>
</tr>
</tbody>
</table>

Table 5.1: Determination of the Z prime score for ADPCP within an amplex red assay against MurE from S. agalactiae

The Z prime score was determined by calculating the mean $V_0$ for MurE in the presence and absence of ADPCP, along with the standard deviation of the means. The Z prime was then calculated. A Z prime score of 0.84 was determined for ADPCP against MurE from S. agalactiae within an amplex red assay.

### 3.6 Stopped activity assay

Development of a stopped MESG assay was previously carried out to reduce the time taken to complete a high throughput screening of inhibitory fragments against the Mur ligases and the amount of data that was required to achieve this goal. These issues are consistent with all continuous assays being used for high throughput screening, and so the development of a stopped amplex red assay was considered.

#### 3.6.1 EDTA is unable to quench the reaction sufficiently

In Chapter 2, it was seen that within a stopped MESG assay, EDTA was able to quench the Mur ligase reaction within the initial rate stage, to allow the secondary reaction to be uncoupled from the Mur ligase reaction. To determine if EDTA could be used to uncouple the secondary reaction from the Mur ligase reaction within a stopped amplex red assay, the amplex red assay was run for the initial rate stage before 10 mM EDTA was added. As can be seen from Figure 5.6, after the addition of EDTA, the reaction rate was decreased but did not plateau. EDTA and EDTA in
complex with Mg do not absorb at 555 nm and so further investigations were required to determine why a plateau in absorbance was not achieved after the addition of EDTA.

One reason why a plateau was not observed after the addition of EDTA could be due to EDTA interfering with the secondary coupling system. To determine if this was occurring, the secondary coupling system was run in the presence and absence of 10 mM EDTA at a set phosphate concentration. As can be seen from Figure 5.7A, in the presence of 10 mM EDTA the reaction rate of the secondary coupling system was increased, suggesting that EDTA was interfering with a component within the secondary coupling system.

To further determine what effect EDTA was having on the secondary coupling system, the absorption at 555 nm of the components of the secondary coupling system in the absence of phosphate were followed in the absence and presence of EDTA. As can be seen from Figure 5.7B, the addition of EDTA caused a greater increase in absorbance at 555 nm. To determine which component of the secondary coupling system EDTA was interfering with, a sequential addition experiment of the secondary coupling components was carried out. In order to be able to see any absorbance change at the point of interference the secondary coupling components were added in reverse order, starting with amplex red. As can be seen from Figure 5.7C, it was after the addition of amplex red that an absorption
rate was seen, suggesting that EDTA was causing the conversion of amplex red to resorufin in the absence of phosphate.

As EDTA interfered with the secondary coupling system of the amplex red assay, EDTA could not be used to quench the Mur ligase reaction and allow for the uncoupling of the secondary reaction within an amplex red assay. This prevented the amplex red assay from being used for high throughput screening of fragments within this project. The amplex red assay could not be used for high throughput screening as a continuous assay as although the amplex red assay was able to be run at smaller final volumes than the MESG assay making it a cost-effective option.
the level of data analysis remained too high for high throughput screening. As the amplex red assay was able to effectively determine inhibition within a continuous assay system, had a Z prime score greater than that seen within the stopped MESG assay (Chapter 2, Section 3.6.4.2), and due to its increased sensitivity allowing it to be run at much smaller volumes than the MESG assay, the amplex red assay was an effective assay for the determination of the IC₅₀ values of inhibitors previously identified within high throughput screens.

3.7 Screening of dual inhibitory fragments

Dual inhibitory fragments were previously identified against MurD and MurE from *S. agalactiae* using high throughput screening within Chapter 4. In order to better understand the inhibitory effects these fragments have on the Mur ligases, an amplex red assay was used to identify the IC₅₀ values of these fragments against MurD and MurE from *S. agalactiae*, as well as try to better understand the binding mode of these fragments against MurD from *S. agalactiae*.

3.7.1 Identification of dual inhibitory fragments with micromolar IC₅₀ values

Fragments J06.01, M02.01, G04.01 and L06.02 were identified to inhibit MurD and MurE from *S. agalactiae* at 1 mM concentration using a stopped MESG assay within Chapter 4. To develop a better understanding of the inhibitory potency of the fragments, dose response curves were generated to determine the concentration of fragment required to inhibit the activity of enzyme by half. To determine the IC₅₀ of the fragments, the amplex red assay was run at various concentrations of fragment against MurD and MurE from *S. agalactiae*. Previous work carried out by Dr Adrian Lloyd and Anita Catherwood identified no interference with the secondary components of the amplex red assay, apart from with J06.01 over 500 µM, allowing for the identification of IC₅₀ values of these fragments using this assay system. The activity of the Mur ligase was determined in the absence and then presence of increasing concentrations of fragments, and the remaining activity, relative to that in the absence of fragment, was plotted against the log concentration of fragment.
As seen in Figure 5.8, the fragments IC₅₀ values varied between 420 µM and 57 µM against MurE from *S. agalactiae*, with fragment J06.01 showing the greatest inhibitory effect, having an IC₅₀ of 57 +/- 7.6 µM. The fragments IC₅₀ values were also varied against MurD from *S. agalactiae* with the fragments having IC₅₀ values between 260 µM and 20 µM, as seen in Figure 5.9. J06.01 showed the greatest inhibitory effect against MurD as well, having an IC₅₀ value of 21.6 +/- 2.9 µM.

Figure 5.8: IC₅₀ determination against MurE from *S. agalactiae*

The IC₅₀ of 4 fragments hits were identified using an amplex red assay. Various concentrations of fragment were incubated with MurE from *S. agalactiae* before activity of MurE was established. Activity was then plotted against log fragment concentration and the IC₅₀ determined. All fragments were run in triplicate with a triplicate background rate being removed from the activity rate. The mean is plotted with error bars showing SD. A variable response curve was then plotted via PRISM.
3.7.2 J06.01 potentially binds to the ATP-binding site of Mur ligases

Fragments identified as having inhibitory effects against MurD and MurE from *S. agalactiae* were originally identified via *in-silico* screening which was targeted towards the ATP-binding site of the Mur ligases. J06.01 was identified as having an IC$_{50}$ of $21.6 \pm 2.9$ µM and $57 \pm 7.6$ µM against MurD and MurE from *S. agalactiae* respectively, the lowest IC$_{50}$ values of the identified dual inhibitory fragments. The binding mode of J06.01 was therefore investigated to determine if it was still targeting the ATP-binding site of the Mur ligases. To achieve this, IC$_{50}$ determination was carried out using an amplex red assay at various ATP concentrations. As can be seen from Figure 5.10, as the ATP concentration increased, so did the IC$_{50}$ for J06.01. The IC$_{50}$ for J06.01 at 15 µM ATP was $21.6 \pm 2.9$ µM, whereas at 60 µM ATP the IC$_{50}$ for J06.01 was $60.76 \pm 40$ µM. This suggests that J06.01 may be competing...
with the ATP, and therefore is potentially binding within the ATP-binding site of the Mur ligases.

If J06.01 is acting in a competitive manner with ATP, a $K_i$ value for this fragment can be determined. The IC$_{50}$ value for an inhibitor can vary based on enzyme and substrate concentration. To overcome this issue, the IC$_{50}$ value can be related to the affinity of the inhibitor via an absolute inhibition constant, $K_i$ \textsuperscript{89}. The $K_i$ value of J06.01 against MurD from \textit{S. agalactiae} can be determined using the Cheng-Prusoff equation describing the relationship between IC$_{50}$ and $K_i$ for a simple competitive inhibitor $\textsuperscript{89}$:

$$K_i = \frac{IC_{50}}{IC_{50} + \frac{[S]}{K_m}}$$

where [S] is the fixed substrate concentration and $K_m$ is the Michaelis constant. If J06.01 is acting in a competitive manner with ATP, then the $K_m^{App}$ value for ATP (47.1 µM), the concentration of ATP used and the observed IC$_{50}$ can be placed into the equation to allow for the computation of a $K_i$ for J06.01. Using this equation.

\textbf{Figure 5.10: The IC$_{50}$ of J06.01 increases in the presence of increased ATP}

The IC$_{50}$ of J06.01 against MurD from \textit{S. agalactiae} was determined in the presence of various concentrations of ATP. The initial rate of MurD was determined at various concentrations of J06.01 at three ATP concentrations. The initial rates were plotted against log J06.01 concentration and the IC$_{50}$ determined. At higher concentrations of ATP, the IC$_{50}$ of J06.01 increased.
and the previously identified IC$_{50}$ values, a $K_i$ of 23.8 $\pm$ 18 $\mu$M can be determined for J06.01 against $S. agalactiae$ MurD.

Potential interactions formed during the binding of J06.01 into the ATP-binding site of MurD from $S. agalactiae$ were predicted during the *in-silico* screen, and are shown in the predicted structure seen in *Figure 5.11*. As can be seen in the predicted binding in *Figure 5.11*, J06.01 has the potential to form three polar contacts within the ATP-binding site of MurD of $S. agalactiae$.

![Figure 5.11: Potential binding of J06.01 into the ATP-binding site of MurD from S. agalactiae](image)

J06.01 has the potential to form a polar contact between a nitrogen within the pentose ring and the oxygen of His278, along with the oxygen of Asn282. Asn282 may also form a polar contact between its nitrogen and a nitrogen within the pentose ring of J06.01. J06.01 has the potential to ‘kink’ within the ATP-binding site towards the phosphate binding region, with the potential of an oxygen within J06.01 to bind with the nitrogen of Arg313.
4. Conclusions and Future Direction

4.1 Conversion of biochemical assays to a high-throughput assays

Many activity assays have been developed over the years to allow the activity of an enzyme to be followed\(^\text{123}\). The sensitivity of the assay and its ability to effectively follow the activity of the enzyme in the presence of an inhibitor can make an assay a better candidate for high throughput screening for inhibitory fragments\(^\text{96}\). An amplex red assay can effectively follow the activity of Mur ligases in the absence and presence of an inhibitor, and was shown to have a Z prime score of 0.8, consistent with other published assays used for the identification of inhibitors\(^\text{93,94}\). An amplex red assay is an attractive assay for high throughput screening due to its increased sensitivity compared to other absorbance assays, and its ability to be followed fluorometrically\(^\text{96,101}\). Its ability to be tracked fluorometrically removes the interference that coloured fragments exhibit in an absorbance assay\(^\text{124}\), preventing as many false positive and false negative results during testing. However, fluorimetry does contain its own challenges for fragment screening, for example, fragment quenching of fluorescence can provide a real challenge to implementation of fluorescent assays. The amplex red assay has however previously been used in high throughput screening for the identification of NOX inhibitors\(^\text{101}\).

Activity assays can either be run as continuous assays whereby the activity of the ligase is followed via a secondary reaction which is occurring concurrently with the activity assay, or via a stopped assay whereby the secondary reaction occurs after the activity assay. Stopped assays provide many benefits over continuous assays during high throughput screening; by reducing the amount of data analysis required by the scientist, removing the requirement for the secondary assay components to be present in excess and increasing the number of fragments that can be tested simultaneously. Sullivan et al used metal chelating agents to convert a continuous assay to a stopped assay to allow high throughput screening of inhibitors against purine biosynthesis enzymes\(^\text{95}\). In a similar fashion, EDTA was used to convert a continuous MESG coupled assay into a stopped MESG coupled assay within Chapter 2. However, EDTA interfered with the secondary coupling
system of the amplex red assay, preventing it from being useful as a stopping agent. Previously, Liu et al were able to use EDTA to quench Acetyl-Coenzyme A Carboxylases within a stopped amplex red assay \(^{125}\). EDTA was present in a high concentration, as within our stopped assays, but addition of amplex red was carried out after the addition of EDTA unlike within our assays. No interference with the assay system from the EDTA was mentioned within the study but absorbance readings were taken only after the addition of EDTA and amplex red \(^{125}\).

Other stopping agents could be used to either quench the Mur ligase reaction or inhibit the activity of the secondary coupling system to allow the amplex red assay to be converted from a continuous assay to a stopped assay. One such agent is the Amplex Red Stop Reagent A33855, that can stop the assay via quenching of the HRP activity \(^{126}\). This reagent has been used to allow the enzymatic measurement of phosphatidic acid in cultured cells and determine the effect of a kinase inhibitor on levels of phosphatidic acid \(^{127}\), and was present within the stopped assays used by Liu et al for high throughput screening of acetyl-coenzyme A carboxylase inhibitors \(^{125}\). This stopping agent has the potential to be able to convert the continuous amplex red assay to a stopped assay for high throughput screening of the Mur ligases.

### 4.2 Role of IC\(_{50}\) values in the determinations of the efficacy of novel inhibitory fragments

Within pharmacology IC\(_{50}\) values are used as a useful tool for measuring the potency and efficacy of an antagonist drug, as they describe the amount of substance required to reduce activity by 50% or more \(^{100}\). Determination of the IC\(_{50}\)S of the dual inhibitory fragments identified fragments with IC\(_{50}\)S ranging from 420 to 20 µM. Previous work by Hrast identified a kinase inhibitor that had IC\(_{50}\)S ranging from 368 to 59 µM against MurC-MurF from \(E.\ coli\) \(^{102}\), suggesting that our dual inhibitory fragments are comparable to other kinase based Mur ligase inhibitors.

However, the IC\(_{50}\) value for an inhibitor can vary based on enzyme and substrate concentration, and so comparison between published IC\(_{50}\) data has its limitations. Within our study, the Mur enzymes were at 5 nM whereas Hrast et al did not reveal
the enzyme concentration employed and so a direct comparison of IC$_{50}$ data is limited. To take substrate concentrations into account, the IC$_{50}$ value can be related to the affinity of the inhibitor via an absolute inhibition constant, $K_i$ $^{89}$, using the Cheng-Prusoff equation describing the relationship between IC$_{50}$ and $K_i$ for a simple competitive inhibitor $^{89}$:

$$K_i = \frac{IC_{50}}{1 + \frac{[S]}{K_m}}$$

Where $K_i$ is the equilibrium constant of the dissociation of the inhibitor from the enzyme, $[S]$ is the fixed substrate concentration and $K_m$ is the Michaelis constant. J06.01 was seen to potentially be acting as a competitive inhibitor of MurD in respect to ATP, and had a $K_i$ of 23.8 +/- 18 µM. This value is similar to the $K_i$ reported by Hrast et al for their compound that had mixed inhibition against ATP within MurD $^{102}$, suggesting that our dual inhibitory fragments are comparable to other kinase based Mur ligase inhibitors.

4.3 Repurposing old drugs for new purposes

J06.01 proved to be the most promising fragment identified within the screen, having dual inhibitory effects and the potential to bind to the ATP-binding site of MurD. Originally from an Enamine kinase inhibitor library, its ability to inhibit kinases will need to be investigated to determine its current level of specificity. Cross reactivity can be an issue when repurposing old drugs especially with protein kinase inhibitors as cross reactivity with a human kinase could lead to negative side effects of antibacterial compounds. Hrast et al eliminated a compound from their screen of kinase inhibitors due to its effect on human kinase activity $^{102}$. One of the final steps taken by Le et al when repurposing human kinase inhibitors for antibacterial compounds against *Sta. aureus* was to confirm their lead compound possessed no affinity to kinases $^{128}$.

J06.01 has since been tested against other Mur ligases from different bacterial species and exhibits IC$_{50}$ values of similar µM values. Due to its ability to inhibit multiple Mur ligases across multiple bacterial species, further development of
J06.01 needs to be carried out. Currently J06.01 has only been tested for its inhibitory effects against MurD and MurE; further testing against MurC and MurF would identify if J06.01 is able to target all the Mur ligases involved in the stepwise addition of amino acids. Crystallographic studies of J06.01 bound to MurD and MurE could confirm whether J06.01 is binding within the ATP-binding site of the Mur ligases and what residues are involved in this interaction. Understanding how J06.01 is binding to the Mur ligases could also provide a starting point for the development of J06.01 into a compound from a fragment 129, focusing on specificity for the Mur ligases over kinases and ability to cross the bacterial membrane.
Chapter 6

MurD and MurE from *S. agalactiae* form a binary complex
1. **Introduction and Aims**

Over the past 20 years, the Mur ligases have been the target of many drug discovery programmes. Inhibitory compounds targeted towards the Mur ligases have been identified, but virtually all lack the ability to act as an antibacterial agent. One hypothesis why inhibitory compounds are unsuccessful at targeting the Mur ligases *in vivo* is that the Mur ligases are forming a complex within the cytoplasm. Complex formation amongst the Mur ligases could prevent inhibitory compounds working *in vivo* either due to sequestering of intermediates or blocking of the site that the inhibitor is targeted towards. Determining if complex formation is occurring between the Mur ligases could give insight into how to design better inhibitory compounds in the future as well as potentially indicate how this part of the peptidoglycan pathway is regulated.

Biological evidence for potential complex formation among the Mur ligases can be found in the presence of a complex between the Mur enzyme MurT and GatD. MurT shares a similar C-terminal domain to the Mur ligases, which is required for complex formation with GatD. Other biological evidence can be found in the presence of the fusion of the MurE and MurF proteins within *Bordetella pertussis*. A study by Laddomada and co-workers found that within *B. pertussis* the MurE and MurF proteins form a fusion protein with a 20 amino acid linker region. Once purified these proteins exist in a state that allows for activity of both proteins. Further studies have been carried out to determine if the individual Mur ligases can form a complex, and if so what proteins are involved. A study by Dessen and co-workers investigating the Mur ligases from *T. maritima* concluded that the Mur ligase proteins are unable to interact with each other, but are able to interact with the structural protein MreB and the lipid 1 – glucosaminylating enzyme, MurG. Interaction between the Mur ligases and MreB was also established by White and co-workers, who were able to show that the Mur ligases localised perpendicular to the long axis of the cell but only when MreB was present. However, a more recent study carried out by Miyachiro and co-workers was able to identify direct interactions between the Mur ligase proteins in heterodimeric, binary complexes.
from *S. pneumoniae* \[^{82}\]. Analytical ultracentrifugation assays of MurC, MurD and MurF were able to identify binary globular compact complexes between all three pairings of proteins. This difference in interaction partners and the ability of the Mur ligases to directly interact with each other means it is still unknown if, or how a complex may be forming between the Mur ligases.

This chapter aimed to use a variety of experimental methods to determine if MurD and MurE from *S. agalactiae* are able to form a binary complex. Computational methods were then used to predict the ability of all the Mur ligase proteins from *E. coli* and *S. agalactiae* to form heterodimeric, binary complexes.
2. Materials and Methods

2.1 KEGG Database for Genomic Layouts

Using the KEGG Genome database, the genomes for *S. agalactiae*, *S. pneumoniae*, *T. martima*, *Caulobacter crescentus* (*C. crescentus*) and *B. pertussis* were identified. The genes identified for each bacterium were then searched for the location of the genes encoding the MurC, MurD, MurE and MurF proteins. Using the genome browser location facility, the exact location and surrounding genome sequences of each Mur ligase could be identified. The location of each Mur ligase gene within each genome was visualised using BioRender.

2.2 Cloning of MurE

2.2.1 Polymerase Chain Reaction

Manually designed DNA oligonucleotides were resuspended following the manufacturer’s protocol (Integrated DNA Technologies). The reaction mixture contained the following components (final concentrations): 10 μM forward primer, 10 μM reverse primer, 250 μM dNTPs and 10 ng template DNA. *S. agalactiae* serotype V chromosomal DNA which was used as template DNA. Q5 DNA polymerase and reaction buffer (NEB) were used within the reaction mixture. Over a period of 30 cycles, a 30 second 95°C denaturing step was followed by a 30 second 55°C annealing step followed by a 72°C extension step. Extension length was determined for 1 minute per 1 kilobase of DNA. A final 10 minute extension was then carried out before samples were stored at 4°C.

2.2.2 Agarose Gel Electrophoresis

1% (w/v) agarose gels were prepared in TAE buffer, with GelRed Nucleic Acid Gel Stain (Biotium). PCR produced DNA was combined with 6x DNA loading dye (NEB) according to the manufacturer’s instructions before being loaded onto the gel. A current of 100 V for 1 hour was applied to allow for separation. DNA was then visualised using a UV transilluminator.


2.2.3 Extraction of amplified DNA

Extraction of amplified DNA was carried out using a Gel Extraction kit (QIAGEN). DNA bands were removed from an agarose gel using a scalpel before DNA was extracted according to the manufacturer’s instructions.

2.2.4 Restriction Digestion

Restriction digests of PCR products and plasmids were performed using the relevant restriction enzymes from NEB. Reaction mixtures contained plasmid DNA with restriction enzymes present a 1/10\textsuperscript{th} of the final reaction volume. Reactions were incubated at 37°C for 2 hours before DNA purification was carried out using a PCR purification kit (QIAGEN). DNA purification was carried out according to the manufacturer’s instructions.

2.2.5 Restriction Cloning Ligation

Ligation mixtures contained approximately 50 ng of linearized vector along with 150 ng of purified DNA plasmid together with T4 DNA ligase (NEB) and ligation buffer. Reaction was incubated at room temperature overnight.

2.2.6 Transformation of Competent Cells

Transformation of chemically competent cells was carried out using NEB5 \textit{E. coli} BL21 (DE3) and Top10 cells. Cryo-preserved competent cells were thawed on ice before being mixed with ligated DNA. Cells were incubated on ice for 30 minutes before being heat shocked via incubation at 42°C for 30 seconds. A further 5 minute incubation on ice was carried out before the cells were added to Super Optimal broth with Catabolite repression (SOC medium) to a final volume 10 times the original cell suspension volume. Cells were incubated at 37°C for one hour at 180 RPM before being plated on selective LB agar.
2.2.7 Construct Validation

Plasmid DNA constructs were verified via Genewiz sequencing. 80-100 ng of DNA was sent with relevant primers. Construct maps were then generated via Snapgene.

![Figure 6. 1: Construct maps of MurE from S. agalactiae](image)

Construct maps of *S. agalactiae* MurE. Construct maps were generated via Snapgene. (A) *S. agalactiae* MurE was cloned into open reading frame 1 of pET 28 using restriction enzyme digest. Restriction enzyme sites used were NheI and XhoI. (B) *S. agalactiae* MurE was cloned into His tagged site 1 of pET DUET using restriction enzyme digest. Restriction enzyme sites used were SbfI and NotI.

2.3 Protein Purification

Protein purification of MurE and the pET DUET system was carried out following the methodology previously described in Chapter 2, Section 2.3.

2.4 Size Exclusion Chromatography

To identify the presence of a MurD-MurE complex, size exclusion chromatography was employed. Individual proteins and their combined sample were separated by size using a Superdex 200 increase 10/300 GL column (GE Healthcare) on an AKTA pure system at room temperature where 100 µL of proteins, both at 2 mg/mL, were loaded via an injection system via a 100 µL loop. Separation of complex sample from lysate was carried out using a HiLoad 26/600 Superdex 200 pg (GE Healthcare) where 6 mL of protein sample was loaded via an
injection system via a 6 mL loop. The column was equilibrated with 1.5 column volumes of Buffer GF (as listed in Chapter 2). Elution was carried out with 1 column volume either at a flow rate of 0.75 mL min\(^{-1}\) and 0.5 mL fractions were collected, or at a flow rate of 2 mL min\(^{-1}\) and 1.2 mL fractions collected. Protein elution was monitored at 280 nm and 254 nm.

### 2.5 Cleavage of 6x His tag from MurD

Cleavage of the N-terminal 6x His tag from \textit{S. agalactiae} MurD was carried out following protein purification of individual protein. Fractions containing pure protein identified via SDS-PAGE were pooled. Protein concentration was determined, and 1 unit of 3C protease per 100 µg of protein was incubated with the protein, along with a final concentration 1 mM DTT overnight. The sample was loaded into dialysis tubing and MurD digestion proceeded concurrently with overnight dialysis at 4°C into Buffer GF. Reverse IMAC was carried out on the digested and dialysed protein using a gravity fed His trap column. 2 mL of Ni resin was placed into a gravity column and washed with 3 column volumes of distilled water to remove storage buffer. The resin was washed with 3 column volumes of Buffer A (as listed in Chapter 2) before the dialysed protein was placed onto the column. Digested protein was eluted in 3 column volumes of Buffer A, before undigested protein was eluted using 3 column volumes of Buffer B. Cleaved protein was identified via SDS-PAGE.

### 2.6 Microscale Thermophoresis

Complex formation between MurD and MurE from \textit{S. agalactiae} was analysed via microscale thermophoresis using a Monolith NT.115 (NanoTemper Technologies, Germany). MurE protein was labelled using Monolith NT protein labelling Blue according to the manufacturer’s instructions via the 6x His tag present. 5 nM histidine tagged MurE and 400 µM MurD from which the tag had been removed were individually incubated with 1 mM MgCl\(_2\) in Buffer GF for 30 minutes at room temperature, before incubation with the other protein was carried out. Protein incubations were carried out for 5 minutes at room temperature.
before being loaded into standard capillaries (NanoTemper Technologies, Germany). Fluorescent readings were taken using Monolith NT.115 Blue conditions. \( K_D \) determinations were carried out using a doubling dilution series of unlabelled MurD in Buffer GF. Substrates were incubated with either labelled MurE or unlabelled MurD for 1 hour before incubation with the other protein sample. Substrate concentrations used were: 1 mM ADPCP, 100 \( \mu \)M UDP-MurNAc-L-Ala-D-Glu, 1 mM L-Lys, 100 \( \mu \)M UDP-MurNAc-L-Ala, and 1 mM D-Glu.

2.7 Mass Spectrometry

Mass spectrometry was carried out by Dr Cleidi Zampronio of WPH Proteomics Facility RTP. An aliquot containing 1 \( \mu \)L of extracted peptides (total sample volume 50 \( \mu \)L) was analysed by means of nanoLC-ESI-MS/MS using an Ultimate 3000/Orbitrap Fusion LC-MS (Thermo Scientific) using a 60 minute LC separation on a 50 cm column. The raw data were searched using MaxQuant against the E. coli database (www.uniprot.org/proteomes), the sequences provided, and the MaxQuant common contaminant database. Scaffold software was used for data analysis and visualisation of the results.

2.8 Activity assay for Mur ligases

Activity assays of the Mur ligases was carried out using an amplex Red coupled assay previously described in Chapter 5. The amplex red coupled assay was carried out in a Cary spectrophotometer at a total reaction volume of 200 \( \mu \)L at 37\(^\circ\)C, and absorbance was tracked at 555 nm. The reaction mixture contained the following components (final concentrations): 50 mM MOPS (pH7.6), 10 mM MgCl\(_2\), 2.5 U per mL PNP, 500 \( \mu \)M Inosine, 50 \( \mu \)M Amplex red, 25 U/mL HRP, 1.25 U/mL Xanthine Oxidase, 80 nM protein sample and the relevant substrates.

To determine dependence on substrate presence, all components apart from one substrate were added and mixed and a background rate was determined. To determine activity of the proteins, each substrate was added sequentially, and absorbance change tracked. To determine the ability of MurE to use UDP-MurNAc-
L-Ala-D-Glu produced by MurD, a MurD activity assay was run until a plateau was observed. L-Lys was then introduced to the assay and the absorbance tracked.

To determine the activity of MurD, 30 µM UDP-MurNAc-L-Ala, 1 mM D-Glu and 200 µM ATP were added to the reaction. To determine the activity of MurE, 30 µM UDP-MurNAc-L-Ala-D-Glu, 200 µM ATP and 500 µM L-Lys were added to the reaction.

2.9 Binary Complex Prediction

2.9.1 PRISM

Binary complex formation between *E. coli* Mur ligases was predicted using the PRISM 2.0 software, [http://cosbi.ku.edu.tr/prism/](http://cosbi.ku.edu.tr/prism/). The PDB codes for the *E. coli* Mur ligases; 2F00 – MurC, 1E0D – MurD, 7B53 – MurE and 1GG4 – MurF were inputted as the target proteins. The template required for predicting complex formation was established by the software.

2.9.2 HADDOCK 2.4

Binary complex formation between the Mur ligases was predicted using the HADDOCK 2.4 software, [https://wenmr.science.uu.nl/haddock2.4/](https://wenmr.science.uu.nl/haddock2.4/). The Mur ligase structures were inputted via their PDB codes or homology model files. Residues of central importance for the interaction, active residues, were selected based on residues identified to potentially be involved with complex formation via PRISM or comparison between *E. coli* residues and *S. agalactiae* residues. Buried residues were removed by the software. Residues that contribute to the interactions but may not be directly involved in the interaction, passive residues, were defined by the software within a 6.5 angstrom radius of active residues. All other parameters were set to standard default settings. The runs were optimized for bioinformatic prediction.

2.9.3 AlphaFold 2

Binary complex formation between the *S. agalactiae* Mur ligases was predicted using the AlphaFold2 software, available via Google Colab. The Mur ligase amino
acid sequences were taken from the KEGG database using the KEGG genome T00091 for *S. agalactiae* 2603 (serotype V) and inputted as the query sequence with a ‘.’ used to specify inter-protein chainbreaks to model complexes. No template information was used. The MSA mode was set to MMseqs2 (UniRef + Environmental) with a pairing mode of unpaired+paired.
3. Results

3.1 The genomic layout of the Mur ligases differs between bacteria

Many proteins that form complexes are encoded close together in the bacterial genome and expressed together under the control of a single promoter. Such groups of genes are termed operons\(^\text{130}\). Identifying genes that fall in the same operon can therefore be a useful predictor that the encoded proteins might form a complex. Analysis of the genomic layout of the Mur ligases in various bacteria were compared. Using the KEGG database, the positioning of the four Mur ligases throughout the genomes of *S. agalactiae*, *S. pneumoniae*, *T. maritima*, *C. crescentus*, and *B. pertussis* were compared, as seen in Figure 6.2.

![Diagram showing the genomic layout of the Mur ligases in various bacteria](image)

**Figure 6.2: Genomic layout of the Mur ligases differs across various bacteria**

Using the KEGG database, the location of the 4 Mur ligases within the genome of various bacteria was determined. The positioning of the Mur ligases within the genome was then visualised and compared across different bacteria that have previously been studied in relation the Mur ligase complex formation, and *S. agalactiae*. (A) Genomic layout of the 4 Mur ligases within *S. agalactiae*. (B) Genomic layout of the 4 Mur ligases within *S. pneumoniae*. (C) Genomic layout of the 4 Mur ligases within *T. maritima*. (D) Genomic layout of the 4 Mur ligases within *C. crescentus*. (E) Genomic layout of the 4 Mur ligases within *B. pertussis*.
Within *S. agalactiae* and *S. pneumoniae* the Mur ligases are spread throughout the genome, whilst in *T. martima* and *C. crescentus* the Mur ligases are within a small section of the genome. Within *B. pertussis*, the MurE and MurF appear as a fusion protein, with MurC and MurD in close proximity. The appearance of a fusion of two Mur ligases and the Mur ligases within a small region of the genome may suggest a level of gene regulation that would be beneficial to complex formation. However, the Mur ligases from *T. martima* were previously shown to be unable to interact with each other \(^{81}\), while the Mur ligases from *S. pneumoniae* were able to form binary complexes \(^{82}\) suggesting that close proximity of the Mur ligases within the genome is not an indicator of complex formation.

### 3.2 Experimental determination of a MurD-MurE binary complex

Previous studies have suggested that there may be the ability for the Mur ligases to form a complex. The presence of a fusion protein of two Mur ligases may suggest the ability for the Mur ligases to form complexes. The presence of a Mur ligase complex could explain some of the issues which have previously arisen when trying to observe antibacterial activity of Mur ligase inhibitors *in vivo*. Determining if the Mur ligases do form a complex could greatly affect future studies into Mur ligase inhibitors. The main focus of the *in-silico* screen and fragment studies presented within this thesis have been for MurD and MurE. Determining if a binary complex exists between these ligases could help focus future work on these projects.

### 3.3 Purification of MurE from *S. agalactiae*

In order to experimentally determine if a binary complex could exist between MurD and MurE from *S. agalactiae* an expression construct of MurE from *S. agalactiae* had to be produced. MurE from *S. agalactiae* serotype 5 was amplified by PCR and cloned into the *NheI* and *XhoI* sites of a pET-28a expression plasmid vector via restriction enzyme cloning. The sequence of the cloned *S. agalactiae* was confirmed, as seen in Supplementary 6. The vector was then transformed into *E. coli BL21 (DE3)* competent cells for protein expression. Protein purification was
carried out using IMAC purification via a nickel column and the purity of the purified protein was assessed via SDS-PAGE, as shown in Figure 6.3A.

![SDS-PAGE gel of Purified MurE from S. agalactiae](image)

**Figure 6.3: SDS-PAGE gel of Purified MurE from S. agalactiae**

Electrophoretically homogeneous protein was obtained via this method with a clear band being seen at around 70 kDa. After dialysis to remove the imidazole present in the buffer and concentration of the protein, a pure protein band at 55 kDa can be seen, as shown in Figure 6.3B. MurE has a molecular weight of ~54 kDa. (A) SDS-PAGE gel of protein in elution buffer. (B) SDS-PAGE gel of protein in elution buffer, and after dialysis into storage buffer.

Electrophoretically homogeneous protein was obtained via this method with a clear band being seen at around 70 kDa. After dialysis to remove the imidazole present in the buffer and concentration of the protein, a pure protein band at 55 kDa can be seen, as shown in Figure 6.3B. MurE has a molecular weight of 55.319 kDa and a theoretical PI of around 6.02. To confirm that the pure protein was MurE, mass spectrometry was carried out on the dialysed protein, along with activity assays to confirm the activity of the protein. As can be seen from Figure 6.4A, the activity of the protein was dependent on the presence of L-Lys, with the activity rate of the protein increasing in the presence of increasing concentrations of L-Lys. MurE from *E. coli* requires the amino acid DAP for activity, and so activity within the assay would be due to the presence of MurE from *S. agalactiae*. As can be seen from Figure 6.4B, mass spectrometry was able to confirm the presence of MurE from *S. agalactiae* within the protein sample with an 89% coverage and 60
exclusive unique peptides. These results confirm that MurE from *S. agalactiae* was purified, and suggest that MurE may have exhibited anomalous mobility within the gel prior to removal of the imidazole.

(A)

3.4 Size Exclusion Chromatography

In order to try and determine the ability of MurD and MurE to form a binary complex, size exclusion chromatography (SEC) was used. SEC works by separating molecules based on their size via filtration through a bead bed. Larger molecules are excluded from the beads and are able to pass through the column at a faster rate than smaller molecules which must pass through the beads themselves. When a complex occurs between proteins, the complex will travel through the column at a faster rate than that of the individual proteins due to its increased size.

(B) Purified protein was further examined to confirm the presence of MurE from *S. agalactiae*. (A) Purified protein was active in the presence of L-Lys, and activity increased in the presence of increasing concentrations of L-Lys, an indicator for the presence of MurE from *S. agalactiae*. (B) Mass spectrometry confirmed the presence of MurE from *S. agalactiae* within the purified protein.

Figure 6. 4: Confirmation of presence of MurE from *S. agalactiae* in protein sample

Purified protein was further examined to confirm the presence of MurE from *S. agalactiae*. (A) Purified protein was active in the presence of L-Lys, and activity increased in the presence of increasing concentrations of L-Lys, an indicator for the presence of MurE from *S. agalactiae*. (B) Mass spectrometry confirmed the presence of MurE from *S. agalactiae* within the purified protein.
3.4.1 Attempted demonstration of complex formation between MurD and MurE observed within a 1:1 mixture

In order to determine whether MurD and MurE from \textit{S. agalactiae} are able to form a complex, the individual proteins and the proteins in a 1:1 ratio were passed through a SEC column and absorbance at 280 nm and 254 nm were tracked.

![SEC analysis graphs](image)

**Figure 6.5:** 280 nm trace generated from SEC analysis of individual MurD, individual MurE and a 1:1 solution of MurD:MurE

MurD and MurE, at 2 mg/mL each, were chromatographed by SEC analysis as individual proteins and in a 1:1 molar ratio mixture. Traces were generated from the 280 nm absorbance change detected during the SEC run of MurD, MurE and 1:1 solution. MurD is shown in green, MurE in purple and 1:1 mixture in orange.
Absorbance changes at 280 nm were then plotted vs. elution volume and compared.

As can be seen from Figure 6.5, individual peaks for MurD and MurE were observed when the proteins were passed through the column as individual proteins. When the proteins were passed through the column in a 1:1 solution, a

(A) MurD

(B) MurE

(C) 1:1

Figure 6.6: SDS-PAGE shows the presence of MurD and MurE in eluted fractions

Fractions relating to increased absorbance at 280 nm from SEC analysis were run on SDS–PAGE gel before being visualised using Comassie blue staining. (A) Fractions relating to increased absorbance at 280 nm from SEC analysis of individual MurD. MurD is eluted between 17.25 mL and 17.75 mL. (B) Fractions relating to increased absorbance at 280 nm from SEC analysis of individual MurE. MurE is eluted between 15.25 mL and 16.75 mL. (C) Fractions relating to increased absorbance at 280 nm from SEC analysis of 1:1 solution of MurD and MurE. MurE is eluted between 15.25 mL and 17.5 mL. MurD is eluted between 16.25 mL and 17.5 mL.
large peak was seen with a secondary peak being observed on the falling edge of the first peak.

When overlayed with the individual traces of MurD and MurE, the 1:1 solution peaks corresponded to the protein peaks present for the individual proteins. To determine if any complex formation was occurring, the fractions from the SEC experiments that corresponded to increased absorbance at 280 nm were analysed electrophoretically by SDS gel to confirm the presence of proteins.

As can be seen from Figure 6.6, MurD was present in the fractions relating to the increased absorbance peak at 280 nm observed during its individual protein run in Figure 6.5, with the most protein being observed at an elution volume of 17.5 mL. MurE was also present in the fraction relating to the increased absorbance peak at 280 nm observed during its individual protein run, with the most protein being observed at an elution volume of 15.75 mL. As can be seen from Figure 6.6C, MurD and MurE were both present within certain fractions related to the increased absorbance peaks at 280 nm observed during the SEC fractionation of the 1:1 MurD/MurE mixture. MurE was mostly observed being eluted between 15.25 mL and 16.5 mL, but was still present at an elution volume of 17.5 mL. MurD was present in elution fractions from 16.5 mL to 17.5 mL.

The elution of MurD and MurE from the 1:1 mixture showed MurE eluting at a later elution stage than during its individual run, with MurD also being present at an earlier elution stage than during its individual run. This could suggest that some interaction between the proteins may have occurred, allowing them to be eluted at different elution volumes than during their individual protein runs. However, due to the very similar chromatographic profiles of MurD and MurE, it is also possible that the individual proteins are too close for complete resolution via a SEC column, and so the formation of a binary complex between MurD and MurE from S. agalactiae could not be confirmed via SEC analysis.

3.5 Microscale Thermophoresis (MST)

Due to the SEC experiments not being able to confirm complex formation between MurD and MurE, another technique had to be used in order to try and determine whether MurD and MurE are able to form a binary complex. There are
many techniques in which the interaction between two proteins can be investigated. MST is a fairly new technique for investigating protein-protein interaction. MST works via measuring the diffusion of molecules in a temperature gradient which has been induced by an infrared laser \(^{131}\). Before heating, an initial fluorescence of the sample is taken. The IR-laser is turned on which leads to a temperature jump within the sample, a T-jump, which leads to an abrupt change in fluorescence intensity, as seen in Figure 6.7.

![Figure 6.7: Schematic diagram of MST fluorescent change due to temperature gradient](image)

MST can be used to determine complex formation via tracking fluorescent changes of molecules within a temperature gradient. Initial fluorescent values are taken, before an IR-laser is switched on inducing a T-jump within the sample. A slow thermophoresis then occurs within the sample, before a plateau is reached.

Fluorescence around the T-jump focuses on the local surroundings of the fluorophore. A slow thermophoresis, which is a diffusion-limited process then occurs. This thermophoretic motion creates a fluorescent gradient which then reaches a plateau when thermodiffusion is counterbalanced by mass diffusion, as seen in Figure 6.7. The fluorescence after thermodiffusion is dependent on the properties of the entire molecule/complex in regards to changes in the size and charge. The movement of the molecules through these temperature gradients can
be detected and quantified by fluorescence, and allows for the determination of the $F_{\text{norm}}$, the normalized fluorescence. $F_{\text{norm}}$ is calculated by dividing the fluorescence after thermodiffusion, $F_1$, by the fluorescence after the temperature jump, $T$-jump, $F_0$. $F_{\text{norm}}$ can then be compared between samples to allow the determination of binding between proteins. When a complex forms, a change in the fluorescence after thermodiffusion and after the $T$-jump results in a change in the recordable $F_{\text{norm}}$.

The fluorescence detected can either be due to the inherent fluorescence of tryptophan residues present in the proteins, or via fluorescent labels that have been covalently linked to the protein via lysine, cysteine or polyhistidine residues. MST offers advantages over other protein-protein interaction analysis methods as it does not require large volumes of protein, with only a 10 µl final volume per capillary. MST does not require one of the proteins to be immobilised to a surface, allowing the whole protein to be accessible for binding, which is beneficial when the binding site is unknown.

### 3.5.1 MurD and MurE from *S. agalactiae* are able to form a binary complex

As the MurD and MurE proteins from *S. agalactiae* already had 6x polyhistidine tags, fluorescent labelling targeting the His tag was used to fluorescently label one of the proteins. The 6x polyhistidine tag had to be cleaved from the other protein to prevent cross-labelling when the two proteins were introduced. The 6x polyhistidine tag was cleaved from MurD via 3C and the cleaved MurD was purified via reverse IMAC, as shown in Supplementary 7. MurE was incubated with a fluorescent label that binds via a His tag prior to incubation with a secondary protein. Homogeneity checks between different capillaries of the labelled proteins was carried out by the Monolith system before initial fluorescent readings were taken. Once homogeneity was confirmed, the ability of MurE to bind to MurD could be established. A control protein was used to confirm that a difference in fluorescence between the single protein and the dual proteins would only be seen when binding between the proteins was occurring. As can be seen from Figure 6.8A, there was no difference in the recordable $F_{\text{norm}}$ between MurE
and MurE in the presence of a control protein. However, there was an increase in the recordable $F_{\text{norm}}$ between MurE and MurE in the presence of MurD. A change in the recordable $F_{\text{norm}}$ suggests that MurD and MurE were able to interact.

The binding affinity of MurD to MurE was then established using MST. A serial dilution of MurD was used to estimate the $K_D$ of MurD against MurE. The binding curve can be seen in Figure 6.8B. A $K_D$ of 49 µM was estimated based on this curve, suggesting that although the proteins can interact, it is not a favourable interaction.

### 3.5.2 The presence of substrates alters the binding and $K_D$ of MurD to MurE

To further investigate the MurD:MurE interaction, various substrates for the two proteins were incubated with the proteins and the ability of the proteins to form a complex with each other was established via MST. As can be seen from Figure 6.9, MurD and MurE were able to still form a complex in the presence of all or only some of their substrates.
The $K_D$ of these interactions were then investigated to determine the effect substrates have on the binding of MurD to MurE. As can be seen from Figure 6.10, the binding of substrates increased the estimated $K_D$ of MurD binding to MurE. The presence of ADPCP, and ADPCP and the UDP intermediates increased the $K_D$ to an extent that a true estimated $K_D$ could not be calculated as the curve was unable to plateau. The curve was able to plateau in the presence of all 3 substrates allowing an estimated $K_D$ to be calculated that is close to the estimated apo $K_D$.
Figure 6. 10: The binding of substrates increases the Kd of MurD to MurE

Fluorescently labelled MurE and MurD were incubated with various substrates for 1 hour before MST to determine the effect substrates have on the complex Kd. The fluorescently labelled MurE in the presence or absence of substrates was then incubated with a serial dilution of MurD in the presence or absence of substrates. The fluorescence of MurE bound to various MurD concentrations was recorded, and the plotted as a binding curve. (A) No substrates present. Estimated Kd of 49 µM. (B) MurE was incubated with 1 mM ADPCP, MurD was incubated with 1 mM ADPCP. Estimated Kd of 79 µM. (C) MurE was incubated with 1 mM ADPCP and 100µM UDP-MurNAc-L-Ala-D-Glu, MurD was incubated with 1 mM ADPCP and 100µM UDP-MurNAc-L-Ala. Estimated Kd of 173 µM. (D) MurE was incubated with 1 mM ADPCP,100µM UDP-MurNAc-L-Ala-D-Glu, and 1 mM L-Lys. MurD was incubated with 1 mM ADPCP, 100µM UDP-MurNAc-L-Ala, and 1 mM D-Glu. Estimated Kd of 61 µM.
The change in $K_D$ in the presence of substrates suggests that the binding of the substrates is weakening but not breaking the complex between MurD and MurE. A hypothesis as to why this may be occurring relates to the domain movement that occurs within the C-terminal domain of the Mur ligases upon binding of the substrates. As can be seen from the known structures of MurC shown in Figure 6.11, an average distance of 28 Å within the C-terminal domain of MurC can be seen when a molecule binds to the ATP-binding site. An average distance of 4 Å can be seen in the same region of MurC when a molecule binds to the UDP intermediate binding site. This flexibility and movement of the C-terminal region can be seen across all four Mur ligases. If the C-terminal of MurD or MurE are involved in the formation of the complex then movement within this region, upon the binding of first ADPCP and then the UDP intermediate could result in the complex weakening, but not fully breaking, resulting in the increased $K_D$ data seen within the MST experiments. This movement and changing of the complex may allow the proteins to remain active while within a complex.

![Figure 6.11: C-terminal domain movement upon binding of substrates within MurC](image)

Upon binding of substrates, the C-terminal domain of MurC from *Haemophilus influenzae* undergoes domain movement. Apo MurC structure (1GQQ – red), MurC with ACP bound (1GQY – brown), and MurC with UMA and ANP bound (1P3D - pink) were all taken from PDB and compared within Pymol. The structures were aligned and any movement in the domain was measured using the measurement tool within Pymol. The C-terminal domain undergoes domain movement with the binding of ACP, and further domain movement occurs with the binding of UMA.
3.6 pET DUET Expression System

MurD and MurE were shown to be able to form a binary complex within MST. MST determines interaction between proteins \textit{in vitro}, which may allow complex formations that do not occur \textit{in vivo} to be seen. To investigate whether MurD and MurE can form a complex within a bacterial cell, a pET DUET expression system was produced. A pET DUET expression system allows two proteins to be co-expressed from one vector, with only one protein containing a polyhistidine tag. After expression, purification of the proteins can be carried out using a standard IMAC purification via a nickel column. The polyhistidine tagged protein will bind to the nickel on the column and be present in the eluted fractions. If the secondary protein can form a complex with the polyhistidine tagged protein, both proteins will be present in the same eluted fractions. If no complex occurs, the untagged protein will be present in the flowthrough or washes of the column, but not within the elution stages.

3.6.1 MurD and MurE can be purified within a complex

To determine if MurD and MurE can form a complex within a bacterial cell, MurD and MurE from \textit{S. agalactiae} serotype 5 were cloned into the pET DUET expression plasmid vector via restriction enzyme cloning. MurE was cloned into cloning site 1 which contains a 6x polyhistidine tag, while MurD was cloned into cloning site 2 which contains an S-tag. The vector was then transformed into \textit{E. coli BL21 (DE3)} competent cells for protein expression following sequence conformation. Protein purification was carried out using IMAC purification via a nickel column and the presence of MurD and MurE was established using SDS-PAGE, as shown in Figure 6.12. As can be seen from Figure 6.12, both MurE and MurD were seen in the same eluted fractions. MurD was seen to not bind to the nickel column independently of MurE as shown in Supplementary 8. This suggests that MurE and MurD from \textit{S. agalactiae} were able to form a complex within a bacterial cell.
3.6.2 Presence of MurD and MurE confirmed via Mass spectrometry

Using a pET DUET expression system, MurE and MurD from *S. agalactiae* were co-purified together. A pET DUET vector, with a polyhistidine tagged MurE and an S-tagged MurD was expressed in *E. coli* BL21 (DE3) competent cells. Purification was carried out using IMAC purification via a nickel column. The presence of MurE and MurD was confirmed in the same elution fractions. MurE and MurD are highlighted on the gel. MurD is highlighted with blue, MurE is highlighted in purple.

*Figure 6.12: MurD and MurE can be co-purified in a complex formation via a pET-DUET system*

Using a pET DUET expression system, MurE and MurD from *S. agalactiae* were co-purified together within a complex. However, as seen in *Figure 6.12*, there were other bands present within the elution fractions containing MurD and MurE. These bands could correspond to other proteins that are also involved within the complex or could correspond to breakdown products of the two proteins of interest, or could be due to contamination with native *E. coli* proteins. To confirm that the proteins identified via the SDS-PAGE were *S. agalactiae* MurE and MurD, and to try and identify any other proteins that were present within the samples, the elution fractions were subjected to mass spectrometry analysis via the WPH Proteomics RTP department at the University of Warwick. The fractions that may have contained *S. agalactiae* MurD and MurE were pooled before the proteins were digested overnight with trypsin. The resulting peptides were then de-salted before being subjected to mass spectrometry analysis. Results were analysed using
Scaffold software with a set 95% protein threshold and a 95% peptide threshold.

The presence of *S. agalactiae* MurE and MurD were confirmed via mass spectrometry, as seen in Figure 6.13.

![Image](image1.png)

**Figure 6.13: The presence of MurD and MurE was confirmed via Mass spectrometry**

Using mass spectrometry, the presence of MurD and MurE from *S. agalactiae* within the pET DUET fractions was confirmed. A sample of the fractions previously shown to contain MurD and MurE from a pET DUET expression were analysed via mass spectrometry to confirm the protein identification and identify any contaminating proteins. One contaminating protein, 50s ribosomal subunit L17 was identified.

The presence of *S. agalactiae* MurE was confirmed via the presence of 21 exclusive unique peptides with a 28% coverage. The presence of *S. agalactiae* MurD was confirmed via the presence of 17 exclusive unique peptides with a 26% coverage. A 50s ribosomal protein L17 was also seen to be present within the sample. The 50s ribosomal protein L17 forms part of the 50s ribosomal subunit [133].
It is unlikely that this the protein is involved within the formation of the complex between \textit{S. agalactiae} MurD and MurE, and so was treated as a contaminant within the sample. Two other contaminants were also present within the sample; trypsin which was present from the digestion step required for mass spectrometry analysis, and human keratin. These results suggest that \textit{S. agalactiae} MurE and MurD were able to form a binary complex.

3.7 Dual expression of MurD and MurE

MurD and MurE from \textit{S. agalactiae} were shown to be able to be purifiable as a complex with each other when co-expressed within a bacterial cell. However, the yield from this method was low. To try and improve the yield of the protein complex, a His tagged \textit{S. agalactiae} MurE and an untagged \textit{S. agalactiae} MurD were expressed separately before the lysates were combined and purified. Protein purification was carried out using IMAC purification via a nickel column and fractions were dialysed into Buffer GF before the presence of \textit{S. agalactiae} MurD and MurE was established using SDS-PAGE, as shown in Figure 6.14.

![Figure 6.14: MurD and MurE can be co-purified in a complex formation via dual protein expression](image)

Using two protein expression systems, MurE and MurD from \textit{S. agalactiae} were co-purified together. A polyhistidine tagged MurE and an un-tagged MurD were separately expressed in \textit{E. coli} BL21 (DE3) competent cells before the cell lysates were combined. Purification was carried out using IMAC purification via a nickel column. The presence of MurE and MurD was confirmed in the same elution fractions. MurE and MurD are highlighted on the gel.
As can be seen from Figure 6.14, MurD was present within the wash and flowthrough of the column. However, MurD was also present within one elution stage where MurE was also present. As was established in Supplementary 8, untagged *S. agalactiae* MurD did not bind to a nickel column independently and so the presence of MurD in an elution stage suggests that MurE and MurD from *S. agalactiae* were able to form a complex.

As can be seen in Figure 6.14, the elution fraction contained a higher proportion of *S. agalactiae* MurE compared to *S. agalactiae* MurD. The appearance of a higher proportion of MurE within the elution fraction could suggest that some MurE present within the elution fraction was not complexed to MurD. To try and purify the protein complex, the elution fractions containing both MurD and MurE were passed through a SEC column and absorbance at 280 nm and 254 nm were tracked. The fractions from the SEC experiment that corresponded to increased absorbance at 280 nm were analysed electrophoretically by SDS gel to confirm the presence of proteins. As can be seen from Figure 6.15, *S. agalactiae* MurE was seen in various fractions across the SEC experiment, but *S. agalactiae* MurD was only seen in the final fraction. MurD and MurE were not present within any of the same fractions from the SEC experiment, as seen in Figure 6.15. This suggests that the protein complex between MurD and MurE was broken during the SEC column, which prevented the purification of the protein complex.

![Figure 6.15: SEC results in breakage of protein complex between *S. agalactiae* MurD and *S. agalactiae* MurD](image)

Fractions relating to increased absorbance at 280 nm from SEC analysis were run on SDS–PAGE gel before being visualised using Coomassie blue staining. *S. agalactiae* MurE was present across multiple fractions. *S. agalactiae* MurD was present at an elution volume of 200 mL. Complex formation between MurD and MurE was not seen after the SEC experiment.
3.7.1 MurD is active within a complex

MurD and MurE from *S. agalactiae* were shown to be able to be purifiable as a complex with each other when co-expressed within a bacterial cell, or when purified together from cell lysates. The Mur ligases are responsible for the addition of amino acids onto the UDP-MurNAc intermediate within the cytoplasm. Whether these proteins still retained the ability to carry out this function while within a complex would provide further information on the biological relevance of a Mur ligase complex.

(A) MurD was active while in complex formation and required the presence of all substrates. (B) MurE was active within the protein sample and required the presence of all substrates. (C) MurE was able to use the UDP-MurNac-L-Ala-D-Glu produced by MurD while in complex.

*Figure 6. 16: Activity of proteins within a complex was identified via an amplex red assay*

Using an amplex red assay the activity of MurD and MurE in complex was investigated. (A) MurD was active while in complex formation and required the presence of all substrates. (B) MurE was active within the protein sample and required the presence of all substrates. (C) MurE was able to use the UDP-MurNac-L-Ala-D-Glu produced by MurD while in complex.
The activity of \textit{S. agalactiae} MurD while within a complex was investigated using an amplex red assay. Initial experiments were carried out into the dependence of activity of MurD upon the addition of all three substrates. To determine whether the presence of all substrates was required for the activity of \textit{S. agalactiae} MurD, an amplex red assay was run via a spectrophotometer, in the absence of a substrate or the ligase. The absorbance change was followed and the initial rate determined. No initial rate was seen upon the addition of only one substrate or in the absence of the protein sample. As can be seen from Figure 6.16A, only after the addition of all three substrates was an initial rate for \textit{S. agalactiae} MurD seen.

The true activity of \textit{S. agalactiae} MurE while within a complex could not be established as the protein complex could not be purified, potentially resulting in MurE being present within the sample that was not in complex with MurD. As can be seen from Figure 6.16B, the \textit{S. agalactiae} MurE present within the sample was active. However, this activity could relate to free MurE or MurE in complex with MurD.

Within complex formation, channelling of substrates may occur between the proteins present. To determine whether the \textit{S. agalactiae} MurE present within the sample could accept the UDP-MurNAc-L-Ala-D-Glu produced by the \textit{S. agalactiae} MurD while within a complex, an activity assay of MurD while within a complex was allowed to run to completion with UDP-MurNAc-L-Ala acting as the limiting factor. L-Lys was then added to the assay and the activity of the sample tracked via a spectrophotometer. As can be seen from Figure 6.16C, after the addition of the L-Lys, activity was seen as the \textit{S. agalactiae} MurE converted the UDP-MurNAc-L-Ala-D-Glu to UDP-MurNAc-L-Ala-D-Glu-L-Lys. This suggested that the MurE was able to use the product of MurD while within a complex, suggesting that channelling of substrates within a Mur ligase complex may be possible.

\textbf{3.8 Computational modelling of predicted Mur ligase complex}

Experimental work carried out into the formation of a binary complex between MurD and MurE from \textit{S. agalactiae} suggested that there may be the ability for
these two proteins to exist in a binary complex. To better understand how this complex may exist, and if other Mur ligases may be able to exist in binary complexes, computational modelling of the binary complexes of the Mur ligases of *E. coli* and *S. agalactiae* were undertaken.

### 3.9 Binary complex prediction of the *E. coli* Mur ligases via PRISM

To investigate the ability of MurC, MurD, MurE and MurF to form binary complexes, the PRISM software was used. PRISM is a prediction algorithm that uses structural similarity and evolutionary conservation in template interfaces to predict protein-protein interactions \(^{134}\).

Experimental work into binary complex formation between MurD and MurE determined that the presence of substrates may alter the ability of the Mur ligases to form binary complexes. The Mur ligases also undergo a conformational change in the presence of substrates. To make sure all proteins were in the same conformation and remove the potential effects of different substrates on the formation of binary complexes, PDB files of the Mur ligases in their apo form were used for binary complex predictions.

Using the known structures of the four apo *E. coli* Mur ligases, PRISM was able to predict whether binary complexes could form between all pairings of the four Mur ligases based on template interfaces. All four Mur ligases were predicted to be able to form a binary complex with all other Mur ligases. For each binary complex, the top hit predicted by PRISM is listed in **Table 6.1**, with the global energy binding score (GEBS), and the template interface used to predict the binding shown.

<table>
<thead>
<tr>
<th>Target 1</th>
<th>Target 2</th>
<th>GEBS (kcal/mol)</th>
<th>Template</th>
</tr>
</thead>
<tbody>
<tr>
<td>MurC</td>
<td>MurD</td>
<td>-35.98</td>
<td>3synAD</td>
</tr>
<tr>
<td>MurD</td>
<td>MurE</td>
<td>-4.32</td>
<td>1t8qBC</td>
</tr>
<tr>
<td>MurF</td>
<td>MurE</td>
<td>-9.75</td>
<td>3aq0EH</td>
</tr>
<tr>
<td>MurC</td>
<td>MurE</td>
<td>-4.63</td>
<td>3qu2AD</td>
</tr>
<tr>
<td>MurC</td>
<td>MurF</td>
<td>-19.97</td>
<td>2fw7AB</td>
</tr>
</tbody>
</table>

**Table 6.1:** PRISM top hit score for binary complex formation amongst the *E. coli* Mur ligases

Using PRISM, binary complex formation amongst the Mur ligases from *E. coli* was predicted. The GEBS and template identification for each hit is listed.
MurC-MurD was predicted to form the strongest binary complex, while MurD-MurE was predicted to form the weakest binary complex.

3.9.1 Binary complex prediction of the *E. coli* Mur ligases via HADDOCK

PRISM was able to predict that the Mur ligases of *E. coli* would be able to form binary complexes based on existing templates of interactions from PDB files. To further investigate the ability of the Mur ligases to form binary complexes, another computational program was used to predict the interactions between the Mur ligases in complex formation. Complex formation between pairs of Mur ligases that fall before and after each other within the pathway of peptidoglycan precursor synthesis were investigated. Using the interfaces determined by PRISM, the residues that may potentially be involved in complex formation were inputted into HADDOCK 2.4 as active residues. Passive residues were determined by the software, and the run was optimised for bioinformatic predictions, which automatically sets the distance restraints and sampling parameters to settings that favour bioinformatic predictions. The final models produced by HADDOCK were then clustered based on similarity before the top hit model from each cluster was provided as a Pymol file by the software. HADDOCK 2.4 was able to predict interactions between all the pairs of Mur ligases using the residues provided. The top hit from the top cluster, as determined by HADDOCK 2.4., for each pair is shown in Figure 6.17.
Using HADDOCK 2.4, and the residues identified by PRISM, pairs of Mur ligases were analysed for their ability to form binary complexes. The top hit for each of these pairings is shown. The residues previously identified by PRISM, and used as active residues by HADDOCK are highlighted in the structures. MurC residues are shown in red, MurD residues are shown blue, MurE residues are shown in purple and MurF residues are shown in green. (A) Predicted binary complex between MurC and MurD. (B) Predicted binary complex between MurD and MurE. (C) Predicted binary complex between MurE and MurF.

Figure 6.17: Structural diagrams to show the interaction areas between pairs of Mur ligases
HADDOCK provides a score for the interactions predicted based on the equation:

\[
\text{HADDOCK score} = 1 \times \text{Van der Waals energy} + 0.2 \times \text{Intermolecular electrostatic energy} + 1 \times \text{Desolvation energy} + 0.1 \times \text{Ambiguous Interaction Restraint energy}
\]

These scores, along with the Z score provided by HADDOCK are shown in Table 6.2. The Z score indicates how many standard deviations from the average cluster this cluster is in terms of Z score.

<table>
<thead>
<tr>
<th></th>
<th>MurC-MurD</th>
<th>MurD-MurE</th>
<th>MurE-MurF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HADDOCK score</strong></td>
<td>-74.3 +/- 1.1</td>
<td>-86.4 +/- 1.0</td>
<td>-64.6 +/- 5.4</td>
</tr>
<tr>
<td><strong>Van der Waals</strong></td>
<td>-50.6 +/- 3.1</td>
<td>-52.9 +/- 4.6</td>
<td>-23.2 +/- 2.6</td>
</tr>
<tr>
<td><strong>Electrostatic</strong></td>
<td>-130.7 +/- 32.8</td>
<td>-195.8 +/- 40</td>
<td>-183.9 +/- 30.8</td>
</tr>
<tr>
<td><strong>Z score</strong></td>
<td>-1.9</td>
<td>-2.1</td>
<td>-1.8</td>
</tr>
</tbody>
</table>

*Table 6.2: HADDOCK top hits for binary complex formation between the Mur ligases from *E. coli*.*

Using HADDOCK 2.4, binary complex formation between the Mur ligases from *E. coli* was predicted. The HADDOCK score, Van der Waals energy score, electrostatic energy score and Z score are listed.

The energy values provided by HADDOCK suggest that the interactions predicted were feasible. Visual inspection of the predicted interactions also suggested that the predicted binary complex formations were feasible as no predicted complex formation blocked the active site of the proteins involved, forced the proximity of repulsive charge:charge interactions or twisted the protein into an unnatural state. These results, along with the PRISM results suggest that the *E. coli* Mur ligases may be able to form binary complexes in which they are active.

### 3.10 Production of homology models of the *S. agalactiae* Mur ligases

The ability of the *E. coli* Mur ligases to form binary complexes was predicted via PRISM and HADDOCK. Currently, *E. coli* is the only bacterium for which all the Mur
ligase structures are known. To predict the ability of the *S. agalactiae* Mur ligases to form binary complexes, homology models of the ligases would need to be produced. One way to produce homology models is via the software SWISS-MODEL. SWISS-MODEL generated homology models by generating a pair-wise alignment to the template sequence provided. Backbone only models were then formed using an average of the atom positions of the template structure, with constraint space programming providing coordinates for regions of insertions or deletions that could not be determined from the template. Side chain modelling was the final stage carried out using weighted positions of corresponding residues within the template structure. To generate the homology models, the amino acid sequence of the

![Homology models of the Mur ligase from *S. agalactiae*](image)

*Figure 6.18: Homology models of the Mur ligase from *S. agalactiae***

Using SWISS-MODEL, homology models of the four Mur ligases from *S. agalactiae* were generated using ‘open’ *E. coli* structures as templates. The homology models were then visualised via Pymol.
four Mur ligases were taken from the KEGG database using the KEGG genome T00091 for *S. agalactiae* 2603 (serotype V).

A user template modelling mode on SWISS-MODEL was then used to model the sequences, with the previously used *E. coli* structures acting as templates. The homology models for the four Mur ligases from *S. agalactiae* generated via SWISS-MODEL are shown in Figure 6.18. 98% of the *S. agalactiae* MurC sequence was modelled against *E. coli* MurC (2F00). 94% of the *S. agalactiae* MurD sequence was modelled against *E. coli* MurD (1E0D). 91% of the *S. agalactiae* MurE sequence was modelled against *E. coli* MurE (7B53). 89% of the *S. agalactiae* MurF sequence was modelled against *E. coli* MurF (1GG4). The homology models produced had high levels of sequence modelling, suggesting that the predicted structures would be very similar to the actual ‘open’ structure of these proteins. This means the homology models could be used to help predict the interaction areas for binary complex formation amongst the Mur ligases from *S. agalactiae*.

3.11 Binary complex prediction of the *S. agalactiae* Mur ligases via HADDOCK

Using the homology models of the *S. agalactiae* Mur ligases, and the previously generated binary complex formation models from PRISM and HADDOCK, the residues potentially involved in complex formation within the *S. agalactiae* Mur ligases were identified. By aligning the homology models of the *S. agalactiae* Mur ligases to the binary complex formation models, residues within the *S. agalactiae* Mur ligases that corresponded to interacting residues within the *E. coli* Mur ligases were identified. If the residues were comparable, or still could form an interaction with its partnering amino acid, residues were considered to be potential interacting residues. HADDOCK was then used to identify if binary complex formation could exist between the *S. agalactiae* proteins using the homology models generated via SWISS-MODEL. Active residues were listed as the residues identified via alignment with the *E. coli* ligases, and passive residues were identified by the software. The software was optimized for bioinformatic predictions. HADDOCK was able to predict the interaction between all the pairs of *S. agalactiae* Mur ligases using the
residues provided. The top hit for each pair is shown in Figure 6.19, and the scores for each hit provided in Table 6.3.

(A) Predicted binary complex between MurC and MurD. (B) Predicted binary complex between MurD and MurE. (C) Predicted binary complex between MurE and MurF.

Figure 6.19: Structural diagrams to show the interaction areas between pairs of Mur ligases from S. agalactiae using HADDOCK

Using HADDOCK 2.4, and the residues identified as corresponding to E. coli interacting residues, pairs of S. agalactiae Mur ligases were analysed for their ability to form binary complexes. The top hit for each of these pairings is shown. The residues previously identified by PRISM, and used as active residues by HADDOCK are highlighted in the structures. MurC residues are shown in red, MurD residues are shown blue, MurE residues are shown in purple and MurF residues are shown in green. (A) Predicted binary complex between MurC and MurD. (B) Predicted binary complex between MurD and MurE. (C) Predicted binary complex between MurE and MurF.
Using HADDOCK 2.4, binary complex formation between the Mur ligases from *S. agalactiae* was predicted. The HADDOCK score, Van der Waals energy score, electrostatic energy score and Z score are listed.

<table>
<thead>
<tr>
<th></th>
<th>MurC-MurD</th>
<th>MurD-MurE</th>
<th>MurE-MurF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HADDOCK score</strong></td>
<td>-75.9 +/-3.4</td>
<td>-96.4 +/-1.8</td>
<td>-85.4 +/-4.1</td>
</tr>
<tr>
<td><strong>Van der Waals</strong></td>
<td>-19.1 +/-5.9</td>
<td>-38.5 +/-7.2</td>
<td>-33.6 +/-4.9</td>
</tr>
<tr>
<td><strong>Electrostatic</strong></td>
<td>-321.9 +/-19.7</td>
<td>-213.1 +/-20.1</td>
<td>-336.1 +/-20.2</td>
</tr>
<tr>
<td><strong>Z score</strong></td>
<td>-2.1</td>
<td>-1.7</td>
<td>-2.1</td>
</tr>
</tbody>
</table>

*Table 6.3: HADDOCK top hits for binary complex formation between the Mur ligases from S. agalactiae*

The energy values provided by HADDOCK suggest that the interactions predicted were feasible. Visual inspection of the predicted interactions was also able to determine that the predicted binary complex formations were feasible as no complex formation blocked the active site of the proteins involved or twisted the protein into an unnatural state which forced the proximity of repulsive charge: charge interactions. These results suggested that the *S. agalactiae* Mur ligases may be able to form binary complexes in which they are active.

### 3.12 Alphafold for binary complex prediction

Alphafold is an AI system that was recently developed by DeepMind to help predict a protein’s 3D structure from its amino acid sequence. Alphafold works by generating multiple sequence alignments (MSA) from a query amino acid sequence via several databases of protein sequences. Alongside this, Alphafold also identifies proteins that have similar structures to the inputted sequence and uses these as templates to generate an initial structure. A final structure is generated via the creation of a 3D backbone structure, before the prediction of side chain placements occurs. Throughout the stages of structure prediction, Alphafold is continuously applying outputs from its own modules back into the structure prediction, allowing refinement of the structure. Due to its ability to assess its own predicted structures, Alphafold has been shown to be able to predict protein
structures with a high level of accuracy, even when no similar structure is known.

As well as being able to predict protein structures, Alphafold has been developed to allow for the prediction of protein complexes. This uses the same learning system based on MSAs and pair representation as standard Alphafold with minor changes to allow for cross-chain genetic information to be incorporated into the system. Alphafold does not require previous experimental data to identify the region of the protein or specific residues that may be involved in complex formation, allowing Alphafold to predict complex structures for previously unidentified complexes.

Alphafold predictions can be evaluated by a variety of means. Firstly, the sequence coverage of the predicted Alphafold models can provide information on how accurate the folding of the individual proteins are. Secondly, comparison of the models produced by Alphafold for their similarity and the variations between models can provide information on how confident Alphafold is within the modelling. Thirdly, Alphafold generates PAE scores that can provide information on how likely the residues are to be in to within the region of the structure that Alphafold has predicted.

A control Alphafold run was carried out with a known binary complex structure of HisF-HisH to determine how accurately Alphafold can predict binary complex formation. As can be seen from Figure 6.20A, Alphafold predicted a structure within 5 angstroms of the known structure of the complex. Sequence coverage was high over the two proteins and comparison of the five models showed highly similar predictions, as seen in Figure 6.20B and C. Co-evolution data for the top model showed low PAE scores for residues within each protein along with residues across the two proteins, as seen in Figure 6.20D.
3.12.1 Binary complex prediction of the *S. agalactiae* Mur ligases via Alphafold

Using Alphafold2, binary complex formation between the *S. agalactiae* Mur ligases was predicted. The protein sequences previously used to generate the homology models of the *S. agalactiae* Mur ligases were inputted into the Alphafold2 Google Colab in their respective pairs. The five models produced were then viewed in Pymol and compared to determine similarity. Along with comparison of the five models produced, the sequence coverage and PAE score of the models were considered when determining the accuracy of the predicted binary complex.
Alphafold was able to produce five models of the binary complex formation of MurC-MurD from *S. agalactiae*. The sequence coverage of the two proteins was high, with around 2000 sequences used to predict the structure of the two proteins as seen in Figure 6.21A. As can be seen in Figure 6.21C, comparison of the five predicted models from Alphafold showed that there were was a high level of consensus in the predicted structure of the top three ranked structures, while rank 4 and 5 models were in a different arrangement.

Figure 6.21: Alphafold predicted binary complex between MurC and MurD from *S. agalactiae*

Using Alphafold2, MurC and MurD from *S. agalactiae* were analysed for their ability to form a binary complex. (A) Sequence coverage of predicted structures of MurC and MurD. (B) PAE scores of rank 1 model of binary complex formation between MurC and MurD. (C) Comparison of predicted structures of binary complex formation of MurC-MurD. Two complex formations were predicted via Alphafold for the binary complex formation between MurC and MurD. Rank 1, 2 and 3 predicted structure is shown on the left, rank 4 and 5 predicted structure is shown on the right. MurC is shown in red and MurD is shown in blue.

The PAE data for the top ranked model is shown in Figure 6.21B. The PAE scores for the individual proteins was low, suggesting a confidence in the prediction.
of the structures of the individual proteins. However, there were very high PAE scores for the location of residues while in binary complex formation, showing poor confidence in the way in which the proteins relate to each other within the model, suggesting a high level of confidence in the intramolecular predictions but low intermolecular predictions.

The presence of multiple complex predictions combined with high PAE scores for intermolecular predictions suggested that the predicted binary complex between MurC and MurD from *S. agalactiae* may not be an accurate representation of binary complex formation.

Alphafold was able to produce five models of the binary complex formation of MurD-MurE from *S. agalactiae*. The sequence coverage of the two proteins was high, with around 2000 sequences used to predict the structure of the two proteins as seen in **Figure 6.22A**. The PAE data for the top ranked model is shown in **Figure 6.22B**. The PAE scores for the individual proteins was low, suggesting a confidence in the prediction of the structures of the individual proteins, although the PAE data for the top ranked model showed regions of higher PAE scores for the location of residues within MurD, suggesting a less accurate prediction of the structure of MurD. There were very high PAE scores for the location of residues while in binary complex formation, showing poor confidence in the way in which the proteins relate to each other within the model, suggesting a low level of confidence in the intermolecular predictions.

Comparison of the five predicted models from Alphafold showed that there was no interaction in models ranked 4 and 5 by Alphafold as seen in **Figure 6.22C**. Models ranked 1, 2 and 3 showed interaction between MurD and MurE, but interaction zones differed between the three models. A lack of consistency between the models showed a lack of accuracy in the model predictions, which when combined with the high PAE scores for intermolecular interactions suggested that the predicted binary complex between MurD and MurE from *S. agalactiae* may not be an accurate representation of binary complex formation.
Alphafold was able to produce five models of the binary complex formation of MurE-MurF from *S. agalactiae*. The sequence coverage of the two proteins was high, with around 2000 sequences used to predict the structure of the two proteins as seen in Figure 6.23A. The PAE data for the top ranked model showed regions of high PAE scores for the location of residues within both MurE and MurF, suggesting a less accurate prediction of the intramolecular predictions within these Mur ligases as seen in Figure 6.23B. There was also high PAE scores for the location of residues while in binary complex formation, as seen in Figure 6.23B, showing poor confidence in the way in which the proteins relate to each other within the model, suggesting a low level of confidence in the intermolecular predictions. As can be
seen in Figure 6.23C, comparison of the five predicted models from Alphafold showed that there was a high level of consensus in the predicted structure of the top two ranked structures, while rank 3, 4 and 5 models were in different arrangements. However, visual inspection of the predicted models showed a lack of interaction between MurE and MurF in these arrangements, with no interaction in models 3, 4 and 5.

A lack of interaction between MurE and MurF within the predicted models, combined with the appearance of multiple complex predictions and high PAE scores for intermolecular interactions suggested that the predicted binary complex between MurE and MurF from *S. agalactiae* may not be an accurate representation of binary complex formation.

Using Alphafold2, MurE and MurF from *S. agalactiae* were analysed for their ability to form a binary complex. (A) Sequence coverage of predicted structures of MurE and MurF. (B) PAE scores of rank 1 model of binary complex formation between MurE and MurF. (C) Comparison of predicted structures of binary complex formation of MurE-MurF. A complex formations were predicted via Alphafold for the binary complex formation between MurE and MurF, while three models showed no interaction. Rank 1 and 2 predicted structure is shown on the left, rank 3 predicted structure is shown on the right. MurE is shown in purple and MurF is shown in green.
3.13 Alphafold predictions present in only one state

Complex predictions of binary complex formation between the *S. agalactiae* Mur ligases generated via Alphafold lack similarity amongst models, along with high PAE scores for the models. The lack of interaction between the Mur ligases within certain models also suggests that these binary complex formation predictions may not be biologically present. Alphafold predictions are produced in only one state, which may affect its ability to accurately predict the binary complex formation of the Mur ligases due to the conformational changes that occur upon binding of substrates. To better understand how conformational change may affect Alphafold’s ability to predict binary complex formation, the binary complex of MurT/GatD was predicted via Alphafold and compared to the known complex formation (PDB: 6GS2).

![Figure 6.24](image)

*Figure 6.24: Alphafold predicts the MurT/GatD complex in a different conformational state to known complex*

Using Alphafold2, the MurT/GatD binary complex was predicted and compared to the known complex formation. MurT C-terminal is shown in yellow, MurT middle domain is shown in orange, GatD is shown in green. (A) Known complex formation of MurT/GatD. PDB: 6GS2 (B) Alphafold predicted complex formation of MurT/GatD.

As can be seen from *Figure 6.24*, the Alphafold prediction of the binary complex of MurT/GatD differs from the known complex formation. Alphafold was able to predict the same interaction of GatD to the C-terminal domain of MurT. However, the N-terminal domain and middle domain of MurT were in a different position within the Alphafold prediction compared to the known complex structure, resulting in a new interaction area of MurT to GatD. The middle domain of MurT
moved a distance of around 20 Å between the known complex structure and the Alphafold prediction, resulting in a ‘closed’ MurT conformation within the Alphafold prediction. MurT binds to Lipid II to allow for amidation \(^{26}\). The binding of Lipid II has been predicted to induce a conformational change within MurT similar to that seen within the Mur ligases upon binding of ATP \(^{79}\), resulting in a ‘closed’ conformation of MurT. The difference of the layout of the middle domain and N-terminal domain of MurT between the known complex structure and predicted Alphafold structure could be due to this conformational change. A conformational change within MurT may have led to a different Alphafold prediction of complex formation between MurT to GatD to that previously identified, suggesting that conformational changes within proteins may have a large effect on the binary complex formation that Alphafold is able to predict.
4. Conclusions and Future Direction

4.1 Formation of a binary complex between the Mur ligases

The ability of the Mur ligases to form a complex, either independently or in the presence of additional structural proteins is still a debated topic. Complex formation between MurD and MurE from *S. agalactiae* was seen experimentally via MST and two protein expression systems. These protocols were able to identify a complex formation between MurD and MurE from *S. agalactiae* that occurred independently of other proteins. MST was able to estimate a dissociation constant for the interaction of MurD and MurE at 49 µM. Miyachiro et al had previously identified $K_D$ values ranging from 283 nM to 23 nM for binary complex formations between the Mur ligases of *S. pneumoniae* using MST, with MurD – MurE having a $K_D$ of 40 nM. Miyachiro et al employed MurE as the ligand while MurD was employed as the ligand within our studies. The binding of the fluorophore to MurE rather than MurD within our studies may have prevented as tight a binary complex formation as that previously seen. However, the difference in $K_D$ does suggest that further investigation into the formation of the binary complex formation between the *S. agalactiae* Mur ligases is required. Analytical ultracentrifugation (AUC) is an analytical technique that allows the study of macromolecules in solution. AUC would allow for the determination of complex formation between MurD and MurE in solution, while also providing data on the number of molecules present within the complex, providing further insight into the formation of the complex between MurD and MurE.

4.2 Role of substrates within binary complex formation

The Mur ligases are multi substrate enzymes, having three unique substrates required for activity of the enzyme. Upon binding of these substrates the Mur ligases undergo a conformational change; the C-terminal domain of the Mur ligases undergoes a rigid body rotation allowing it to be brought towards the N-terminal and central domain. The capping of ATP by the C-terminal domain appears to induce this conformational change, and allows for the binding of the nucleotide substrate. A final rotation of the C-terminal domain then causes the enzyme to
enter its active ‘closed’ conformation\textsuperscript{63}. This domain movement that occurs due to the binding of substrates may play a role in complex formation between the Mur ligases. The $K_D$ of the complex formation between MurD and MurE was seen to change in the presence of substrates, suggesting that substrates may affect the complex formation between the Mur ligases.

The effect of substrates on the stability of the complex would need further investigation, potentially via AUC which can provide information on the shape of macromolecules and conformational changes within macromolecules\textsuperscript{141}, allowing AUC to be used to investigate the effect substrates have on complex formation.

4.3 Complex formation effect on enzyme activity

MurD from \textit{S. agalactiae} was seen to be active while in complex formation via an activity assay. Activity assays were also able to determine that MurE was able to use the UDP-MurNAc-L-Ala-D-Glu formed by MurD. One hypothesis for why the Mur ligases may form a complex within the cytoplasm is to allow for the channelling of the UDP intermediates\textsuperscript{82,83}. Channelling of substrates can provide kinetic advantages as seen with polyketide synthase modules where the $K_{cat}$ was increased 10 to 100 fold when channelling was available\textsuperscript{142}. The ability of the Mur ligases to channel UDP intermediates while in complex formation could be established by using a heavy labelled UDP-MurNAc-L-Ala within an activity assay of the complex proteins. Tracking of the production of heavy labelled UDP-MurNAc-L-Ala-D-Glu-L-Lys in comparison to unlabelled UDP-MurNAc-L-Ala-D-Glu-L-Lys would allow for the determination of whether MurE preferentially turned over the product of MurD to free substrate\textsuperscript{143}. Channelling of the UDP intermediates could provide an explanation into the lack of inhibitors that are able to work \textit{in vivo} against the Mur ligases, due to increased substrate concentrations.

However, the Mur ligases can become inhibited by their UDP substrates, as shown with MurE from \textit{P. aeruginosa} becoming inhibited by UDP-MurNAc-L-Ala-D-Glu at concentrations higher than 300 $\mu$M\textsuperscript{52}. Complex formation of the Mur ligases could result in a regulation of the Mur ligases that results in a decrease of enzyme activity. Further biochemical testing via activity assays could determine if complex formation causes a downregulation of enzyme activity.
4.4 Role of computational predictions for structure determination

Computational software can provide predictions for structures which have not yet been solved. HADDOCK predicted the formation of binary complexes between the Mur ligases of *E. coli* and *S. agalactiae*, based on the residues predicted via PRISM, suggesting potential structures for the binary complexes of the Mur ligases. Computational modelling is constantly evolving, and therefore interaction predictions can shift depending on the software used. Alphafold is an artificial intelligence program designed around a deep learning system that is able to predict a protein’s 3D structure from its amino acid sequence. Binary complex predictions for the Mur ligases via Alphafold greatly differed from the predicted structures generated via HADDOCK. Alphafold could be viewed as a preferable software for the prediction of complex formation amongst the Mur ligases due to its ability to predict complex formation without previous knowledge of residues involved in the complex, allowing an unbiased prediction. However, Alphafold’s ability to predict complexes is limited. Alphafold is only able to predict structures in a single state. The inability of Alphafold to reproduce the MurT/GatD binary complex suggests that conformational changes within the proteins does affect the ability of Alphafold to predict complex formation. The Mur ligases are known to undergo a conformational change upon the binding of substrates, allowing them to be present in multiple conformational states. MST $K_D$ data suggested that the binding of substrates may play an important role in the formation of the binary complex between MurD and MurE from *S. agalactiae*, potentially limiting the ability of Alphafold to accurately predict binary complex formation between the Mur ligases.

The models produced via HADDOCK and Alphafold provide potential interaction regions within the Mur ligases that may be involved in complex formation. However, these are only predictions and require experimental procedures to identify how the binary complexes are forming. One way to determine how the binary complex formations are forming between the Mur ligases is to use carbene footprinting. Carbene is introduced to the proteins and labels areas of the protein that are accessible. Mass spectrometry is then used to identify the residues.
to which the carbene was unable to bind, due to them being involved within complex formation \textsuperscript{144}. Mutation of these residues could then be carried out to identify the residues that are essential for complex formation. Identification of the specific regions and residues involved in complex formation could allow for targeted fragment screens that would inhibit the formation of the Mur ligase complex, allowing the development of antibiotics targeted towards the Mur ligases.
Chapter 7

Discussion and Final Conclusion
1. Impact of fragment screening on the development of novel inhibitors

The development of novel inhibitors is a task that scientists have been attempting to tackle for many years. One newer approach to this problem is the screening of fragments. Fragments are small chemical scaffolds, generally smaller than 250 Da, that can act as the basis for the development, in this instance, of an antibacterial compound. There are a number of different techniques that allow for the screening of fragments. X-ray crystallography allows for the structural characterisation of the binding ability of fragments to a protein of interest, as seen within Chapter 3, while in silico screening can allow for the targeted screening of fragments to a specific region of interest within a protein as carried out in Chapter 4.

Both X-ray crystallography and in silico screening can act as a starting point for the development of a fragment screen that can then be tested for inhibitory effects against a protein of interest, as seen in Chapter 3 and Chapter 4. Development of hit fragments can then be carried out to improve their efficacy and cell permeability to allow for the development of an antibacterial compound that can enter clinical trials. Currently six fragment derived drugs have passed through clinical trials and been approved for clinical use. Most recently the novel kinase inhibitor compound, Asciminib, was approved for the treatment of chronic myeloid leukaemia. The process of discovering Asciminib began with an NMR fragment screen of 500 diverse fragments. Erdafitinib, a drug approved for the treatment of urothelial carcinomas with genetic alterations in the FGFR2 or FGFR3 genes, began in the lab via the repurposing of compounds from a previous fragment screen into a virtual screen, allowing for the identification of a compound that bound within the intended target. These success stories show that fragment screening can play a pivotal role in the development of novel compounds, and potentially could be used for the discovery of a novel antibacterial compound.
2. Role of multi-targeting in inhibitor design

Multi-targeted inhibitors are a more attractive approach for the development of novel antibacterial compounds, due to their ability to reduce the emergence of resistance. Single targeted antibacterial compounds are prone to the emergence of resistance, with many single targeted antibacterial compounds developing resistance before they can make it through clinical trials. Recently, a promising antibacterial compound GSK 052, an inhibitor of bacterial leucyl tRNA-synthetase, rapidly selected resistance in bacteria within phase II clinical trials, with resistance emerging in patients against the new antibacterial compound within 2 days \(^{148}\). Many long-established antibacterial compounds such as β-lactams and quinolones are able to effectively target multiple proteins and so confer resistance at a slower rate \(^{121}\).

Due to the reduction in the emergence of resistance to multi-targeting antibacterial compounds, the Mur ligases are a very attractive target for the development of antibacterial compounds. Due to their similar catalytic mechanism and similar domain topology, it is possible that novel multi-targeting inhibitors can be designed and developed to act against the Mur ligases. Within Chapter 3 and Chapter 4, inhibitory fragments that were able to target both MurD and MurE were identified via high throughput biochemical screens.

3. Role of complex formation of the Mur ligases within the design of inhibitory fragments

The formation of a complex involving the Mur ligases has been suggested as one potential reason why a suitable \textit{in vivo} antibacterial compound against the Mur ligases has yet to be identified. Previous studies have identified the potential for the Mur ligases to interact either with each other in binary complex formations \(^{82}\), or with structural proteins such as MreB and MurG \(^{149}\). The ability of MurD and MurE from \textit{S. agalactiae} to form a binary complex was investigated within Chapter 6, with evidence suggesting that these two proteins can form a binary complex independent of other proteins.
The identification of a complex formation between the Mur ligases could greatly affect the development of antibacterial compounds targeted towards the Mur ligases. Previous fragment screens against the Mur ligases have focused on the known structures of the individual proteins; identifying areas of interest such as that used within the X-ray crystallography screen of Chapter 3. These sites however may become inaccessible to antibacterial compounds in the presence of a complex formation between the Mur ligases, preventing previously identified inhibitory fragments from having in vivo activity \textsuperscript{102,116}. Understanding how the Mur ligases form complexes would provide structural data that would guide future inhibitory screens to prevent this issue arising.

Along with allowing for better predictions of the binding ability of inhibitory compounds within fragment screening, better understanding of complex formation between the Mur ligases could provide a greater understanding of the kinetics of the Mur ligases. The ability of the Mur ligases to potentially channel intermediates within a complex could greatly affect the IC\textsubscript{50} values of inhibitory fragments \textsuperscript{150}, preventing them from being effective antibacterial compounds. The development of biochemical assays that consider the formation of Mur ligase complexes could allow for the identification of inhibitory fragments that have antibacterial effects in vivo \textsuperscript{151}.

4. Final conclusions

Antibacterial resistance is increasing, and new antibacterial compounds are desperately required to fight the rising number of antibacterial resistant infections \textsuperscript{152}. Proteins involved in peptidoglycan formation are an attractive target, with the Mur ligases presenting a unique target due to the ability to design a multi-targeted inhibitor with the potential to act upon all four Mur ligases, potentially reducing the emergence of antibacterial resistance to newly developed drugs.

Fragment screening provides an attractive starting point for the development of new antibacterial compounds due to its ability to identify potential fragment scaffolds from large screens \textsuperscript{129}. Biochemical testing then allows for the identification of the functional effect of fragments identified via fragment screens.
on the proteins of interest. These two techniques work hand in hand to allow for the development and optimization of antibacterial compounds from small chemical fragments. Fragment screens and biochemical testing have been used to produce effective new antibacterial compounds, but for the development of new antibacterial compounds targeted towards the Mur ligases, we must have a greater understanding of the ability of the Mur ligases to form complexes to develop antibacterial compounds that are effective in vivo.
Supplementary Data
**Supplementary 1**

**Skeletal diagrams of elaborated fragment screen**

---

<table>
<thead>
<tr>
<th>PIPERAZINE ANALOGUES</th>
<th>![PIPERAZINE ANALOGUES Diagram]</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="OSA_000724" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000728" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000748" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000744" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000745" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000744" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000746" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000744" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARYL ANALOGUES</th>
<th>![ARYL ANALOGUES Diagram]</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="OSA_000743" alt="ARYL ANALOGUES" /></td>
<td><img src="OSA_000744" alt="ARYL ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000745" alt="ARYL ANALOGUES" /></td>
<td><img src="OSA_000746" alt="ARYL ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000747" alt="ARYL ANALOGUES" /></td>
<td><img src="OSA_000748" alt="ARYL ANALOGUES" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXTENDED ANALOGUES</th>
<th>![EXTENDED ANALOGUES Diagram]</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="OSA_000750" alt="EXTENDED ANALOGUES" /></td>
<td><img src="OSA_000754" alt="EXTENDED ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000755" alt="EXTENDED ANALOGUES" /></td>
<td><img src="OSA_000758" alt="EXTENDED ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000760" alt="EXTENDED ANALOGUES" /></td>
<td><img src="OSA_000763" alt="EXTENDED ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000764" alt="EXTENDED ANALOGUES" /></td>
<td><img src="OSA_000766" alt="EXTENDED ANALOGUES" /></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>PIPERAZINE ANALOGUES</th>
<th>![PIPERAZINE ANALOGUES Diagram]</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="OSA_000771" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000773" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000774" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000775" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
<tr>
<td><img src="OSA_000776" alt="PIPERAZINE ANALOGUES" /></td>
<td><img src="OSA_000777" alt="PIPERAZINE ANALOGUES" /></td>
</tr>
</tbody>
</table>

---

223
<table>
<thead>
<tr>
<th>MORPHOLINE ANALOGUES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Morpholine Analogue 1" /></td>
<td><img src="image2" alt="Morpholine Analogue 2" /></td>
</tr>
<tr>
<td><img src="image3" alt="Morpholine Analogue 3" /></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMBINED FRAGMENT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image4" alt="Combined Fragment" /></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>378</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image5" alt="Chemical Structure 378" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>META ANALOGUES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image6" alt="Meta Analogue 1" /></td>
<td><img src="image7" alt="Meta Analogue 2" /></td>
</tr>
<tr>
<td><img src="image8" alt="Meta Analogue 3" /></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARA ANALOGUES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image9" alt="Para Analogue 1" /></td>
<td><img src="image10" alt="Para Analogue 2" /></td>
</tr>
<tr>
<td><img src="image11" alt="Para Analogue 3" /></td>
<td></td>
</tr>
</tbody>
</table>

224
SULFONAMIDE ANALOGUES
**Supplementary 2**

**Activity of MurD in the presence of elaborated fragments**

<table>
<thead>
<tr>
<th>Fragment ID</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>Fragment ID</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>83.88</td>
<td>77.63</td>
<td>77.43</td>
<td>773</td>
<td>17.25</td>
<td>14.29</td>
<td>26.86</td>
</tr>
<tr>
<td>2</td>
<td>123.35</td>
<td>131.61</td>
<td>127.54</td>
<td>774</td>
<td>31.94</td>
<td>39.83</td>
<td>35.44</td>
</tr>
<tr>
<td>4</td>
<td>74.79</td>
<td>76.21</td>
<td>66.23</td>
<td>775</td>
<td>87.49</td>
<td>78.11</td>
<td>81.99</td>
</tr>
<tr>
<td>71</td>
<td>108.09</td>
<td>83.91</td>
<td>195.42</td>
<td>776</td>
<td>25.00</td>
<td>18.77</td>
<td>22.75</td>
</tr>
<tr>
<td>738</td>
<td>-26.99</td>
<td>-18.03</td>
<td>-21.64</td>
<td>777</td>
<td>-275.11</td>
<td>-77.22</td>
<td>-290.36</td>
</tr>
<tr>
<td>739</td>
<td>31.72</td>
<td>19.65</td>
<td>22.80</td>
<td>778</td>
<td>61.37</td>
<td>108.11</td>
<td>35.78</td>
</tr>
<tr>
<td>740</td>
<td>36.27</td>
<td>12.11</td>
<td>18.94</td>
<td>779</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>741</td>
<td>125.32</td>
<td>149.16</td>
<td>134.86</td>
<td>780</td>
<td>-8.14</td>
<td>-20.97</td>
<td>0.05</td>
</tr>
<tr>
<td>742</td>
<td>10.32</td>
<td>2.81</td>
<td>9.65</td>
<td>781</td>
<td>-464.09</td>
<td>-523.26</td>
<td>-622.96</td>
</tr>
<tr>
<td>743</td>
<td>85.47</td>
<td>96.87</td>
<td>139.61</td>
<td>782</td>
<td>102.43</td>
<td>94.15</td>
<td>107.48</td>
</tr>
<tr>
<td>744</td>
<td>113.56</td>
<td>116.99</td>
<td>112.33</td>
<td>783</td>
<td>29.19</td>
<td>37.50</td>
<td>34.12</td>
</tr>
<tr>
<td>745</td>
<td>70.02</td>
<td>87.12</td>
<td>56.99</td>
<td>784</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>746</td>
<td>24.09</td>
<td>35.25</td>
<td>29.54</td>
<td>785</td>
<td>148.63</td>
<td>148.63</td>
<td>148.63</td>
</tr>
<tr>
<td>747</td>
<td>113.91</td>
<td>87.33</td>
<td>107.54</td>
<td>786</td>
<td>0.67</td>
<td>1.30</td>
<td>0.25</td>
</tr>
<tr>
<td>748</td>
<td>131.07</td>
<td>156.15</td>
<td>89.50</td>
<td>787</td>
<td>-38.10</td>
<td>-70.50</td>
<td>-28.91</td>
</tr>
<tr>
<td>749</td>
<td>19.54</td>
<td>11.55</td>
<td>22.56</td>
<td>788</td>
<td>24.76</td>
<td>15.05</td>
<td>17.17</td>
</tr>
<tr>
<td>750</td>
<td>132.40</td>
<td>166.99</td>
<td>100.86</td>
<td>789</td>
<td>12.24</td>
<td>12.74</td>
<td>24.02</td>
</tr>
<tr>
<td>751</td>
<td>50.12</td>
<td>30.08</td>
<td>39.17</td>
<td>790</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>752</td>
<td>78.22</td>
<td>81.34</td>
<td>77.12</td>
<td>791</td>
<td>-14.49</td>
<td>-29.69</td>
<td>-24.23</td>
</tr>
<tr>
<td>753</td>
<td>45.13</td>
<td>44.39</td>
<td>36.03</td>
<td>792</td>
<td>2191.22</td>
<td>-134.96</td>
<td>737.47</td>
</tr>
<tr>
<td>754</td>
<td>1.40</td>
<td>0.84</td>
<td>0.40</td>
<td>793</td>
<td>717.68</td>
<td>-80.36</td>
<td>128.09</td>
</tr>
<tr>
<td>755</td>
<td>7.96</td>
<td>18.28</td>
<td>19.67</td>
<td>794</td>
<td>100.99</td>
<td>75.35</td>
<td>59.62</td>
</tr>
<tr>
<td>756</td>
<td>86.30</td>
<td>86.36</td>
<td>102.94</td>
<td>795</td>
<td>54.47</td>
<td>53.66</td>
<td>73.15</td>
</tr>
<tr>
<td>757</td>
<td>32.52</td>
<td>30.71</td>
<td>43.74</td>
<td>796</td>
<td>10.51</td>
<td>9.36</td>
<td>14.63</td>
</tr>
<tr>
<td>758</td>
<td>6.82</td>
<td>7.66</td>
<td>5.11</td>
<td>797</td>
<td>70.34</td>
<td>70.32</td>
<td>70.32</td>
</tr>
<tr>
<td>759</td>
<td>10.64</td>
<td>10.77</td>
<td>19.21</td>
<td>798</td>
<td>644.21</td>
<td>679.62</td>
<td>679.62</td>
</tr>
<tr>
<td>760</td>
<td>100.74</td>
<td>98.82</td>
<td>117.73</td>
<td>799</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>761</td>
<td>125.65</td>
<td>94.34</td>
<td>129.37</td>
<td>800</td>
<td>94.03</td>
<td>111.29</td>
<td>156.47</td>
</tr>
<tr>
<td>762</td>
<td>60.88</td>
<td>71.78</td>
<td>55.54</td>
<td>801</td>
<td>51.78</td>
<td>75.27</td>
<td>67.80</td>
</tr>
<tr>
<td>763</td>
<td>107.00</td>
<td>89.13</td>
<td>97.41</td>
<td>802</td>
<td>563.83</td>
<td>736.34</td>
<td>518.88</td>
</tr>
<tr>
<td>764</td>
<td>84.34</td>
<td>118.92</td>
<td>95.39</td>
<td>803</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>765</td>
<td>18.48</td>
<td>22.78</td>
<td>22.31</td>
<td>804</td>
<td>150.72</td>
<td>158.73</td>
<td>142.07</td>
</tr>
<tr>
<td>766</td>
<td>103.40</td>
<td>89.52</td>
<td>84.35</td>
<td>805</td>
<td>167.52</td>
<td>82.05</td>
<td>95.71</td>
</tr>
<tr>
<td>767</td>
<td>65.34</td>
<td>33.01</td>
<td>55.60</td>
<td>806</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>768</td>
<td>259.73</td>
<td>131.09</td>
<td>200.67</td>
<td>807</td>
<td>-76.59</td>
<td>-110.41</td>
<td>-3.48</td>
</tr>
<tr>
<td>769</td>
<td>108.46</td>
<td>263.05</td>
<td>238.89</td>
<td>808</td>
<td>92.49</td>
<td>193.31</td>
<td>138.85</td>
</tr>
<tr>
<td>770</td>
<td>48.45</td>
<td>52.09</td>
<td>42.93</td>
<td>809</td>
<td>-11.45</td>
<td>-45.29</td>
<td>-28.38</td>
</tr>
<tr>
<td>771</td>
<td>19.32</td>
<td>28.08</td>
<td>41.94</td>
<td>810</td>
<td>-4.67</td>
<td>-0.92</td>
<td>-4.24</td>
</tr>
<tr>
<td>772</td>
<td>35.79</td>
<td>42.46</td>
<td>34.91</td>
<td>811</td>
<td>1585.64</td>
<td>68.75</td>
<td>-336.97</td>
</tr>
</tbody>
</table>
Supplementary 3

Validation of an MESG coupled assay with MurE from *S. agalactiae*

**Assay was dependent on presence of all substrates and ligase**

![Graphs showing the activity of MurE with different substrates](image)

*Figure S3. 1: The activity of MurE relies on the presence of all three substrates*

The activity of MurE was tracked using a MESG coupled assay. All components of the assay were incubated at 37°C barring one substrate which was added after 2 minutes. No activity was seen within any of the assays until all three substrates were present. (A) Comparison of initial rate when individual substrates were omitted and when all substrates were present. (B) L-Lys added after 1 minute. (C) UDP-MurNAc-L-Ala-D-Glu (UDP-2P) added after 1 minute. (D) ATP added after 1 minute.

**Assay was linear to protein concentration**

![Graph showing the linear relationship between MurE concentration and initial rate](image)

*Figure S3. 2: MESG coupled reaction is reliant on MurE concentration*

The activity of *S. agalactiae* MurE was determined via the MESG coupled assay. The assay was tracked in the presence of various MurE concentrations. The initial rate of the reaction was determined and plotted against MurE concentration. A linear relationship was observed between MurE concentration and initial rate.
The IC$_{50}$ of ADPCP against MurE was determined using a stopped MESG coupled assay. Substrate concentrations were at their $K_m$ values. The concentration of ADPCP was increased and the initial rate of MurE determined. The IC$_{50}$ value was determined as the concentration of ADPCP that reduced activity of MurE by 50%. All experiments were run in triplicate with error bars indicating SD.

Figure S3: ADPCP has an IC$_{50}$ value of 2.7 µM against MurE from *S. agalactiae*

### Z prime

<table>
<thead>
<tr>
<th></th>
<th>MurE</th>
<th>MurE + ADPCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>0.1387</td>
<td>0.02708</td>
</tr>
<tr>
<td>SD</td>
<td>0.00922</td>
<td>0.00381</td>
</tr>
<tr>
<td>Z prime</td>
<td>$Z = 1 - \frac{(3(0.00922) + 3(0.00381))}{(0.1387 - 0.02708)}$</td>
<td>$Z = 0.65$</td>
</tr>
</tbody>
</table>

**Z prime Score**
Enamine fragment screen IDs and SMILES
### Activity of MurD in the presence of Enamine fragments

<table>
<thead>
<tr>
<th>Fragment ID</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>Fragment ID</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>A02</td>
<td>75.46</td>
<td>85.66</td>
<td>68.17</td>
<td>C08</td>
<td>79.62</td>
<td>91.68</td>
<td>81.82</td>
</tr>
<tr>
<td>A03</td>
<td>7.47</td>
<td>14.40</td>
<td>12.76</td>
<td>C09</td>
<td>82.39</td>
<td>103.83</td>
<td>81.82</td>
</tr>
<tr>
<td>A04</td>
<td>59.17</td>
<td>68.93</td>
<td>67.92</td>
<td>C10</td>
<td>135.27</td>
<td>101.72</td>
<td>105.70</td>
</tr>
<tr>
<td>A05</td>
<td></td>
<td></td>
<td></td>
<td>C11</td>
<td>53.57</td>
<td>51.34</td>
<td>46.80</td>
</tr>
<tr>
<td>A06</td>
<td>66.54</td>
<td>52.11</td>
<td>44.52</td>
<td>C12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A07</td>
<td>32.09</td>
<td>36.32</td>
<td>35.49</td>
<td>C13</td>
<td>117.07</td>
<td>123.65</td>
<td>98.72</td>
</tr>
<tr>
<td>A08</td>
<td></td>
<td></td>
<td></td>
<td>C14</td>
<td>110.04</td>
<td>114.16</td>
<td>120.09</td>
</tr>
<tr>
<td>A09</td>
<td></td>
<td></td>
<td></td>
<td>C15</td>
<td>106.75</td>
<td>100.77</td>
<td>81.03</td>
</tr>
<tr>
<td>A10</td>
<td></td>
<td></td>
<td></td>
<td>C16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A11</td>
<td>56.09</td>
<td>55.21</td>
<td>62.02</td>
<td>C17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A12</td>
<td></td>
<td></td>
<td></td>
<td>C18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A13</td>
<td>122.52</td>
<td>94.50</td>
<td>140.85</td>
<td>C19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A14</td>
<td></td>
<td></td>
<td></td>
<td>C20</td>
<td>81.27</td>
<td>106.40</td>
<td>90.67</td>
</tr>
<tr>
<td>A15</td>
<td>82.85</td>
<td>94.47</td>
<td>71.92</td>
<td>C21</td>
<td>30.08</td>
<td>46.97</td>
<td>34.51</td>
</tr>
<tr>
<td>A16</td>
<td>75.38</td>
<td>105.98</td>
<td>93.12</td>
<td>C22</td>
<td>35.58</td>
<td>43.82</td>
<td>11.66</td>
</tr>
<tr>
<td>A17</td>
<td></td>
<td></td>
<td></td>
<td>C23</td>
<td>70.55</td>
<td>103.92</td>
<td>106.93</td>
</tr>
<tr>
<td>A18</td>
<td></td>
<td></td>
<td></td>
<td>D02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A19</td>
<td>68.34</td>
<td>54.23</td>
<td>58.29</td>
<td>D03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A20</td>
<td>70.35</td>
<td>88.84</td>
<td>102.71</td>
<td>D04</td>
<td>57.72</td>
<td>93.21</td>
<td>131.71</td>
</tr>
<tr>
<td>A21</td>
<td></td>
<td></td>
<td></td>
<td>D05</td>
<td>106.73</td>
<td>186.73</td>
<td>102.16</td>
</tr>
<tr>
<td>A22</td>
<td>57.69</td>
<td>56.98</td>
<td>58.29</td>
<td>D06</td>
<td>56.02</td>
<td>71.47</td>
<td>49.12</td>
</tr>
<tr>
<td>A23</td>
<td>95.18</td>
<td>86.53</td>
<td>103.35</td>
<td>D07</td>
<td>60.13</td>
<td>82.48</td>
<td>62.43</td>
</tr>
<tr>
<td>B02</td>
<td>36.09</td>
<td>42.86</td>
<td>39.19</td>
<td>D08</td>
<td>59.47</td>
<td>43.37</td>
<td>57.50</td>
</tr>
<tr>
<td>B03</td>
<td></td>
<td></td>
<td></td>
<td>D09</td>
<td>565.19</td>
<td>480.93</td>
<td>267.92</td>
</tr>
<tr>
<td>B04</td>
<td></td>
<td></td>
<td></td>
<td>D10</td>
<td>63.25</td>
<td>50.44</td>
<td>51.42</td>
</tr>
<tr>
<td>B05</td>
<td>63.85</td>
<td>60.94</td>
<td>65.13</td>
<td>D11</td>
<td>47.68</td>
<td>48.12</td>
<td>43.10</td>
</tr>
<tr>
<td>B06</td>
<td>80.97</td>
<td>100.71</td>
<td>77.71</td>
<td>D12</td>
<td>76.44</td>
<td>60.04</td>
<td>53.53</td>
</tr>
<tr>
<td>B07</td>
<td>30.89</td>
<td>38.44</td>
<td>50.60</td>
<td>D13</td>
<td>78.57</td>
<td>79.98</td>
<td>79.32</td>
</tr>
<tr>
<td>B08</td>
<td></td>
<td></td>
<td></td>
<td>D14</td>
<td>127.21</td>
<td>154.25</td>
<td>139.66</td>
</tr>
<tr>
<td>B09</td>
<td>48.14</td>
<td>47.15</td>
<td>50.11</td>
<td>D15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B10</td>
<td>84.01</td>
<td>89.92</td>
<td>81.01</td>
<td>D16</td>
<td>69.98</td>
<td>96.64</td>
<td>77.12</td>
</tr>
<tr>
<td>B11</td>
<td>88.27</td>
<td>75.33</td>
<td>77.30</td>
<td>D17</td>
<td>116.91</td>
<td>115.88</td>
<td>109.70</td>
</tr>
<tr>
<td>B12</td>
<td>79.83</td>
<td>85.87</td>
<td>95.61</td>
<td>D18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B13</td>
<td>107.24</td>
<td>123.79</td>
<td>137.94</td>
<td>D19</td>
<td>48.91</td>
<td>56.75</td>
<td>51.12</td>
</tr>
<tr>
<td>B14</td>
<td>137.17</td>
<td>203.35</td>
<td>137.42</td>
<td>D20</td>
<td>67.87</td>
<td>65.01</td>
<td>60.84</td>
</tr>
<tr>
<td>B15</td>
<td>90.26</td>
<td>88.53</td>
<td>87.69</td>
<td>D21</td>
<td>7.24</td>
<td>15.88</td>
<td>31.76</td>
</tr>
<tr>
<td>B16</td>
<td>72.46</td>
<td>67.79</td>
<td>86.07</td>
<td>D22</td>
<td>100.30</td>
<td>107.94</td>
<td>83.82</td>
</tr>
<tr>
<td>B17</td>
<td>109.44</td>
<td>106.09</td>
<td>87.30</td>
<td>D23</td>
<td>81.71</td>
<td>156.08</td>
<td>107.64</td>
</tr>
<tr>
<td>B18</td>
<td></td>
<td></td>
<td></td>
<td>E02</td>
<td>125.21</td>
<td>-6.20</td>
<td>56.68</td>
</tr>
<tr>
<td>B19</td>
<td></td>
<td></td>
<td></td>
<td>E03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B20</td>
<td>55.14</td>
<td>75.44</td>
<td>62.38</td>
<td>E04</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B21</td>
<td>63.99</td>
<td>78.46</td>
<td>65.19</td>
<td>E05</td>
<td>22.96</td>
<td>24.42</td>
<td>20.98</td>
</tr>
<tr>
<td>B22</td>
<td>116.98</td>
<td>123.42</td>
<td>120.84</td>
<td>E06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B23</td>
<td>72.71</td>
<td>90.95</td>
<td>69.25</td>
<td>E07</td>
<td>47.32</td>
<td>69.33</td>
<td>68.67</td>
</tr>
<tr>
<td>C02</td>
<td></td>
<td></td>
<td></td>
<td>E08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C03</td>
<td>128.25</td>
<td>99.09</td>
<td>102.92</td>
<td>E09</td>
<td>66.70</td>
<td>84.45</td>
<td>81.16</td>
</tr>
<tr>
<td>C04</td>
<td>30.26</td>
<td>18.01</td>
<td>6.56</td>
<td>E10</td>
<td>49.29</td>
<td>28.42</td>
<td>54.71</td>
</tr>
<tr>
<td>C05</td>
<td>40.28</td>
<td>41.19</td>
<td>40.64</td>
<td>E11</td>
<td>42.62</td>
<td>40.15</td>
<td>44.32</td>
</tr>
<tr>
<td>C06</td>
<td>68.67</td>
<td>95.62</td>
<td>86.74</td>
<td>E12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C07</td>
<td>72.67</td>
<td>72.95</td>
<td>76.89</td>
<td>E13</td>
<td>81.50</td>
<td>107.73</td>
<td>85.48</td>
</tr>
<tr>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>E14</td>
<td>74.07</td>
<td>50.25</td>
<td>62.82</td>
<td>F19</td>
<td>90.59</td>
<td>97.82</td>
<td>90.94</td>
</tr>
<tr>
<td>E15</td>
<td>68.19</td>
<td>65.88</td>
<td>65.90</td>
<td>F20</td>
<td>62.51</td>
<td>70.15</td>
<td>67.64</td>
</tr>
<tr>
<td>E16</td>
<td>109.61</td>
<td>155.45</td>
<td>108.07</td>
<td>F21</td>
<td>64.42</td>
<td>135.58</td>
<td>202.91</td>
</tr>
<tr>
<td>E17</td>
<td>198.85</td>
<td>210.72</td>
<td>128.35</td>
<td>F22</td>
<td>99.36</td>
<td>95.34</td>
<td>95.54</td>
</tr>
<tr>
<td>E18</td>
<td>67.60</td>
<td>93.13</td>
<td>102.78</td>
<td>F23</td>
<td>23.57</td>
<td>42.16</td>
<td>35.67</td>
</tr>
<tr>
<td>E19</td>
<td>87.84</td>
<td>65.33</td>
<td>72.16</td>
<td>G02</td>
<td>137.79</td>
<td>174.97</td>
<td>117.74</td>
</tr>
<tr>
<td>E20</td>
<td>132.60</td>
<td>120.94</td>
<td>96.82</td>
<td>G03</td>
<td>64.09</td>
<td>64.09</td>
<td>65.55</td>
</tr>
<tr>
<td>E21</td>
<td>22.48</td>
<td>25.58</td>
<td>21.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E22</td>
<td>67.60</td>
<td>93.13</td>
<td>102.78</td>
<td>G04</td>
<td>85.09</td>
<td>85.09</td>
<td>85.09</td>
</tr>
<tr>
<td>E23</td>
<td>22.48</td>
<td>25.58</td>
<td>21.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E24</td>
<td>81.04</td>
<td>90.89</td>
<td>83.71</td>
<td>G05</td>
<td>23.57</td>
<td>42.16</td>
<td>35.67</td>
</tr>
<tr>
<td>E25</td>
<td>67.60</td>
<td>93.13</td>
<td>102.78</td>
<td>G06</td>
<td>85.32</td>
<td>76.12</td>
<td>84.90</td>
</tr>
<tr>
<td>F02</td>
<td>116.91</td>
<td>115.88</td>
<td>109.70</td>
<td>G07</td>
<td>61.45</td>
<td>60.79</td>
<td>66.33</td>
</tr>
<tr>
<td>D17</td>
<td>41.07</td>
<td>65.72</td>
<td>55.86</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D18</td>
<td>49.01</td>
<td>103.82</td>
<td>91.76</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D19</td>
<td>103.18</td>
<td>97.59</td>
<td>88.82</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D20</td>
<td>62.51</td>
<td>70.15</td>
<td>67.64</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D21</td>
<td>108.20</td>
<td>213.22</td>
<td>145.31</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D22</td>
<td>99.39</td>
<td>122.45</td>
<td>105.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D23</td>
<td>43.78</td>
<td>83.43</td>
<td>54.94</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E02</td>
<td>125.21</td>
<td>-6.20</td>
<td>56.68</td>
<td>G14</td>
<td>88.25</td>
<td>86.08</td>
<td>76.79</td>
</tr>
<tr>
<td>E03</td>
<td>G16</td>
<td>94.01</td>
<td>103.82</td>
<td>91.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E04</td>
<td>G17</td>
<td>86.35</td>
<td>99.74</td>
<td>85.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E05</td>
<td>81.41</td>
<td>158.29</td>
<td>110.65</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E06</td>
<td>47.32</td>
<td>69.33</td>
<td>68.67</td>
<td>G19</td>
<td>60.77</td>
<td>57.35</td>
<td>67.60</td>
</tr>
<tr>
<td>E07</td>
<td>64.28</td>
<td>74.59</td>
<td>68.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E08</td>
<td>61.45</td>
<td>50.27</td>
<td>50.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E09</td>
<td>66.70</td>
<td>84.45</td>
<td>81.16</td>
<td>G21</td>
<td>65.63</td>
<td>61.81</td>
<td>50.55</td>
</tr>
<tr>
<td>E10</td>
<td>49.29</td>
<td>28.42</td>
<td>54.71</td>
<td>G22</td>
<td>88.25</td>
<td>109.68</td>
<td>112.09</td>
</tr>
<tr>
<td>E11</td>
<td>42.62</td>
<td>40.15</td>
<td>44.32</td>
<td>G23</td>
<td>88.25</td>
<td>86.08</td>
<td>76.79</td>
</tr>
<tr>
<td>E12</td>
<td>G10</td>
<td>103.04</td>
<td>92.65</td>
<td>93.99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E13</td>
<td>18.23</td>
<td>33.35</td>
<td>25.94</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E14</td>
<td>81.50</td>
<td>107.73</td>
<td>85.48</td>
<td>G11</td>
<td>66.16</td>
<td>134.14</td>
<td>158.02</td>
</tr>
<tr>
<td>E15</td>
<td>74.07</td>
<td>50.25</td>
<td>62.82</td>
<td>G12</td>
<td>64.07</td>
<td>58.16</td>
<td>40.42</td>
</tr>
<tr>
<td>E16</td>
<td>68.19</td>
<td>65.88</td>
<td>65.90</td>
<td>G13</td>
<td>64.07</td>
<td>58.16</td>
<td>40.42</td>
</tr>
<tr>
<td>E17</td>
<td>109.61</td>
<td>155.45</td>
<td>108.07</td>
<td>G14</td>
<td>64.07</td>
<td>58.16</td>
<td>40.42</td>
</tr>
<tr>
<td>E18</td>
<td>66.05</td>
<td>51.92</td>
<td>46.33</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E19</td>
<td>24.97</td>
<td>29.29</td>
<td>26.94</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E20</td>
<td>24.97</td>
<td>29.29</td>
<td>26.94</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E21</td>
<td>102.74</td>
<td>101.98</td>
<td>116.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E22</td>
<td>92.51</td>
<td>92.06</td>
<td>87.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E23</td>
<td>176.22</td>
<td>140.94</td>
<td>155.28</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F02</td>
<td>81.04</td>
<td>90.89</td>
<td>83.71</td>
<td>G15</td>
<td>79.32</td>
<td>72.90</td>
<td>83.96</td>
</tr>
<tr>
<td>F03</td>
<td>66.59</td>
<td>90.58</td>
<td>43.01</td>
<td>G16</td>
<td>79.32</td>
<td>72.90</td>
<td>83.96</td>
</tr>
<tr>
<td>F04</td>
<td>85.78</td>
<td>70.53</td>
<td>162.88</td>
<td>G17</td>
<td>79.32</td>
<td>72.90</td>
<td>83.96</td>
</tr>
<tr>
<td>F05</td>
<td>98.24</td>
<td>96.23</td>
<td>83.84</td>
<td>G18</td>
<td>79.32</td>
<td>72.90</td>
<td>83.96</td>
</tr>
<tr>
<td>F06</td>
<td>62.25</td>
<td>72.95</td>
<td>52.25</td>
<td>H01</td>
<td>79.32</td>
<td>72.90</td>
<td>83.96</td>
</tr>
<tr>
<td>F07</td>
<td>68.61</td>
<td>66.20</td>
<td>78.86</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F08</td>
<td>31.00</td>
<td>23.77</td>
<td>17.85</td>
<td>H10</td>
<td>56.97</td>
<td>57.22</td>
<td>59.43</td>
</tr>
<tr>
<td>F09</td>
<td>19.38</td>
<td>24.82</td>
<td>21.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F10</td>
<td>84.23</td>
<td>78.64</td>
<td>81.60</td>
<td>H11</td>
<td>56.97</td>
<td>57.22</td>
<td>59.43</td>
</tr>
<tr>
<td>F11</td>
<td>62.23</td>
<td>80.01</td>
<td>55.65</td>
<td>H12</td>
<td>56.97</td>
<td>57.22</td>
<td>59.43</td>
</tr>
<tr>
<td>F12</td>
<td>116.29</td>
<td>198.85</td>
<td>94.71</td>
<td>H13</td>
<td>56.97</td>
<td>57.22</td>
<td>59.43</td>
</tr>
<tr>
<td>F13</td>
<td>58.26</td>
<td>51.34</td>
<td>58.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F14</td>
<td>58.26</td>
<td>51.34</td>
<td>58.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F15</td>
<td>121.82</td>
<td>115.57</td>
<td>107.69</td>
<td>H14</td>
<td>58.60</td>
<td>52.35</td>
<td>62.87</td>
</tr>
<tr>
<td>F16</td>
<td>71.10</td>
<td>75.02</td>
<td>73.88</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F17</td>
<td>83.91</td>
<td>76.57</td>
<td>87.64</td>
<td>H15</td>
<td>71.52</td>
<td>81.38</td>
<td>79.18</td>
</tr>
<tr>
<td>F18</td>
<td>44.03</td>
<td>45.66</td>
<td>43.70</td>
<td>H16</td>
<td>71.52</td>
<td>81.38</td>
<td>79.18</td>
</tr>
<tr>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>I10</td>
<td></td>
<td></td>
<td></td>
<td>K23</td>
<td>95.06</td>
<td>92.19</td>
<td>114.30</td>
</tr>
<tr>
<td>I11</td>
<td></td>
<td></td>
<td></td>
<td>L02</td>
<td>138.70</td>
<td>111.54</td>
<td>66.89</td>
</tr>
<tr>
<td>I12</td>
<td></td>
<td></td>
<td></td>
<td>L03</td>
<td>11.85</td>
<td>59.23</td>
<td>34.75</td>
</tr>
<tr>
<td>I13</td>
<td>118.81</td>
<td>196.83</td>
<td>130.27</td>
<td>L04</td>
<td>32.08</td>
<td>31.85</td>
<td>30.44</td>
</tr>
<tr>
<td>I14</td>
<td>46.17</td>
<td>58.71</td>
<td>33.99</td>
<td>L05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I15</td>
<td>94.84</td>
<td>91.72</td>
<td>88.10</td>
<td>L06</td>
<td>127.60</td>
<td>17.20</td>
<td>71.74</td>
</tr>
<tr>
<td>I16</td>
<td></td>
<td></td>
<td></td>
<td>L07</td>
<td>59.91</td>
<td>68.46</td>
<td>30.67</td>
</tr>
<tr>
<td>I17</td>
<td>81.80</td>
<td>85.28</td>
<td>102.92</td>
<td>L08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I18</td>
<td>62.63</td>
<td>64.12</td>
<td>60.70</td>
<td>L09</td>
<td>68.13</td>
<td>42.06</td>
<td>31.98</td>
</tr>
<tr>
<td>I19</td>
<td>33.17</td>
<td>40.80</td>
<td>56.28</td>
<td>L10</td>
<td>32.20</td>
<td>69.00</td>
<td>93.98</td>
</tr>
<tr>
<td>I20</td>
<td>22.81</td>
<td>24.52</td>
<td>25.03</td>
<td>L11</td>
<td>35.54</td>
<td>57.92</td>
<td>47.10</td>
</tr>
<tr>
<td>I21</td>
<td>79.90</td>
<td>75.78</td>
<td>80.60</td>
<td>L12</td>
<td>103.81</td>
<td>107.18</td>
<td>104.41</td>
</tr>
<tr>
<td>I22</td>
<td></td>
<td></td>
<td></td>
<td>L13</td>
<td>92.79</td>
<td>105.10</td>
<td>112.30</td>
</tr>
<tr>
<td>I23</td>
<td>130.95</td>
<td>136.98</td>
<td>143.02</td>
<td>L14</td>
<td>108.28</td>
<td>156.95</td>
<td>109.57</td>
</tr>
<tr>
<td>J02</td>
<td>78.61</td>
<td>91.01</td>
<td>82.16</td>
<td>L15</td>
<td>69.45</td>
<td>90.24</td>
<td>71.03</td>
</tr>
<tr>
<td>J03</td>
<td>22.46</td>
<td>25.47</td>
<td>26.86</td>
<td>L16</td>
<td>99.17</td>
<td>85.82</td>
<td>68.94</td>
</tr>
<tr>
<td>J04</td>
<td>66.28</td>
<td>16.16</td>
<td>49.19</td>
<td>L17</td>
<td>26.82</td>
<td>18.54</td>
<td>25.06</td>
</tr>
<tr>
<td>J05</td>
<td>75.03</td>
<td>50.61</td>
<td>67.19</td>
<td>L18</td>
<td>108.27</td>
<td>82.14</td>
<td>73.50</td>
</tr>
<tr>
<td>J06</td>
<td>12.49</td>
<td>11.83</td>
<td>13.39</td>
<td>L19</td>
<td>65.23</td>
<td>74.17</td>
<td>61.71</td>
</tr>
<tr>
<td>J07</td>
<td></td>
<td></td>
<td></td>
<td>L20</td>
<td>66.57</td>
<td>50.99</td>
<td>69.48</td>
</tr>
<tr>
<td>J08</td>
<td>84.61</td>
<td>58.75</td>
<td>63.25</td>
<td>L21</td>
<td>68.94</td>
<td>58.29</td>
<td>52.26</td>
</tr>
<tr>
<td>J09</td>
<td>57.39</td>
<td>32.42</td>
<td>47.21</td>
<td>L22</td>
<td>50.45</td>
<td>13.87</td>
<td>28.54</td>
</tr>
<tr>
<td>J10</td>
<td>59.69</td>
<td>51.81</td>
<td>55.42</td>
<td>L23</td>
<td>114.37</td>
<td>140.30</td>
<td>116.78</td>
</tr>
<tr>
<td>J11</td>
<td>69.47</td>
<td>80.60</td>
<td>78.69</td>
<td>M02</td>
<td>19.96</td>
<td>22.24</td>
<td>35.09</td>
</tr>
<tr>
<td>J12</td>
<td>31.54</td>
<td>80.08</td>
<td>43.84</td>
<td>M03</td>
<td>80.74</td>
<td>102.61</td>
<td>81.11</td>
</tr>
<tr>
<td>J13</td>
<td>72.42</td>
<td>75.04</td>
<td>74.50</td>
<td>M04</td>
<td>-14.88</td>
<td>-17.80</td>
<td>-21.63</td>
</tr>
<tr>
<td>J14</td>
<td>54.21</td>
<td>28.71</td>
<td>41.12</td>
<td>M05</td>
<td>12.76</td>
<td>27.89</td>
<td>42.65</td>
</tr>
<tr>
<td>J15</td>
<td>70.88</td>
<td>110.39</td>
<td>81.51</td>
<td>M06</td>
<td>117.31</td>
<td>54.87</td>
<td>89.38</td>
</tr>
<tr>
<td>J16</td>
<td>92.77</td>
<td>64.68</td>
<td>101.61</td>
<td>M07</td>
<td>-141.79</td>
<td>-19.55</td>
<td>-65.88</td>
</tr>
<tr>
<td>J17</td>
<td></td>
<td></td>
<td></td>
<td>M08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J18</td>
<td>42.21</td>
<td>55.88</td>
<td>33.02</td>
<td>M09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J19</td>
<td>85.23</td>
<td>100.90</td>
<td>55.68</td>
<td>M10</td>
<td>52.03</td>
<td>73.38</td>
<td>73.06</td>
</tr>
<tr>
<td>J20</td>
<td>94.97</td>
<td>95.58</td>
<td>93.62</td>
<td>M11</td>
<td>77.15</td>
<td>99.97</td>
<td>64.21</td>
</tr>
<tr>
<td>J21</td>
<td>75.28</td>
<td>98.39</td>
<td>78.94</td>
<td>M12</td>
<td>89.67</td>
<td>125.26</td>
<td>145.33</td>
</tr>
<tr>
<td>J22</td>
<td>118.86</td>
<td>105.39</td>
<td>107.02</td>
<td>M13</td>
<td>60.46</td>
<td>52.83</td>
<td>43.99</td>
</tr>
<tr>
<td>J23</td>
<td>91.32</td>
<td>90.12</td>
<td>91.73</td>
<td>M14</td>
<td>100.09</td>
<td>94.68</td>
<td>113.99</td>
</tr>
<tr>
<td>K02</td>
<td></td>
<td></td>
<td></td>
<td>M15</td>
<td>67.08</td>
<td>87.26</td>
<td>47.90</td>
</tr>
<tr>
<td>K03</td>
<td>71.81</td>
<td>62.33</td>
<td>72.72</td>
<td>M16</td>
<td>129.79</td>
<td>107.58</td>
<td>86.14</td>
</tr>
<tr>
<td>K04</td>
<td></td>
<td></td>
<td></td>
<td>M17</td>
<td>87.38</td>
<td>80.17</td>
<td>95.88</td>
</tr>
<tr>
<td>K05</td>
<td>66.16</td>
<td>60.02</td>
<td>63.79</td>
<td>M18</td>
<td>73.37</td>
<td>64.92</td>
<td>86.43</td>
</tr>
<tr>
<td>K06</td>
<td>67.47</td>
<td>58.60</td>
<td>62.20</td>
<td>M19</td>
<td>82.51</td>
<td>89.55</td>
<td>109.65</td>
</tr>
<tr>
<td>K07</td>
<td>75.61</td>
<td>77.33</td>
<td>73.38</td>
<td>M20</td>
<td>59.90</td>
<td>70.35</td>
<td>56.48</td>
</tr>
<tr>
<td>K08</td>
<td>46.00</td>
<td>51.26</td>
<td>46.33</td>
<td>M21</td>
<td>22.26</td>
<td>16.28</td>
<td>43.02</td>
</tr>
<tr>
<td>K09</td>
<td>71.63</td>
<td>62.10</td>
<td>87.73</td>
<td>M22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K10</td>
<td>68.51</td>
<td>63.64</td>
<td>60.95</td>
<td>M23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K11</td>
<td>74.65</td>
<td>72.62</td>
<td>79.64</td>
<td>M02</td>
<td>131.41</td>
<td>91.68</td>
<td>25.52</td>
</tr>
<tr>
<td>K12</td>
<td>109.46</td>
<td>153.88</td>
<td>176.70</td>
<td>M03</td>
<td>51.37</td>
<td>76.67</td>
<td>32.75</td>
</tr>
<tr>
<td>K13</td>
<td>120.26</td>
<td>127.96</td>
<td>125.61</td>
<td>M04</td>
<td>66.28</td>
<td>92.75</td>
<td>118.77</td>
</tr>
<tr>
<td>K14</td>
<td></td>
<td></td>
<td></td>
<td>M05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K15</td>
<td>79.26</td>
<td>108.49</td>
<td>103.22</td>
<td>M06</td>
<td>120.92</td>
<td>112.71</td>
<td>62.10</td>
</tr>
<tr>
<td>K16</td>
<td></td>
<td></td>
<td></td>
<td>M07</td>
<td>34.06</td>
<td>82.04</td>
<td>58.05</td>
</tr>
<tr>
<td>K17</td>
<td></td>
<td></td>
<td></td>
<td>M08</td>
<td>72.29</td>
<td>81.16</td>
<td>21.03</td>
</tr>
<tr>
<td>K18</td>
<td></td>
<td></td>
<td></td>
<td>M09</td>
<td>31.07</td>
<td>29.57</td>
<td>27.60</td>
</tr>
<tr>
<td>K19</td>
<td></td>
<td></td>
<td></td>
<td>M10</td>
<td>84.34</td>
<td>67.91</td>
<td>59.04</td>
</tr>
<tr>
<td>K20</td>
<td>90.45</td>
<td>72.16</td>
<td>71.91</td>
<td>N11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K21</td>
<td>91.93</td>
<td>92.73</td>
<td>100.97</td>
<td>N12</td>
<td>125.21</td>
<td>98.36</td>
<td>109.08</td>
</tr>
<tr>
<td>K22</td>
<td></td>
<td></td>
<td></td>
<td>N13</td>
<td>155.44</td>
<td>130.19</td>
<td>115.86</td>
</tr>
<tr>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>N14</td>
<td>48.50</td>
<td>41.29</td>
<td>40.26</td>
<td>A02</td>
<td>106.71</td>
<td>93.96</td>
<td>100.84</td>
</tr>
<tr>
<td>N15</td>
<td>89.13</td>
<td>93.67</td>
<td>100.93</td>
<td>A03</td>
<td>78.63</td>
<td>103.89</td>
<td>75.85</td>
</tr>
<tr>
<td>N16</td>
<td>17.56</td>
<td>12.27</td>
<td>19.74</td>
<td>A04</td>
<td>76.54</td>
<td>82.80</td>
<td>78.05</td>
</tr>
<tr>
<td>N17</td>
<td>53.67</td>
<td>60.10</td>
<td>41.21</td>
<td>A05</td>
<td>113.43</td>
<td>129.18</td>
<td>154.67</td>
</tr>
<tr>
<td>N18</td>
<td>72.96</td>
<td>71.76</td>
<td>69.75</td>
<td>A06</td>
<td>118.90</td>
<td>266.34</td>
<td></td>
</tr>
<tr>
<td>N19</td>
<td>67.00</td>
<td>319.26</td>
<td>122.08</td>
<td>A07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N20</td>
<td>97.89</td>
<td>111.96</td>
<td>155.78</td>
<td>A08</td>
<td>102.65</td>
<td>95.93</td>
<td>92.46</td>
</tr>
<tr>
<td>N21</td>
<td></td>
<td></td>
<td></td>
<td>A09</td>
<td>101.96</td>
<td>135.79</td>
<td>100.57</td>
</tr>
<tr>
<td>N22</td>
<td></td>
<td></td>
<td></td>
<td>A10</td>
<td>51.26</td>
<td>43.55</td>
<td>45.10</td>
</tr>
<tr>
<td>N23</td>
<td></td>
<td></td>
<td></td>
<td>A11</td>
<td>111.42</td>
<td>48.94</td>
<td>94.62</td>
</tr>
<tr>
<td>O02</td>
<td>48.00</td>
<td>72.96</td>
<td>45.44</td>
<td>A12</td>
<td>129.00</td>
<td>153.19</td>
<td>123.29</td>
</tr>
<tr>
<td>O03</td>
<td>108.87</td>
<td>113.79</td>
<td>101.00</td>
<td>A13</td>
<td>135.72</td>
<td>116.57</td>
<td>109.52</td>
</tr>
<tr>
<td>O04</td>
<td>13.65</td>
<td>16.40</td>
<td>18.98</td>
<td>A14</td>
<td>9.07</td>
<td>14.12</td>
<td>5.81</td>
</tr>
<tr>
<td>O05</td>
<td></td>
<td></td>
<td></td>
<td>A15</td>
<td>150.62</td>
<td>86.11</td>
<td>97.54</td>
</tr>
<tr>
<td>O06</td>
<td>111.39</td>
<td>129.46</td>
<td>95.62</td>
<td>A16</td>
<td>107.50</td>
<td>126.32</td>
<td>145.46</td>
</tr>
<tr>
<td>O07</td>
<td></td>
<td></td>
<td></td>
<td>A17</td>
<td>59.16</td>
<td>49.73</td>
<td>74.08</td>
</tr>
<tr>
<td>O08</td>
<td></td>
<td></td>
<td></td>
<td>A18</td>
<td>119.42</td>
<td>97.05</td>
<td>81.47</td>
</tr>
<tr>
<td>O09</td>
<td>18.29</td>
<td>88.94</td>
<td>82.04</td>
<td>A19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O10</td>
<td></td>
<td></td>
<td></td>
<td>A20</td>
<td>85.67</td>
<td>82.60</td>
<td>63.08</td>
</tr>
<tr>
<td>O11</td>
<td>266.34</td>
<td>236.95</td>
<td>-32.69</td>
<td>B02</td>
<td>108.14</td>
<td>135.25</td>
<td>176.49</td>
</tr>
<tr>
<td>O12</td>
<td>118.90</td>
<td>135.50</td>
<td>139.21</td>
<td>B03</td>
<td>38.23</td>
<td>75.54</td>
<td>56.77</td>
</tr>
<tr>
<td>O13</td>
<td>132.85</td>
<td>139.54</td>
<td>127.76</td>
<td>B04</td>
<td>95.08</td>
<td>99.72</td>
<td>90.95</td>
</tr>
<tr>
<td>O14</td>
<td></td>
<td></td>
<td></td>
<td>B05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O15</td>
<td>106.62</td>
<td>84.28</td>
<td>83.47</td>
<td>B06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O16</td>
<td></td>
<td></td>
<td></td>
<td>B07</td>
<td>79.94</td>
<td>86.43</td>
<td>66.74</td>
</tr>
<tr>
<td>O17</td>
<td>89.27</td>
<td>107.55</td>
<td>93.13</td>
<td>B08</td>
<td>87.36</td>
<td>116.32</td>
<td>125.13</td>
</tr>
<tr>
<td>O18</td>
<td></td>
<td></td>
<td></td>
<td>B09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O19</td>
<td>95.78</td>
<td>104.02</td>
<td>90.35</td>
<td>B10</td>
<td>22.39</td>
<td>64.81</td>
<td>42.44</td>
</tr>
<tr>
<td>O20</td>
<td>70.22</td>
<td>82.28</td>
<td>69.82</td>
<td>B11</td>
<td>23.18</td>
<td>22.84</td>
<td>16.01</td>
</tr>
<tr>
<td>O21</td>
<td>75.78</td>
<td>61.51</td>
<td>62.91</td>
<td>B12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O22</td>
<td>48.24</td>
<td>71.96</td>
<td>108.94</td>
<td>B13</td>
<td>97.09</td>
<td>117.25</td>
<td>120.27</td>
</tr>
<tr>
<td>O23</td>
<td>90.45</td>
<td>83.22</td>
<td>85.83</td>
<td>B14</td>
<td>9.41</td>
<td>3.34</td>
<td>0.34</td>
</tr>
<tr>
<td>P02</td>
<td>81.41</td>
<td>61.18</td>
<td>37.85</td>
<td>B15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P03</td>
<td></td>
<td></td>
<td></td>
<td>B16</td>
<td>99.27</td>
<td>79.45</td>
<td>124.80</td>
</tr>
<tr>
<td>P04</td>
<td>72.90</td>
<td>82.00</td>
<td>123.39</td>
<td>B17</td>
<td>40.28</td>
<td>37.15</td>
<td>47.68</td>
</tr>
<tr>
<td>P05</td>
<td>65.86</td>
<td>44.11</td>
<td>94.41</td>
<td>B18</td>
<td>98.84</td>
<td>54.30</td>
<td>91.16</td>
</tr>
<tr>
<td>P06</td>
<td>84.78</td>
<td>102.52</td>
<td>92.33</td>
<td>B19</td>
<td>124.54</td>
<td>113.57</td>
<td>102.82</td>
</tr>
<tr>
<td>P07</td>
<td>45.25</td>
<td>47.65</td>
<td>40.09</td>
<td>B20</td>
<td>34.99</td>
<td>44.65</td>
<td>44.21</td>
</tr>
<tr>
<td>P08</td>
<td>21.80</td>
<td>27.10</td>
<td>32.64</td>
<td>C02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P09</td>
<td>52.35</td>
<td>28.70</td>
<td>43.50</td>
<td>C03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P10</td>
<td>46.77</td>
<td>81.27</td>
<td>71.41</td>
<td>C04</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P11</td>
<td></td>
<td></td>
<td></td>
<td>C05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P12</td>
<td>118.16</td>
<td>133.19</td>
<td>149.24</td>
<td>C06</td>
<td>89.21</td>
<td>102.19</td>
<td>158.96</td>
</tr>
<tr>
<td>P13</td>
<td>106.17</td>
<td>86.89</td>
<td>82.83</td>
<td>C07</td>
<td>78.24</td>
<td>45.34</td>
<td>59.94</td>
</tr>
<tr>
<td>P14</td>
<td>23.18</td>
<td>47.38</td>
<td>34.91</td>
<td>C08</td>
<td>86.87</td>
<td>87.71</td>
<td>85.85</td>
</tr>
<tr>
<td>P15</td>
<td>84.50</td>
<td>98.39</td>
<td>100.54</td>
<td>C09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P16</td>
<td></td>
<td></td>
<td></td>
<td>C10</td>
<td>68.02</td>
<td>75.42</td>
<td>70.54</td>
</tr>
<tr>
<td>P17</td>
<td>113.48</td>
<td>116.05</td>
<td>85.67</td>
<td>C11</td>
<td>132.92</td>
<td>198.43</td>
<td>168.87</td>
</tr>
<tr>
<td>P18</td>
<td>102.85</td>
<td>102.04</td>
<td>82.55</td>
<td>C12</td>
<td>155.21</td>
<td>141.10</td>
<td>208.62</td>
</tr>
<tr>
<td>P19</td>
<td>103.82</td>
<td>130.35</td>
<td>69.45</td>
<td>C13</td>
<td>20.83</td>
<td>11.53</td>
<td>18.38</td>
</tr>
<tr>
<td>P20</td>
<td>77.45</td>
<td>89.11</td>
<td>60.97</td>
<td>C14</td>
<td>98.88</td>
<td>64.61</td>
<td>132.70</td>
</tr>
<tr>
<td>P21</td>
<td>133.13</td>
<td>135.34</td>
<td>139.16</td>
<td>C15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P22</td>
<td>89.58</td>
<td>75.31</td>
<td>80.74</td>
<td>C16</td>
<td>24.75</td>
<td>23.54</td>
<td>21.39</td>
</tr>
<tr>
<td>P23</td>
<td>85.33</td>
<td>133.17</td>
<td>89.75</td>
<td>C17</td>
<td>69.26</td>
<td>62.02</td>
<td>61.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C18</td>
<td>95.66</td>
<td>107.72</td>
<td>73.28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>D20</td>
<td>65.96</td>
<td>47.97</td>
<td>60.04</td>
<td>F20</td>
<td>60.99</td>
<td>54.85</td>
<td>31.81</td>
</tr>
<tr>
<td>D02</td>
<td>86.66</td>
<td>66.74</td>
<td>93.85</td>
<td>G02</td>
<td>28.73</td>
<td>21.09</td>
<td>39.62</td>
</tr>
<tr>
<td>D03</td>
<td>61.25</td>
<td>53.37</td>
<td>46.88</td>
<td>G03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D04</td>
<td>86.74</td>
<td>107.36</td>
<td>137.26</td>
<td>G04</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D05</td>
<td>63.47</td>
<td>73.50</td>
<td>86.00</td>
<td>G05</td>
<td>36.55</td>
<td>33.79</td>
<td>34.52</td>
</tr>
<tr>
<td>D06</td>
<td>70.67</td>
<td>81.57</td>
<td>72.73</td>
<td>G06</td>
<td>90.29</td>
<td>71.76</td>
<td>108.14</td>
</tr>
<tr>
<td>D07</td>
<td></td>
<td></td>
<td></td>
<td>G07</td>
<td>76.78</td>
<td>74.38</td>
<td>81.57</td>
</tr>
<tr>
<td>D08</td>
<td></td>
<td></td>
<td></td>
<td>G08</td>
<td>63.88</td>
<td>77.37</td>
<td>76.85</td>
</tr>
<tr>
<td>D09</td>
<td></td>
<td></td>
<td></td>
<td>G09</td>
<td>33.52</td>
<td>32.64</td>
<td>43.56</td>
</tr>
<tr>
<td>D10</td>
<td>26.89</td>
<td>55.17</td>
<td>40.94</td>
<td>G10</td>
<td>78.52</td>
<td>66.95</td>
<td>70.84</td>
</tr>
<tr>
<td>D11</td>
<td>55.10</td>
<td>40.65</td>
<td>47.37</td>
<td>G11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D12</td>
<td>77.04</td>
<td>91.49</td>
<td>86.45</td>
<td>G12</td>
<td>60.30</td>
<td>103.98</td>
<td>81.13</td>
</tr>
<tr>
<td>D13</td>
<td></td>
<td></td>
<td></td>
<td>G13</td>
<td>167.97</td>
<td>118.92</td>
<td>43.34</td>
</tr>
<tr>
<td>D14</td>
<td>36.94</td>
<td>32.47</td>
<td>48.38</td>
<td>G14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D15</td>
<td>141.88</td>
<td>72.00</td>
<td>111.98</td>
<td>G15</td>
<td>164.95</td>
<td>102.46</td>
<td>104.82</td>
</tr>
<tr>
<td>D16</td>
<td>60.25</td>
<td>88.47</td>
<td>73.35</td>
<td>G16</td>
<td>99.78</td>
<td>84.66</td>
<td>56.77</td>
</tr>
<tr>
<td>D17</td>
<td>10.53</td>
<td>10.10</td>
<td>8.78</td>
<td>G17</td>
<td>54.48</td>
<td>47.24</td>
<td>47.24</td>
</tr>
<tr>
<td>D18</td>
<td>99.17</td>
<td>86.88</td>
<td>55.73</td>
<td>G18</td>
<td>75.03</td>
<td>72.84</td>
<td>52.00</td>
</tr>
<tr>
<td>D19</td>
<td>27.43</td>
<td>25.23</td>
<td>26.77</td>
<td>G19</td>
<td>10.24</td>
<td>7.23</td>
<td>6.73</td>
</tr>
<tr>
<td>D20</td>
<td></td>
<td></td>
<td></td>
<td>G20</td>
<td>43.81</td>
<td>42.93</td>
<td>40.08</td>
</tr>
<tr>
<td>E02</td>
<td>131.54</td>
<td>175.80</td>
<td>95.39</td>
<td>H02</td>
<td>184.84</td>
<td>146.37</td>
<td>155.18</td>
</tr>
<tr>
<td>E03</td>
<td></td>
<td></td>
<td></td>
<td>H03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E04</td>
<td>136.17</td>
<td>135.25</td>
<td>108.14</td>
<td>H04</td>
<td>120.65</td>
<td>69.67</td>
<td>77.09</td>
</tr>
<tr>
<td>E05</td>
<td>23.26</td>
<td>22.82</td>
<td>23.91</td>
<td>H05</td>
<td>118.33</td>
<td>61.50</td>
<td>82.78</td>
</tr>
<tr>
<td>E06</td>
<td>52.91</td>
<td>70.98</td>
<td>67.04</td>
<td>H06</td>
<td>366.23</td>
<td>154.90</td>
<td>-37.42</td>
</tr>
<tr>
<td>E07</td>
<td>87.36</td>
<td>47.73</td>
<td>77.63</td>
<td>H07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E08</td>
<td>128.37</td>
<td>132.08</td>
<td>83.42</td>
<td>H08</td>
<td>89.68</td>
<td>92.46</td>
<td>104.74</td>
</tr>
<tr>
<td>E09</td>
<td></td>
<td></td>
<td></td>
<td>H09</td>
<td>159.89</td>
<td>469.46</td>
<td>55.15</td>
</tr>
<tr>
<td>E10</td>
<td>83.13</td>
<td>84.74</td>
<td>82.76</td>
<td>H10</td>
<td>103.16</td>
<td>51.42</td>
<td>76.64</td>
</tr>
<tr>
<td>E11</td>
<td>110.86</td>
<td>105.82</td>
<td>108.20</td>
<td>H11</td>
<td>100.22</td>
<td>164.05</td>
<td>162.04</td>
</tr>
<tr>
<td>E12</td>
<td>137.96</td>
<td>134.27</td>
<td>86.90</td>
<td>H12</td>
<td>35.05</td>
<td>65.96</td>
<td>67.97</td>
</tr>
<tr>
<td>E13</td>
<td>96.98</td>
<td>81.96</td>
<td>83.20</td>
<td>H13</td>
<td>136.90</td>
<td>60.64</td>
<td>99.94</td>
</tr>
<tr>
<td>E14</td>
<td>135.72</td>
<td>59.46</td>
<td>110.19</td>
<td>H14</td>
<td>111.20</td>
<td>118.59</td>
<td>152.18</td>
</tr>
<tr>
<td>E15</td>
<td>94.40</td>
<td>83.99</td>
<td>71.22</td>
<td>H15</td>
<td>142.89</td>
<td>72.68</td>
<td>77.04</td>
</tr>
<tr>
<td>E16</td>
<td>123.07</td>
<td>106.27</td>
<td>101.22</td>
<td>H16</td>
<td>94.51</td>
<td>97.20</td>
<td>73.35</td>
</tr>
<tr>
<td>E17</td>
<td>46.73</td>
<td>70.43</td>
<td>56.38</td>
<td>H17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E18</td>
<td>83.30</td>
<td>107.87</td>
<td>56.75</td>
<td>H18</td>
<td>50.57</td>
<td>48.16</td>
<td>55.40</td>
</tr>
<tr>
<td>E19</td>
<td></td>
<td></td>
<td></td>
<td>H19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E20</td>
<td>75.11</td>
<td>60.85</td>
<td>53.61</td>
<td>H20</td>
<td>44.76</td>
<td>66.26</td>
<td>60.82</td>
</tr>
<tr>
<td>F02</td>
<td></td>
<td></td>
<td></td>
<td>I02</td>
<td>99.06</td>
<td>76.70</td>
<td>103.00</td>
</tr>
<tr>
<td>F03</td>
<td>110.18</td>
<td>132.43</td>
<td>69.63</td>
<td>I03</td>
<td>75.64</td>
<td>104.39</td>
<td>45.30</td>
</tr>
<tr>
<td>F04</td>
<td>79.63</td>
<td>70.60</td>
<td>98.40</td>
<td>I04</td>
<td>90.76</td>
<td>119.49</td>
<td>88.44</td>
</tr>
<tr>
<td>F05</td>
<td>70.43</td>
<td>45.63</td>
<td>97.63</td>
<td>I05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F06</td>
<td>77.32</td>
<td>99.33</td>
<td>124.82</td>
<td>I06</td>
<td>156.02</td>
<td>85.35</td>
<td>183.14</td>
</tr>
<tr>
<td>F07</td>
<td>39.04</td>
<td>37.42</td>
<td>55.03</td>
<td>I07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F08</td>
<td>53.30</td>
<td>120.96</td>
<td>85.27</td>
<td>I08</td>
<td>151.78</td>
<td>112.85</td>
<td>78.78</td>
</tr>
<tr>
<td>F09</td>
<td>357.08</td>
<td>139.50</td>
<td>38.93</td>
<td>I09</td>
<td>234.89</td>
<td>182.98</td>
<td>182.98</td>
</tr>
<tr>
<td>F10</td>
<td>77.88</td>
<td>74.99</td>
<td>76.54</td>
<td>I10</td>
<td>50.13</td>
<td>86.45</td>
<td>67.82</td>
</tr>
<tr>
<td>F11</td>
<td>65.85</td>
<td>93.06</td>
<td>93.06</td>
<td>I11</td>
<td>98.32</td>
<td>101.01</td>
<td>74.80</td>
</tr>
<tr>
<td>F12</td>
<td>79.17</td>
<td>79.84</td>
<td>108.73</td>
<td>I12</td>
<td>56.22</td>
<td>106.94</td>
<td>142.89</td>
</tr>
<tr>
<td>F13</td>
<td>63.38</td>
<td>90.59</td>
<td>98.66</td>
<td>I13</td>
<td>112.99</td>
<td>134.49</td>
<td>122.73</td>
</tr>
<tr>
<td>F14</td>
<td></td>
<td></td>
<td></td>
<td>I14</td>
<td>76.15</td>
<td>54.98</td>
<td>111.20</td>
</tr>
<tr>
<td>F15</td>
<td>62.79</td>
<td>71.39</td>
<td>59.63</td>
<td>I15</td>
<td>62.49</td>
<td>100.78</td>
<td>86.00</td>
</tr>
<tr>
<td>F16</td>
<td>97.93</td>
<td>58.62</td>
<td>122.12</td>
<td>I16</td>
<td>64.95</td>
<td>68.76</td>
<td>64.95</td>
</tr>
<tr>
<td>F17</td>
<td>49.00</td>
<td>42.42</td>
<td>34.52</td>
<td>I17</td>
<td>55.07</td>
<td>44.10</td>
<td>57.92</td>
</tr>
<tr>
<td>F18</td>
<td>92.58</td>
<td>85.78</td>
<td>65.38</td>
<td>I18</td>
<td>70.75</td>
<td>65.71</td>
<td>68.56</td>
</tr>
<tr>
<td>F19</td>
<td>54.19</td>
<td>46.51</td>
<td>41.25</td>
<td>I19</td>
<td>11.55</td>
<td>14.76</td>
<td>8.63</td>
</tr>
<tr>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>L20</td>
<td>75.54</td>
<td>54.48</td>
<td>74.45</td>
<td>L20</td>
<td>46.40</td>
<td>45.78</td>
<td>53.02</td>
</tr>
<tr>
<td>J02</td>
<td>96.51</td>
<td>96.05</td>
<td>90.25</td>
<td>M02</td>
<td>59.09</td>
<td>47.73</td>
<td>91.76</td>
</tr>
<tr>
<td>J03</td>
<td>164.52</td>
<td>78.78</td>
<td>89.68</td>
<td>M03</td>
<td>69.00</td>
<td>76.24</td>
<td>94.01</td>
</tr>
<tr>
<td>J04</td>
<td>22.09</td>
<td>17.31</td>
<td>16.68</td>
<td>M04</td>
<td>78.44</td>
<td>98.60</td>
<td>63.14</td>
</tr>
<tr>
<td>J05</td>
<td>71.85</td>
<td>67.68</td>
<td>93.13</td>
<td>M05</td>
<td>69.00</td>
<td>76.24</td>
<td>94.01</td>
</tr>
<tr>
<td>J06</td>
<td>64.53</td>
<td>25.14</td>
<td>44.84</td>
<td>M06</td>
<td>72.64</td>
<td>63.61</td>
<td>133.35</td>
</tr>
<tr>
<td>J07</td>
<td>143.67</td>
<td>-9.04</td>
<td>85.97</td>
<td>M07</td>
<td>86.43</td>
<td>90.75</td>
<td>98.02</td>
</tr>
<tr>
<td>J08</td>
<td>102.65</td>
<td>69.98</td>
<td>97.55</td>
<td>M08</td>
<td>105.28</td>
<td>66.12</td>
<td>116.40</td>
</tr>
<tr>
<td>J09</td>
<td>76.31</td>
<td>76.78</td>
<td>92.53</td>
<td>M09</td>
<td>34.18</td>
<td>96.51</td>
<td>92.57</td>
</tr>
<tr>
<td>J10</td>
<td>52.60</td>
<td>191.75</td>
<td>128.64</td>
<td>M10</td>
<td>44.19</td>
<td>62.51</td>
<td>54.17</td>
</tr>
<tr>
<td>J11</td>
<td>59.57</td>
<td>94.18</td>
<td>76.71</td>
<td>M11</td>
<td>111.42</td>
<td>64.39</td>
<td>123.52</td>
</tr>
<tr>
<td>J12</td>
<td>108.96</td>
<td>108.29</td>
<td>96.53</td>
<td>M12</td>
<td>167.30</td>
<td>163.27</td>
<td>91.04</td>
</tr>
<tr>
<td>J13</td>
<td></td>
<td></td>
<td></td>
<td>M13</td>
<td>81.19</td>
<td>97.98</td>
<td>97.31</td>
</tr>
<tr>
<td>J14</td>
<td></td>
<td></td>
<td></td>
<td>M14</td>
<td>59.80</td>
<td>32.92</td>
<td>38.75</td>
</tr>
<tr>
<td>J15</td>
<td>41.38</td>
<td>42.33</td>
<td>50.39</td>
<td>M15</td>
<td>62.71</td>
<td>62.37</td>
<td>65.73</td>
</tr>
<tr>
<td>J16</td>
<td>74.58</td>
<td>112.88</td>
<td>105.82</td>
<td>M16</td>
<td>25.87</td>
<td>46.14</td>
<td>40.65</td>
</tr>
<tr>
<td>J17</td>
<td>24.24</td>
<td>26.44</td>
<td>25.69</td>
<td>M17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J18</td>
<td>64.87</td>
<td>77.81</td>
<td>112.70</td>
<td>M18</td>
<td>105.32</td>
<td>107.94</td>
<td>61.21</td>
</tr>
<tr>
<td>J19</td>
<td></td>
<td></td>
<td></td>
<td>M19</td>
<td>83.81</td>
<td>77.45</td>
<td>96.09</td>
</tr>
<tr>
<td>J20</td>
<td>48.27</td>
<td>56.16</td>
<td>52.00</td>
<td>M20</td>
<td>42.12</td>
<td>29.03</td>
<td>36.05</td>
</tr>
<tr>
<td>K02</td>
<td>87.05</td>
<td>106.51</td>
<td>114.62</td>
<td>N02</td>
<td>129.99</td>
<td>142.74</td>
<td>135.32</td>
</tr>
<tr>
<td>K03</td>
<td>72.76</td>
<td>101.49</td>
<td>73.92</td>
<td>N03</td>
<td>51.44</td>
<td>45.73</td>
<td>44.49</td>
</tr>
<tr>
<td>K04</td>
<td>60.02</td>
<td>103.35</td>
<td>113.77</td>
<td>N04</td>
<td>176.96</td>
<td>218.67</td>
<td>84.27</td>
</tr>
<tr>
<td>K05</td>
<td></td>
<td></td>
<td></td>
<td>N05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K06</td>
<td>52.14</td>
<td>101.49</td>
<td>149.46</td>
<td>N06</td>
<td>45.34</td>
<td>55.77</td>
<td>53.91</td>
</tr>
<tr>
<td>K07</td>
<td>85.35</td>
<td>52.45</td>
<td>109.22</td>
<td>N07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K08</td>
<td>78.48</td>
<td>109.76</td>
<td>94.70</td>
<td>N08</td>
<td>92.57</td>
<td>118.76</td>
<td>74.27</td>
</tr>
<tr>
<td>K09</td>
<td></td>
<td></td>
<td></td>
<td>N09</td>
<td>102.96</td>
<td>103.66</td>
<td>92.53</td>
</tr>
<tr>
<td>K10</td>
<td>107.34</td>
<td>85.81</td>
<td>97.15</td>
<td>N10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K11</td>
<td>148.82</td>
<td>525.76</td>
<td>264.73</td>
<td>N11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K12</td>
<td>64.61</td>
<td>106.61</td>
<td>177.83</td>
<td>N12</td>
<td>92.83</td>
<td>97.87</td>
<td>66.97</td>
</tr>
<tr>
<td>K13</td>
<td>13.70</td>
<td>23.30</td>
<td>26.96</td>
<td>N13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K14</td>
<td>101.12</td>
<td>165.29</td>
<td>143.45</td>
<td>N14</td>
<td>141.21</td>
<td>120.38</td>
<td>96.42</td>
</tr>
<tr>
<td>K15</td>
<td>120.10</td>
<td>109.69</td>
<td>133.54</td>
<td>N15</td>
<td>20.72</td>
<td>14.86</td>
<td>6.61</td>
</tr>
<tr>
<td>K16</td>
<td>116.69</td>
<td>74.36</td>
<td>103.25</td>
<td>N16</td>
<td>135.05</td>
<td>100.45</td>
<td>51.40</td>
</tr>
<tr>
<td>K17</td>
<td>49.99</td>
<td>51.78</td>
<td>40.81</td>
<td>N17</td>
<td>11.08</td>
<td>8.70</td>
<td>4.97</td>
</tr>
<tr>
<td>K18</td>
<td>54.48</td>
<td>79.27</td>
<td>51.19</td>
<td>N18</td>
<td>110.36</td>
<td>84.91</td>
<td>94.56</td>
</tr>
<tr>
<td>K19</td>
<td>76.42</td>
<td>140.49</td>
<td>70.50</td>
<td>N19</td>
<td>109.55</td>
<td>111.09</td>
<td>107.36</td>
</tr>
<tr>
<td>K20</td>
<td>53.02</td>
<td>53.68</td>
<td>65.09</td>
<td>N20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L02</td>
<td>152.55</td>
<td>109.22</td>
<td>123.82</td>
<td>O02</td>
<td>140.04</td>
<td>156.95</td>
<td>123.58</td>
</tr>
<tr>
<td>L03</td>
<td></td>
<td></td>
<td></td>
<td>O03</td>
<td>119.34</td>
<td>120.74</td>
<td>125.36</td>
</tr>
<tr>
<td>L04</td>
<td>101.84</td>
<td>59.90</td>
<td>67.31</td>
<td>O04</td>
<td>139.15</td>
<td>94.89</td>
<td>97.44</td>
</tr>
<tr>
<td>L05</td>
<td>38.39</td>
<td>44.54</td>
<td>32.47</td>
<td>O05</td>
<td>1.97</td>
<td>3.51</td>
<td>2.72</td>
</tr>
<tr>
<td>L06</td>
<td>12.94</td>
<td>20.26</td>
<td>14.97</td>
<td>O06</td>
<td>121.27</td>
<td>124.51</td>
<td>107.83</td>
</tr>
<tr>
<td>L07</td>
<td></td>
<td></td>
<td></td>
<td>O07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L08</td>
<td></td>
<td></td>
<td></td>
<td>O08</td>
<td>96.94</td>
<td>79.09</td>
<td>78.86</td>
</tr>
<tr>
<td>L09</td>
<td>132.66</td>
<td>112.04</td>
<td>120.61</td>
<td>O09</td>
<td>123.04</td>
<td>163.59</td>
<td>147.37</td>
</tr>
<tr>
<td>L10</td>
<td>42.45</td>
<td>42.31</td>
<td>42.97</td>
<td>O10</td>
<td>-4.98</td>
<td>183.99</td>
<td>80.75</td>
</tr>
<tr>
<td>L11</td>
<td>107.73</td>
<td>146.70</td>
<td>208.51</td>
<td>O11</td>
<td>153.30</td>
<td>176.48</td>
<td>111.65</td>
</tr>
<tr>
<td>L12</td>
<td>97.87</td>
<td>164.39</td>
<td>93.17</td>
<td>O12</td>
<td>189.36</td>
<td>146.70</td>
<td>134.94</td>
</tr>
<tr>
<td>L13</td>
<td>134.94</td>
<td>126.20</td>
<td>87.57</td>
<td>O13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L14</td>
<td></td>
<td></td>
<td></td>
<td>O14</td>
<td>591.27</td>
<td>284.21</td>
<td>-112.21</td>
</tr>
<tr>
<td>L15</td>
<td></td>
<td></td>
<td></td>
<td>O15</td>
<td>71.89</td>
<td>102.80</td>
<td>32.92</td>
</tr>
<tr>
<td>L16</td>
<td>69.32</td>
<td>59.91</td>
<td>60.92</td>
<td>O16</td>
<td>39.98</td>
<td>49.38</td>
<td>48.61</td>
</tr>
<tr>
<td>L17</td>
<td>66.62</td>
<td>72.18</td>
<td>77.15</td>
<td>O17</td>
<td>47.68</td>
<td>47.90</td>
<td>35.62</td>
</tr>
<tr>
<td>L18</td>
<td>89.51</td>
<td>57.48</td>
<td>73.28</td>
<td>O18</td>
<td>103.19</td>
<td>111.53</td>
<td>76.64</td>
</tr>
<tr>
<td>L19</td>
<td>84.91</td>
<td>74.81</td>
<td>84.47</td>
<td>O19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fragment ID</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P02</td>
<td>74.27</td>
<td>113.89</td>
<td>120.84</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P03</td>
<td>122.46</td>
<td>62.45</td>
<td>80.75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P04</td>
<td>253.62</td>
<td>129.18</td>
<td>120.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P05</td>
<td>92.22</td>
<td>132.15</td>
<td>110.43</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P06</td>
<td>91.30</td>
<td>98.71</td>
<td>60.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P07</td>
<td>69.98</td>
<td>80.87</td>
<td>55.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P08</td>
<td>182.83</td>
<td>440.50</td>
<td>282.47</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P09</td>
<td>32.14</td>
<td>138.51</td>
<td>85.43</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P10</td>
<td>86.00</td>
<td>73.24</td>
<td>104.14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P11</td>
<td>98.99</td>
<td>69.76</td>
<td>35.83</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P12</td>
<td>29.23</td>
<td>32.25</td>
<td>32.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P13</td>
<td>445.58</td>
<td>120.72</td>
<td>53.42</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P14</td>
<td>64.33</td>
<td>62.65</td>
<td>96.58</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P15</td>
<td>91.15</td>
<td>136.84</td>
<td>143.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P16</td>
<td>34.88</td>
<td>32.87</td>
<td>31.59</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P17</td>
<td>100.12</td>
<td>72.25</td>
<td>108.67</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P18</td>
<td>78.84</td>
<td>83.22</td>
<td>88.49</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary 6

Sequence of MurE from *S. agalactiae*

```
```

Supplementary 7

Cleavage of His tag from *S. agalactiae* MurD

![Figure S7. 1: Cleavage of His tag from MurD from S. agalactiae](image)

MurD from *S. agalactiae* was purified via IMAC Ni column. Overnight dialysis was carried out into Buffer GF in the presence of 3C to cleave the His tag. The sample was then purified via reverse IMAC and the cleaved protein present in the flow-through was stored for use within MST.

Supplementary 8

pET DUET MurD does not bind to Ni IMAC column

MurD was cloned into the second open reading frame of pET DUET with no tag. Expression and purification of MurD was carried out using the same conditions as the duel pET DUET system. MurD was seen within the flow-through and wash steps, but was not present within the elution.

![Figure S8. 1: MurD does not bind an IMAC Ni column without a His tag](image)

MurD without a His tag does not bind to a Ni IMAC column. pET DUET MurD was expressed and purified via an Ni IMAC column. MurD was present within the flow-through and wash steps. MurD was not present within the elution steps.
Bibliography


38. Brötz, H. et al. Role of lipid-bound peptidoglycan precursors in the formation


82. Miyachiro, M. M. *et al.* Complex Formation between Mur Enzymes from


117. Perdih, A. *et al.* Discovery of novel benzene 1,3-dicarboxylic acid inhibitors of bacterial MurD and MurE ligases by structure-based virtual screening


142. Wu, N., Tsuji, S. Y., Cane, D. E. & Khosla, C. Assessing the Balance between Protein-Protein Interactions and Enzyme-Substrate Interactions in the


145. NICE. *Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Technology appraisal guidance.* www.nice.org.uk/guidance/ta813 (2022).


